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ABSTRACT
CYP3A4 is one of the most abundant P450s in human liver, accounting for 10 to 60% 
of total liver P450 (Guengerich, 1990; Krivoruk et al, 1994; Shimada et al, 1994) 
and has been estimated to metabolise 60% of pharmaceuticals currently in use, for 
example cyclosporin, nifedipine and terfenadine (Cholerton et al, 1992; Jounaidi et 
a l, 1994). The levels of CYP3A4 can be up-regulated in vivo by a number of 
structurally diverse compounds, for example the glucocorticoid dexamethasone, and 
the antibiotic rifampicin (Watkins, 1992). Due to the potential for clinically 
significant drug interactions it is important to determine whether a new chemical 
entity is an inducer of CYP3A4 early in the drug developmental process.
Previously in our laboratory (Williams, 1997), a plasmid construct containing 
approximately Ikb of the 5'-regulatory region of the human CYP3A4 gene, coupled to 
a reporter gene for human secreted placental alkaline phosphatase (SPAP), was 
engineered and used to develop an in vitro transfection system for the assessment of 
the induction of human CYP3A4 by xenobiotics. This system was used to 
demonstrate the induction of CYP3 A4-dependent reporter gene expression by 
dexamethasone, PCN and phenobarbitone.
The initial aim of the research presented in this thesis was to further develop this 
system in an attempt to improve the reproducibility and robustness. The ultimate aim 
of this approach would be to modify the system to render it useful for the high 
throughput screening of xenobiotics. Another goal of the project was to attempt to 
generate a stable cell line expressing the alkaline phosphatase reporter gene under the 
direct control of the CYP3A4 regulatory region. Success in this approach would
dramatically reduce problems associated with poor reproducibility and would greatly 
increase the potential for the use of this system as a high throughput screen. The final 
aim of this project was to use the system to attempt to gain information concerning 
the molecular mechanisms underlying induction of CYP3A4 by xenobiotics.
Specifically, the major advances made during this research have been:
1) The system originally developed in this laboratory has been extensively modified, 
rendering it more reproducible, more robust, and suitable for use in high- 
throughput screening.
2) Induction of CYP3A4-dependent reporter gene expression by carbamazepine, 
dexamethasone, metyrapone, PCN, phenobarbitone, phenylbutazone, phenytoin, 
rifampicin, spironolactone and sulfinpyrazone has been demonstrated.
3) Clotrimazole, erythromycin and triacetyloleandomycin did not induce CYP3A4- 
dependent reporter gene expression, indicating that these compounds may act at a 
post-transcriptional level to induce CYP3A4.
4) The anti-glucocorticoid RU-486 was found to block dexamethasone-dependent 
induction of CYP3A4-dependent reporter gene expression.
5) A role for the human glucocorticoid receptor in CYP3A4 induction by a number 
of agents was also demonstrated; the precise molecular mechanisms of this role 
were not elucidated, but possibilities have been discussed.
These results demonstrate that this assay provides a sensitive, specific and high 
throughput screen for the assessment of xenobiotic induction of human CYP3A4 in 
vitro.
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CHAPTER 1 - INTRODUCTION
1.1 Xenobiotic exposure
Throughout their lives, humans and other animals are exposed to a wide range of 
compounds foreign to the body, known as xenobiotics (Gonzalez & Gelboin, 1991). 
Exposure to xenobiotics may occur deliberately (drugs and food additives), 
accidentally (food contaminants and pesticides) or coincidentally (industrial 
chemicals and environmental pollutants) (Gibson & Skett, 1994).
To exert an effect, whether therapeutic or toxic, the active compound (either the 
xenobiotic or its metabolites) must attain an effective concentration at its site of action 
(Wingard et al., 1991). The overall disposition of a xenobiotic in the body is dictated 
by four factors, sometimes referred to as ADME (Rang et al., 1996). The first of 
these factors is absorption (the ability of the xenobiotic to enter the systemic 
circulation), the rate of which will depend on the physicochemical properties of the 
xenobiotic, its initial dose and formulation, and the route of administration. The 
second factor is the distribution of the xenobiotic within the body (plasma protein 
binding, partitioning into body fat and tissue specific localisation). The third factor is 
the metabolism (or biotransformation) of the xenobiotic which will be discussed in the 
following section (Section 1.1.1). The fourth factor is the excretion of the xenobiotic 
and its metabolites from the body.
Xenobiotics and their metabolites may be excreted from the body by a number of 
routes including the lung (important for the elimination of anaesthetic gases and 
compounds with low vapour pressure), saliva, sweat and breast milk. However the 
main elimination routes are by renal and biliary excretion (Rang et al., 1996).
1.1.1 Metabolism
The major organ of drug metabolism is the liver (Watkins, 1992). In some cases 
extrahepatic tissues, frequently the site of absorption or excretion (e.g. the lung, 
kidney or gastrointestinal mucosa), may also play an important role in the metabolism 
of a compound (Rang et al., 1996). Metabolism of xenobiotics is generally regarded 
as occurring in two phases, however some workers have proposed the existence of a 
third phase (Gibson & Skett, 1994).
Phase 1 (or functionalisation) reactions either introduce or uncover a functional group 
in the molecule (e.g. -OH, -NH2 , -SH, -COOH), activating it for subsequent Phase 2 
(or conjugation) reactions, which render the compound more water soluble, thereby 
facilitating excretion in either urine or bile.
The third phase (Phase 3) of drug metabolism involves the further processing of phase 
2 products.
A single compound may undergo multiple pathways of metabolism.
In some cases, the metabolism of a xenobiotic can result in the production of toxic 
metabolites capable of causing carcinogenesis, teratogenesis, and other adverse 
reactions such as Lupus Erythematosus and other autoimmune-based idiosyncratic 
drug reactions (McKinnon & Nebert, 1991).
The possible pathways of drug metabolism are illustrated in Table 1-1.
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1.1.1.1 Phase 1 metabolism
The mixed-fimction oxidase system (cytochrome P450-dependent) is capable of many 
diverse functionalisation reactions and will be considered later. Other oxidative 
enzymes include alcohol dehydrogenase, aldehyde dehydrogenase, alkylhydrazine 
oxidase, amine oxidases, aromatases and xanthine oxidase.
Hepatic microsomes can catalyse a number of reductive reactions. These generally 
require NADPH, but are inhibited by oxygen. Azo- and nitro-reduction can be 
catalysed by cytochrome P450 and NADPH-cytochrome c (P450) reductase, some 
heterocyclics are ring cleaved by reduction, and fluorocarbons of the halothane type 
are defluorinated under anaerobic conditions (Gibson & Skett, 1994).
The hydrolysis of esters, amides, hydrazides and carbamates is carried out by a 
variety of enzymes present both in the plasma and the liver (e.g. plasma esterases). 
Epoxide hydratase carries out the hydration of epoxides to form the dihydrodiol.
Other less common phase 1 reactions include ring cyclisation, N-carboxylation, 
dimérisation, transamidation, isomérisation, decarboxylation and dithioacetylation 
(Gibson & Skett, 1994).
1.1.1.2 Phase 2 metabolism
Phase 2 reactions are carried out by a diverse range of enzymes as illustrated in 
Table 1-2. These reactions involve the conjugation of endogenous compounds to the 
activated metabolites of the Phase 1 reactions and generally lead to water-soluble 
products that may be excreted in urine or bile.
1.1.1.3 Phase 3 metabolism
A large number of Phase 1 metabolites are detoxified by conjugation with the 
tripeptide glutathione (glutamyl-cysteinyl-glycine). Further processing of these 
conjugates can then occur, and this is considered by some to constitute a third phase 
of xenobiotic metabolism (Gibson & Skett, 1994).
Subsequent to glutathione conjugation, a glutamyltranspeptidase, and a peptidase can 
further metabolise the conjugate, yielding the cysteine conjugate of the xenobiotic. 
The cysteine conjugate can then be N-acetylated to yield the N-acetylcysteine 
conjugate or mercapturic acid (Gibson & Skett, 1994). Depending on the substrate 
and species involved the glycylcysteine and cysteine conjugates and the mercapturic 
acids may occur as excretion products.
Sulphur-containing conjugates secreted in bile can also be further metabolised by an 
enzyme in the gut called C-S lyase (or cysteine conjugate p-lyase).
Table 1-2 The reactions of Phase 2 drug metabolism
Reaction Enzyme Functional group 
to be conjugated
Glucuronidation UDP-Glucuronyltransferase -OH
Glycosidation UDP-Glycosyltransferase
-COOH
-NH2
-SH
-OH
Sulfation Sulfotransferase
-COOH
-SH
-NH2
Méthylation Methyltransferase
-SO2NH2
-OH
-OH
Acétylation Acetyltransferase
-NH2
-NH2
-SO2NH2
Amino acid conjugation
-OH
-COOH
Glutathione conjugation Glutathione-S-transferase Epoxide
Organic halide
Fatty acid conjugation -OH
Condensation Various
(Gibson & Skett, 1994)
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1.1.1.4 Factors affecting metabolism of xenobiotics
A range of factors can affect the metabolism of a xenobiotic by an enzyme, as 
summarised in Figure 1-1. These may be divided into factors that affect the 
concentration of the drug at the site of the enzyme, and those that affect the level of 
enzyme activity.
The intracellular concentration of a chemical is primarily dependent on dose, route of 
administration and physicochemical and structural properties such as electrophilicity, 
nucleophilicity, lipophilicity, polarity and plasma protein binding (Gibson & Skett, 
1994).
Factors that can affect the level of expression or the activity of an enzyme include 
age, gender, species, strain, pathology, genetic differences (e.g. polymorphisms), 
cofactor availability, nutrition and enzyme inhibition or induction by other 
xenobiotics.
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1.2 The cytochrome P450 superfamily
The cytochrome P450 (P450) superfamily is the term used to group a large number of 
structurally similar haem-thiolate proteins that have been identified in both eukaryotes 
(animals, fungi and plants) and prokaryotes. It has been proposed (Nelson et ah,
1993) that this gene superfamily has existed for more than 3.5 billion years, evolving 
at a non-linear rate.
1.2.1 General properties of cytochromes P450
P450s are mono-oxygenase enzymes ranging in size from 45 to 60 kDa (Gonzalez & 
Gelboin, 1991; Gonzalez & Gelboin, 1992), first identified in 1958 (Klingenberg, 
1958) and isolated in 1964 (Omura & Sato, 1964a; Omura & Sato, 1964b). With the 
exception of bacterial P450 isozymes, they are intrinsically membrane bound (the 
majority is attached to the endoplasmic reticulum of cells, however some forms are 
bound to the mitochondrial membrane). The term P450 derives from the fact that 
after binding of carbon monoxide to the reduced (ferrous) form these enzymes exhibit 
light absorption maxima at 450nm. All P450s contain iron protoporphyrin IX as the 
prosthetic group (Figure 1-2), and thus contain a haem-binding domain (including a 
cysteine residue), located near the carboxyl terminus of the polypeptide chain, which 
is conserved in all cytochrome P450s studied, from bacterial to mammalian forms 
(Gibson & Skett, 1994).
P450s are capable of the metabolism of vast numbers of structurally diverse substrates 
that are related only by their apparent lipophilicity. The bacterial forms generally 
have high substrate specificity, the mitochondrial forms tend to be involved in highly
specific steroid hydroxylations and those forms bound to the endoplasmic reticulum 
of the cell generally have broad substrate specificities (Gonzalez & Gelboin, 1992). 
P450-dependent reactions play a vital role in the biosynthesis and metabolism of a 
large number of endogenous compounds such as steroids, bile acids, fatty acids, 
prostaglandins, leukotrienes, biogenic amines, phytoalexins and retinoids (Nelson et 
al., 1993). These enzymes are also responsible for the metabolism of a vast range of 
xenobiotics including drugs, natural plant products and environmental pollutants 
(Nelson et al., 1996).
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1.2.2 Catalytic cycle of cytochromes P450
The mixed function oxidase (MFO) system consists of cytochrome P450 (the terminal 
oxidase), NADPH-cytochrome P450 reductase (a flavoprotein, sometimes termed 
NADPH-cytochrome c reductase) and a lipid component (Gibson & Skett, 1994).
The overall reaction of cytochrome P450-catalysed mixed function oxidation 
conforms to the following stoichiometry where RH represents the substrate, and ROH 
represents the oxidised metabolite; subsequent decomposition or rearrangement of the 
metabolite may occur. The reaction requires the presence of both NADPH and 
molecular oxygen, in addition to the components of the mixed function oxidase 
system.
NADPH + H ++O 2 +RH .. Cytochrome P450  ^ + H^O + ROH
The haemoprotein component of cytochrome P450 is both the oxygen- and substrate- 
binding locus, its key feature being the ability of the haem iron to undergo cyclic 
oxidation/reduction reactions in conjunction with the associated NADPH-cytochrome 
P450 reductase.
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NADPH-cytochrome P450 reductase is a vital component of the MFO system due to 
the ability of the flavoprotein to transfer reducing equivalents from NADPH + H  ^to 
cytochrome P450 in the following manner (Gibson & Skett, 1994).
NADPH + H+ —^  (FAD P450 reductase  ^  ^Cytochrome P450
The precise role of the lipid component is unclear; however it may facilitate electron 
transfer, provide a template for the interaction of cytochrome P450 and NADPH- 
cytochrome P450 reductase molecules or may be required for substrate binding 
(Gibson & Skett, 1994).
The catalytic cycle begins with the binding of the substrate to the oxidised P450 
enzyme, followed by haem reduction and binding of molecular oxygen; this is 
followed by electron rearrangement, oxygen insertion and product release. The 
catalytic cycle is illustrated in more detail in Figure 1-3. Some examples of reactions 
performed by the microsomal mixed function system are detailed in Table 1-3.
12
Figure 1-2 Iron protoporphyrin IX
CH.
N— Fe —N
CH=CH.COOHCHXH:
COOHCHgCHg CH3
(Taken from Gibson & Skett, 1994)
Figure 1-3 Catalytic cycle of cytochrome P450
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bg reductase
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Fe-RH
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NADPH-cytochrome 
P450 reductase NADPH
Fe2+-RH
RH = Drug substrate; ROH = hydroxylated metabolite 
* May provide a source of 2^  ^electron input for some 
P450s and some substrates (Schenkman et al., 1994). 
(Taken from Gibson & Skett 1994)
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Table 1-3 Reactions performed by the mixed-function oxidase system
Reaction Substrate
Aromatic hydroxylation Lignocaine
Aliphatic hydroxylation Pentobarbitone
Epoxidation Benzo[a]pyrene
N-Dealkylation Diazepam
0-Dealkylation Codeine
S-Dealkylation 6-Methylthiopurine
Oxidative deamination Amphetamine
N-Oxidation 3-Methylpyridine
2-Acetylaminofluorene
S-Oxidation Chlorpromazine
Phosphothionate oxidation Parathion
Dehalogenation Halothane
Alcohol oxidation Ethanol
(Gibson & Skett, 1994)
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1.2.3 Classification and nomenclature of cytochromes P450
Much of the early literature refers to individual P450s by ‘trivial’ names, some P450s 
having several such names (for example the protein product of rat CYP2B1 has been 
referred to as P450 b, PB-4, PB-B and PBRLM 5 (Nelson et ah, 1993)). To eliminate 
the confusion caused by the existence of multiple names for the same enzyme, a 
classification of P450s according to their primary amino acid sequence similarities 
has been proposed and generally accepted (Nelson et al., 1993). Within this system a 
P450 protein sequence from one gene family is defined as usually having < 40% 
amino acid identity to a P450 protein from any other family. Mammalian sequences 
within the same subfamily are always >55% identical.
Each P450 gene almost always produces a single protein, there being only a few 
exceptions to this rule where “functional” alternative splicing produces an enzyme 
with new catalytic activity (Nelson et al., 1993).
The recommended system for naming a P450 gene or cDNA is as follows: 
Cytochrome P450 denoted by: GYP (or Cyp for the mouse)
Family denoted by: Arabic number.
Subfamily denoted by: capital letter (lower case for mouse)
Individual gene: Arabic number (in mouse: Arabic number)
E.g. Rat: CYP2A1
E.g. Human: CYP2A6 
E.g. Mouse: Cyp2a5
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To date, genes within a defined subfamily have been found to lie within the same 
“gene cluster”; this is referred to as non-segregating. It is probable that such clusters 
have arisen via gene duplication events, mostly during the last 400 million years and 
it is thus expected that each subfamily might be a genetically segregating distinct 
entity (Nelson et al., 1993).
Thus far 74 gene families have been described of which 14 exist in all mammals 
examined to date; these 14 families comprise 26 subfamilies of which 20 have been 
mapped in the human genome (Nelson et al., 1996).
Table 1-4 illustrates the identified functions of the mammalian P450 families.
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Table 1-4 The functions of the mammalian P450 families
P450 Family General functions
CYPl Metabolism of polycyclic hydrocarbons, halogenated and 
heterocyclic hydrocarbons, and aromatic amines
CYP2 Metabolism of drugs and environmental chemicals
CYP3 Metabolism of drugs and environmental chemicals
CYP4 Fatty acid hydroxylases
CYP5 Thromboxane synthase
CYP7A Cholesterol 7a-hydroxylase
CYP7B Unknown
CYP8 Prostacyclin synthase
CYPll Cholesterol side-chain cleavage, steroid 11 p-hydroxylase, and 
aldosterone synthase (mitochondrial enzyme)
CYP17 Steroid 17a-hydroxylase
CYP19 Aromatisation of androgens
CYP21 Steroid 21-hydroxylase
CYP24 Steroid 24-hydroxylase (mitochondrial enzyme)
CYP27 Steroid 27-hydroxylase (mitochondrial enzyme)
CYP51 Sterol biosynthesis
(Adapted from Nelson et al., 1996)
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1.3 Cytochrome P450 expression
P450s are expressed in almost every cell in a mammalian body but this expression is 
highly tissue-specific for individual P450s with the highest P450 concentrations being 
found in the liver. Within a specific tissue the expression of a particular P450 is 
frequently clearly zonated; this is notably marked in the mature mammalian liver 
where most of the cytochrome P450 genes are constitutively expressed and induced in 
the perivenous region within the acinus, the microcirculatory unit of the liver 
(Oinonen & Lindros, 1994; Gebhardt, 1992). The total hepatic expression and 
zonation of a number of CYP genes is affected by pituitary dependent hormones, 
including growth hormone (GH) and thyroid hormones. This has been demonstrated 
in rats where it has been shown that these hormones repress the expression of 
CYP2B1, CYP2B2 and CYP3A2 (Oinonen & Lindros, 1994; Oinonen & Lindros, 
1995).
The major P450s expressed in adult human liver include CYP1A2, the CYP2C 
subfamily, CYP2D6, CYP2E1 & CYP3A4 (Figure 1-4).
Very little data is available regarding the expression of individual P450s in human 
foetal liver. CYP^ 2C8-10 appear to be absent, explaining the observation that 
hydroxylations of mephenytoin, tolbutamide and benzopyrene are very low (Shimada 
et al., 1986; Knodell et al., 1987; Jacqz-Aigrain & Cresteil, 1992). In contrast, 
ethylmorphine N-demethylase associated with the CYP3A subfamily reaches 75% of 
adult activity (Jacqz-Aigrain & Cresteil, 1992).
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Extremely large variation, both inter-individual and inter-ethnic, has been observed in 
the expression of P450s in humans (Watkins, 1992). This is due to the influence of a 
range of factors as described above (Section 1.1.1.4) and in more detail later (Section 
1.3.1). Many xenobiotics, including drugs, dietary factors and environmental 
contaminants, are capable of altering the level of a particular P450 either through 
inhibition or induction. A number of genetic polymorphisms in P450s have also been 
identified within human sub-populations; these are discussed in more detail later 
(Section 1.3.2). Differences in expression can lead to unpredictable responses to 
drugs, and to altered susceptibility to carcinogenesis or other forms of toxicity (Daly 
et al., 1993).
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Figure 1-4 The cytochrome P450 composition of human liver
2B6
3A4
28.8%
Other
28.0%
12.7%
18.2%
(Shimada et al., 1994)
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1.3.1 Cytochrome P450 regulation
The level of expression of a specific CYP gene within a specific tissue may be 
controlled by a number of different factors. As well as regulation by genetic factors, 
P450 expression is controlled or influenced by both other endogenous factors and by 
xenobiotic exposure. Examples of endogenous factors capable of affecting the 
expression of some CYP genes include cytokines (e.g. interleukin-6 represses the 
expression of CYP3A4, (Muntane-Relat et al., 1995)) and hormones, including those 
of the pituitary and adrenal glands, and the sex hormones (androgens and estrogens) 
(Chen et al., 1994; Larsen et al., 1994).
Many P450s are constitutively expressed, whereas a number are expressed only in the 
presence of an inducer. Constitutive gene expression is often subject to sex-specific 
or developmental regulation, occurring at the transcriptional level, as is observed 
amongst members of the rat CYP2C subfamily, which are also inducible (Waxman & 
Azaroff, 1992). For example CYP2C11 and CYP2C13 are male-specific, whereas 
CYP2C12 is female-specific; this sexual dimorphism occurs in response to different 
patterns of growth hormone secretion that are under the control of androgens and 
estrogens respectively (Chen et al., 1994; Larsen et al., 1994).
Developmental regulation is important in the expression of many P450s and 
frequently involves the switching on of genes during development that were inactive 
at birth, in response to hormone changes (for example those occurring during 
puberty). Rat CYP2C6 is activated 3 weeks after birth by the albumin D region 
binding protein (DBF), reaching maximal transcriptional activation at puberty, 
corresponding to the production of DBP (Yano et al., 1992).
The transcriptional mechanisms of developmental control frequently involve 
hepatocyte nuclear factors (HNFs), as is seen with the developmental control of
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CYP2E1 by HNFl-a in the developing rat (Mendel & Crabtree, 1991). 
Developmental regulation is also an important factor in the expression of human 
genes, as in the case of the human CYP3A7 gene which is present in the foetus and is 
largely replaced by CYP3A4 shortly after birth (Komori et al., 1990).
P450s of the CYPll, CYP 17 and CYP21 families, active in the metabolism of 
endogenous steroids, are under the control of the second messenger cAMP via 
upstream regulatory regions in response to the peptide hormone adrenocorticotrophic 
hormone (ACTH) (Honda et al., 1993).
The expression of a gene involves several stages. Initially the gene is unwound ftrom 
the chromatin; RNA polymerase then binds to the promoter, transcribing the DNA 
into a pre-mRNA copy of the gene, which is then processed to give mRNA. The 
mRNA is then modified by splicing, after which it is transported into the cytoplasm 
where it is translated into the apoprotein, which itself may be further modified (e.g. by 
glycosylation or phosphorylation) to produce the active enzyme. Factors modulating 
the level of expression of a particular P450 may act at one or more different levels 
within the expression process (Goldfarb, 1990), as is summarised in Figure 1-5.
The regulatory region of the gene, which controls the rate of transcription of the 
coding region of the gene, may contain a variety of transcription factor binding sites 
to which both xenobiotic or endogenous compounds may bind, either directly or via a 
receptor, to up- or down-regulate the expression of the gene (Goldfarb, 1990).
In the case of receptor-mediated induction, the activation of the gene involves the 
binding of the inducer to a cytosolic receptor. The ligand-receptor complex then 
translocates to the nucleus, binding to transcriptional enhancer elements located in the 
upstream regulatory region of the target gene, referred to as xenobiotic response 
elements (XREs). Response elements consist of a specific consensus sequence that is
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recognised by the ligand receptor complex. Binding of the complex to the XRE 
causes an increase in the rate of transcription from the promoter, thus increasing 
levels of mRNA, thereby leading to increased protein product of the target gene 
(Gonzalez, 1989).
1.3.1.1 The aromatic hydrocarbon (Ah) receptor
The induction of the CYPlAl gene by polycyclic aromatic hydrocarbons (PAHs) 
such as benzo[a]pyrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) has 
been shown to be mediated by the Ah receptor in rats, mice and humans (Hoffman et 
al., 1991; Carrier et al., 1994; Boucher et al., 1995; Boobis et al., 1990). Isolation and 
characterisation of the Ah receptor (Ema et al., 1992) has shown that it contains a 
basic helix-loop-helix structure, characteristic of many transcription factors including 
the Drosophila Per and Sim proteins, and the Ah receptor nuclear translocator protein 
(Amt) (Hoffrnan et al., 1991; Ema et al., 1992). In the absence of ligand, the Ah 
receptor is associated with a dimer of the heat-shock protein Hsp90; upon ligand 
binding the Hsp90 dimer dissociates and Amt binds, forming a complex capable of 
binding to AhREs (Ah receptor responsive elements). AhREs, located approximately 
Ikb upstream of the CYPlAl gene, contain a specific TCACGC sequence which has 
been shown to behave as an inducible enhancer of CYPlAl gene transcription 
(Kubota et al., 1991). There is also evidence supporting the existence of negative 
regulatory elements involved in both rat and human CYPlAl regulation (Boucher et 
al., 1993).
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1.3.1.2 The peroxisome proliferator activated receptor (PPAR)
Isozymes of the CYP 4A family are involved in the hydroxylation of lipid substrates 
such as fatty acids and prostaglandins (Sharma et ah, 1989). They are inducible at the 
transcriptional level by xenobiotics known as peroxisome proliferators (PPs), which 
include some hypolipidaemic drugs (e.g. clofibrate), industrial plasticisers (e.g. 
phthalate esters) and environmental contaminants such as herbicides (Hardwick et al., 
1987; Moody et al., 1991). In rats, PPs act as non-genotoxic carcinogens, producing 
hepatomegaly as a result of liver hyperplasia (Reddy & Lalwai, 1983).
Much work has been carried out to investigate the molecular toxicology of PPs in an 
attempt to determine the risk posed to man by exposure to these chemicals. CYP4A 
induction is believed to act via receptors termed peroxisome proliferator activated 
receptors (PPARs), the first of which to be isolated was the mouse PPAR (Issemann 
& Green, 1990). The PPAR gene family consists of four closely related PPAR 
subtypes, a, p, y and 5 which are members of the steroid hormone receptor 
superfamily (Tugwood et al., 1996). The a  subtype is the major isoform involved in 
CYP4A induction (Aldridge et al., 1995).
PPAR binds to upstream enhancer elements (PPREs), which display the consensus 
sequence TGACCT separated by Ibp. It has also been demonstrated that dimérisation 
and co-operative binding of PPAR and retinoid X receptors (RXRs) to the PPREs 
(when bound to their cognate ligands) is necessary for transcriptional induction 
(Kleiwer et al., 1992). At present the precise molecular mechanisms involved in 
PPAR activation are unclear and it remains to be established whether the PPAR is 
involved in all the hepatic pleiotropic effects of PPs observed on the liver (Stringer,
1992), although by using gene knockout mice, it has been established that enzyme
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induction does not occur (Lee et al., 1995) and the carcinogenic response does not 
occur in response to PPs (Gonzalez,F.J., personal communication).
1.31.3 Other mechanisms of induction
A number of other P450s are inducible at the transcriptional level by xenobiotics, but 
in many of the cases the molecular mechanisms require further elucidation.
For example, several P450 isoforms, including CYP2A, CYP2B, CYP2C and 
CYP3A, are inducible at the transcriptional level by phenobarbitone (PB) and related 
barbiturates (Larsen et al., 1994), however no receptor proteins have yet been isolated. 
Several possible mechanisms of PB-mediated induction have been proposed, 
including receptor-dependant mechanisms or a situation where PB blocks the 
metabolism of a repressor precursor, or an endogenous inducer (causing accumulation 
of that inducer) (Waxman & Azaroff, 1992; Shaw et al., 1993).
Specific regulatory sequences, termed ‘barbie boxes’ have been identified in 
eukaryotic and prokaryotic PB-inducible genes, and have been implicated in the 
induction response (Liang et al., 1995; He & Fulco, 1991). In the rat CYP2B2 gene 
responsive elements (REs) have been identified that bind proteins that are enriched in 
response to PB-treatment (Shephard et al., 1994). REs have also been identified that 
appear to be involved in PB-induction in reporter gene assays (Trottier et al., 1995). 
The CYP3A subfamily is inducible at the transcriptional level by a number of agents, 
including dexamethasone, in species such as the rat, rabbit and human (Schuetz et al., 
1993; Barwick et al., 1996). The molecular mechanisms involved are still being 
elucidated (Quattrochi et al., 1995; Barwick et al., 1996; Huss et al., 1996) and are 
discussed in more detail in Sections 1.4.4 and 1.7.
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Regulation of P450s at the post-transcriptional level has also been demonstrated; for 
example mRNA stabilisation is observed in CYP1A2 induction (Okey, 1990).
Several mechanisms of induction may occur in the response of a single gene to a 
single inducer; for example the CYP3A1/CYP3A23 genes are induced by 
dexamethasone and PCN at both the transcriptional stage and by mRNA stabilisation 
(Simmons et al., 1987). Little is known about the mechanism of mRNA stabilisation. 
Other identified mechanisms include increased mRNA translation and post- 
translational regulation. In the case of CYP2E1, protein product stabilisation and 
inhibition of degradation of the CYP2E1 apoprotein appear to be the primary 
mechanisms of induction (Song et al., 1989). There is evidence that post-translational 
mechanisms are also involved in CYP3A1/CYP3A23 and CYP3A2 induction by 
dexamethasone (Eliasson et al., 1994; Telhada et al., 1992).
1.3.14 Inhibition and down regulation
Substances may act to inhibit or down regulate P450s by a number of different 
mechanisms.
Negative regulation of cytochrome P450s can occur at the post-translational level. 
Protein kinase A appears to be involved in the regulation of cytochrome P450 activity, 
whereby phosphorylation of serine at a conserved target site leads to the inactivation 
of several P450 isoforms, including CYP2B1, CYP2C2 and CYP2E1 (Goldfarb,
1990). The mechanisms by which the cytokines and growth factors down-regulate 
P450 expression have not been elucidated (Muntane-Relat et al., 1995).
Mechanisms of inhibition include interference with the synthesis or degradation of the 
enzyme, the depletion of cofactors or direct interaction with the enzyme.
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Direct interaction with the enzyme may involve either reversible (competition at 
active site) or irreversible (formation of metabolite-intermediate complex or 
autocatalytic inactivation) inhibition of enzyme activity.
Several mechanisms of substrate-mediated P450 inactivation have been characterised 
including destruction of the prosthetic haem via N-alkyl/arylation (i.e. secobarbital), 
haem destruction by products that irreversibly bind to the apocytochrome (i.e.CCU), 
and apocytochrome alkylation by a reactive intermediate (i.e. chloramphenicol) 
(Halpert et al., 1994).
In mechanism-based inactivation the parent drug is non-inhibitory and requires at 
least one catalytic cycle of the enzyme before it is activated to the inhibitory species. 
Examples of this include the 17a-acetylenic steroids such as ethinylestradiol and the 
progestin gestodene, which act in this way to selectively destroy the CYP3 A4 enzyme 
(Guengerich, 1990).
P450 inhibitors containing alkylamine-based groups may be oxidised to nitroso 
metabolites that have a high affinity for the ferrous (reduced) form of P450, 
sequestering it irreversibly in a catalytically inactive state. To restore activity, new 
synthesis of the enzyme is required which takes a couple of days (Murray, 1992). 
Triacetyloleandomycin (TAG) induces its own metabolism to form a demethylated 
metabolite that forms a complex with P450 leading to inactivation of the enzyme and 
inhibition of activity; a similar reaction occurs with the macrolide antibiotic 
erythromycin (Pessayre et al., 1981).
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Figure 1-5 Mechanisms of induction of cytochrome P450
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1.3.2 Polymorphisms
Bimodal or highly variable metabolism of a xenobiotic can sometimes be attributed to 
polymorphisms within the gene coding for the enzyme responsible for its metabolism 
(Daly et al., 1993). Polymorphisms are differences (e.g. insertions or deletions) or 
mutations in either the regulatory or the coding region of a gene. Changes within the 
regulatory region can affect the modulation of expression of the gene both by 
endogenous and exogenous compounds thus altering the rate of transcription of the 
gene, whereas alterations in the coding region can lead to aberrant mRNA splicing 
and/or changes in the amino acid sequence of the protein resulting in altered catalytic 
activity.
Polymorphisms have been described for both phase 1 and phase 2 enzymes. These 
polymorphisms can significantly alter the effectiveness of drug therapy and the 
susceptibility to toxicity, cancer and other disease states (Daly et al., 1993).
The first such P450 polymorphism elucidated involved the human CYP2D6 gene 
(Nakamura et al., 1987) which is important in the metabolism of a number of 
clinically important drugs including cardiovascular agents such as debrisoquine and 
propranolol, psychotropic agents such as imipramine and thioridazine, as well as other 
compounds such as codeine (Daly et al., 1993). Approximately 5-10% of Caucasians 
and 1% of Asian populations catalyse the oxidation of debrisoquine and other 
CYP2D6 substrates at a reduced rate (Nakamura et al., 1987). The human CYP2D6 
gene has been analysed and 21 different polymorphisms have been identified within 
the coding region of the gene to date, leading to aberrant mRNA splicing and/or 
protein products with abnormal enzymatic activities (Daly et al., 1993).
These polymorphisms can give rise to wide inter-individual variation in drug 
metabolism (Evans et al., 1980). The CYP2D6 gene is therefore of major importance
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in drug-mediated toxicity occurring in poor metabolisers. The poor metaboliser 
phenotype has also been correlated with decreased carcinogenesis in some lung 
cancer patients, although substantial controversy still exists for this claim (Daly et al.,
1993).
Genetic polymorphisms have been identified in the human CYP2E1 5'-regulatory 
region (Nedelcheva et al., 1996) which are responsible for inter-individual variation in 
drug metabolism, such as variation in metabolism of low molecular weight 
carcinogens, including nitrosamines (Hayashi et al., 1991).
Polymorphisms have also been identified in CYPlAl, CYP1A2, the CYP2C 
subfamily, and may also occur in CYP2A6, and the CYP3A subfamily (Daly et al., 
1993; Kleinbloesem et al., 1984). Polymorphisms have also been identified in other 
phase 1 enzymes (such as serum cholinesterase) and phase 2 enzymes such as the 
glutathione S-transferase family (Daly et al., 1993).
Further study of these polymorphisms is therefore important for the accurate 
prediction of drug-mediated toxicity and for improved understanding of human 
susceptibility to disease states such as xenobiotic-induced cancer.
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1.4 The CYP3A Sub-family
To date, at least 23 CYP3 A genes have been identified in a variety of mammalian 
species (Table 1-5). All of the isozymes within the CYP3 family exhibit greater than 
70% sequence similarity, and are thus grouped as belonging to one sub-family:
CYP3 A. The apparent CYP3A phylogenetic conservation and the localisation of the 
human CYP3A genes to the same chromosome suggests that CYP3A genes evolved 
through a process of DNA mediated duplication of a primordial CYP3A gene 
(Schuetz & Guzelian, 1995).
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Table 1-5 CYP3A subfamily members identified to date
Gene symbol Trivial name Species
CYP3A1 pcnl, PCNa, 6p-4, pIGC2 Rat
CYP3A2 pcn2, PCNb/c, PB-1, 6P-1/3 Rat
CYP3A3 HLp Human
CYP3A4 nf-25, hPCNl, nf-10 Human
CYP3A5 hPCN3, HLp2 Human
CYP3A5P 3A5P (pseudogene) Human
CYP3A6 3c Rabbit
CYP3A7 HFLa, HFL33, HLp2 Human
CYP3A8 MKnf2 Monkey
CYP3A9 olf3 Rat
CYP3A10 Hamster
CYP3a-ll IIIAml Mouse
CYP3A12 PBD-1 Dog
CYP3al3 IIIAm2 Mouse
CYP3A14 Guinea Pig
CYP3A15 Guinea Pig
CYP3al6 Mouse
CYP3A17 Guinea Pig
CYP3A18 Rat
CYP3A19 Dwarf Goat
CYP3A20 Guinea Pig
CYP3A21 Marmoset
CYP3A22 Miniature Pig
CYP3A23 cDEX, RL33, 6p4 Rat
(Adapted from Nelson et a l, 1993 & Nelson et al., 1996)
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1.4.1 Human CYP3A
The human CYP3A subfamily consists of four highly homologous genes (CYP3A3, 
CYP3A4, CYP3A5 and CYP3A7) and one pseudogene (CYP3A5P). CYP3A5P was 
isolated from a human cDNA library and contains several large insertions, deletions 
and in-frame termination codons. It has yet to be determined whether this is a 
processed or non-processed CYP3A pseudogene (Schuetz & Guzelian, 1995).
The CYP3A locus is positioned on chromosome 7, at position 7q22.1, where 
CYP3A7 and CYP3A5 have been reported to lie in tandem in the human genome 
(Nelson et al., 1993; Jounaidi et al., 1994; Brooks et al., 1988).
It is currently unclear whether CYP3A3 and CYP3A4 represent the product of distinct 
genes at different genetic loci, or whether they represent alleles corresponding to an 
identical genetic locus (Watkins, 1994). These genes are so highly related (98% 
sequence homology (Watkins, 1994) that their relative expression at the mRNA level, 
as determined by oligonucleotide hybridisation, is in dispute (Bork et al., 1989; 
Schuetz et al., 1989) and at the protein level is unknown (Wrighton et al., 1989).
The purified proteins migrate in SDS-polyacrylamide gels at slightly different 
apparent molecular weights: P450 3A3/4: 51kDa; P450 3A7: 51.5 kDa and P450 3A5: 
52kDa (Schuetz et al., 1993).
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1.4.1.1 Sequence comparisons
All the isozymes of the human CYP3A subfamily exhibit a high degree of homology. 
CYP3A3 and CYP3A4 differ by only 11 of 503 amino acids (Molowa et al., 1986; 
Schuetz et al., 1994). From a comparison of full-length sequences, CYP3A3 and 
CYP3A4 have been reported to exhibit 98% similarity. CYP3A5 has 84% similarity 
with CYP3A4 (Aoyama et al., 1989) and 88% similarity with CYP3A7 (Schuetz et 
al., 1994). CYP3A7 and CYP3A4 have 87% similarity between amino acids 
(Hashimoto et al., 1993; Maenpaa et al., 1993).
1.4.1.2 CYP3A regulatory region comparisons
Sequence comparisons of the 5'-flanking regions of CYP3A4 (+1 to -1255), CYP3A5 
(+1 to -1250) and CYP3A7 (+1 to -1174) have demonstrated that the 5'-flanking 
region of CYP3A4 is approximately 92% similar to the corresponding region of 
CYP3A7. Between nucleotides -1 to -700 CYP3A4 is 74% similar to CYP3A5, 
however this similarity drops to less than 42% upstream from -700, indicating that a 
gene modification event has occurred in the CYP3A5 gene (Hashimoto et al., 1993). 
The 5'-flanking region of each of the human CYP3A isozymes contains putative 
binding sites for transcriptional regulatory factors including the oestrogen receptor, 
the glucocorticoid receptor, the octamer-binding protein (Oct 1), the CAAT-binding 
protein (CP-1), hepatic nuclear factors -4 and -5, and P53 (Hashimoto et al., 1993;
Itoh et al., 1992; Jounaidi et al., 1994).
The major identified regulatory regions of CYP3A4, CYP3A5 and CYP3A7 are 
illustrated in Figure 1-6. Regions marked with a question mark in the flanking 
regions of CYP3A4, CYP3A5 and CYP3A7 have been reported (Hashimoto et al.,
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1993; Itoh et al., 1992; Jounaidi et al., 1994) but bear either little or no sequence 
similarity with the consensus sequences reportedly used in their determination (Dr. N. 
Plant, personal communication); for example the PRE/GRE of CYP3A4/CYP3A7 has 
the sequence AAGAACCCAGAACC, whereas the consensus sequence is 
GGTACAnnnTGTTCT (Beato, 1989).
Regions marked GRE* or ERE* in CYP3A4 or CYP3A5 were determined by 
computer analysis (Vector Nti v4.0) (Dr. Nick Plant, personal communication) using 
consensus sequences (Beato, 1989).
Sequence alignments have identified specific motifs in each of the 5' flanking regions. 
CYP3A4 contains a motif termed NFSE (-287 to -296) (Hashimoto et al., 1993), 
CYP3A5 contains a motif termed 3A5SE (-369 to -381) (Jounaidi et al., 1994), and 
CYP3A7 contains a motif HFLaSE (-729 to -737) (Itoh et al., 1992). Both NFSE and 
HFLaSE motifs are present but mutated in CYP3A5. Several deletions exist in the 5'- 
fianking region of CYP3A5 with respect to CYP3A4 and CYP3A7, notably one of 
fifty nucleotides from -60 to -110 and six of smaller size from -842 to -1150 
(Jounaidi et al., 1994). The role of these specific elements in the regulation of the 
genes is currently unclear.
In addition, the promoter of CYP3A5 contains a CATA box (TATA box in CYP3A4 
and CYP3A7), and a basic transcription element (BTE) which contains two 
differences compared to the BTE in CYP3A4 and CYP3A7.
It is important to note however that these putative sites have been assigned purely by 
computerised sequence analysis on the basis of 50% or greater sequence homology. 
No conclusive functional evidence is available.
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Figure l-6a Sequence of CYP3A4 (-1105 to +1 bp)
- 1 1 0 5  CTGCAGTGACCACTGCCCCATCATTGCTGGCTGAGGTGGTTGGGGTCCATCTGGCTATCTGGGCAG 
C o n s t r u c t  s t a r t  GRE
-1 0 3 9  CTGTTCTCTTCTCTCCTTTCTCTCCTGTTTCCAGACATGCAGTATTTCCAGAGAGAAGGGGCCACT
-  9 7 3  CTTTGGCAAAGAACCTGTCTAACTTGCTATCTATGGCAGGACCTTTGAAGGGTTCACAGGAAGCAG
-  9 0 7  CACAAATTGATACTATTCCACCAAGCCATCAGCTCCATCTCATCCATGCCCTGTCTCTCCTTTAGG
-  8 4 1  GGTCCCCTTGCCAACAGAATCACAGAGGACCAGCCTGAAAGTGCAGAGACAGCAGCTGAGGCACAG
-  7 7 5  CCAAGAGCTCTGGCTGTATTAATGACCTAAGAAGTCACCAGAAAGTCAGAAGGATGCATAGCAGAG
-  7 0 9  GCCCAGCAATCTCAGCTAAGTCAACTCCACCAGCCTTTCTAGTTGCCCACTGTGTGTACAGCACCC
-  6 4 3  TGGTAGGGACCAGAGCCATGACAGGGAATAAGACTAGACTATGCCCTTGAGGAGCTCACCTCTGTT
-  5 7 7  CAGGGAAACAGGCGTGGAAACACAATGGTGGTAAAGAGGAAAGAGGACAATAGGATTGCATGAAGG
-  5 1 1  GGATGGAAAGTGCCCAGGGGAGGAAATGGTTACATCTGTGTGAGGAGTTTGGTGAGGAAAGACTCT
-  4 4 5  AAGAGAAGGCTCTGTCTGTCTGGGTTTGGAAGGATGTGTAGGAGTCTTCTAGGGGGCACAGGCACA
-  3 7  9 CTCCAGGCATAGGTAAAGATCTGTAGGTGTGGCTTGTTGGGATGAATTTCAAGTATTTTGGAATGA
-  3 1 3  GGACAGCCATAGAGACAAGGGCAAGAGAGAGGCGATTTAATAGATTTTATGCCAATGGCTCCACTT
-  2 4 7  GAGTTTCTGATAAGAACCCAGAACCCTTGGACTCCCCAGTAACATTGATTGAGTTGTTTATGATAC
-  1 8 1  CTCATAGAATATGAACTCAAAGGAGGTCAGTGAGTGGTGTGTGTGTGATTCTTTGCCAACTTCCAA
-  1 1 5  GGTGGAGAAGCCTCTTCCAACTGCAGGCAGAGCACAGGTGGCCCTGCTACTGGCTGCAGCTCCAGC
C o n s t r u c t  e n d
4 9 CCTGCCTCCTTCTCTAGCATATAAACAATCCAACAGCCTCACTGAATCACTG + 1
TATA b o x
This sequence is numbered upstream from the transcription start site (+1). The region 
between -1087 and -57bp has previously been engineered into the pCMV-cSPAP 
plasmid (Williams J. 1997) as illustrated in Figure 2-1 and Figure 2-la.
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1.4.2 CYP3A expression in humans
Studies on the regulation of expression of the individual human P450 3A isozymes 
have been severely hampered by the lack of probes that specifically recognise a single 
member of these immunochemically related gene products. In addition, studies using 
either oligonucleotide or partial cDNA probes are capable of determining only the 
presence of mRNA encoding a protein and not whether the protein itself is being 
expressed (Schuetz et al., 1994; Wrighton et al., 1990). These problems, coupled 
with the wide variation in expression of the CYP3 A isoforms in some tissues, have 
led to much disagreement in the literature about expression of the CYP3 A subfamily.
1.4.2.1 CYP3A expression in the liver
Cytochromes P450 belonging to the CYP3A gene subfamily account for 
approximately 25% of the total cytochrome P450 present in adult human liver 
(Watkins, 1994), although this has been reported to vary between 10-60% 
(Guengerich, 1990; Krivoruk et al., 1994). The source of this population 
heterogeneity in CYP3A expression is still not fully understood. Reasons proposed 
include the inductive effects of xenobiotic agents (either environmental, dietary or 
therapeutic), some form of genetic polymorphism, or the result of underlying disease- 
or injury- related hepatocellular damage, or aberrant secretion patterns for hormones 
that may be involved in CYP3A regulation (Thummel et al., 1994a).
There are conflicting reports as to whether any gender difference in CYP3A 
expression in adult liver exists in humans, with a higher expression being reported in 
females by some workers (Hunt et al., 1992; Horsmans et al., 1992) but not others 
(Schuetz et al., 1994). Hepatic CYP3A expression does not appear to be affected by 
ageing (Hunt et al., 1992).
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In the adult liver, CYP3A4 generally accounts for the majority of CYP3A subfamily, 
although the levels are highly variable (Schuetz et ah, 1994).
CYP3A5 is expressed polymorphically in 10-30% of adult human livers in variable 
amounts, accounting for 6 to 60% (Wrighton et ah, 1990; Schuetz et ah, 1994), and in 
one reported case 100%, of the total cytochrome P450 3A family in those livers in 
which it is expressed (Aoyama et ah, 1989). Hepatic CYP3A5 appears to be 
expressed in a greater percentage of children compared with adults (Wrighton et ah, 
1990).
The presence of CYP3A7 mRNA has been demonstrated in 54% of adult livers 
(Schuetz et ah, 1994) but the protein appears to be expressed at low levels only 
(Kitada et ah, 1985; Komori et ah, 1988).
The CYP3 A content of foetal microsomes is approximately one third of the adult 
content (determined using a polyclonal antibody (Cresteil et ah, 1985)). A number of 
studies have demonstrated differences in substrate specificity between adult and foetal 
livers, providing evidence for differences in CYP3A isozymes between adults and 
foetuses (Jacqz-Aigrain & Cresteil, 1992; Wrighton et ah, 1990; Ladona et ah, 1989). 
The presence of CYP3A3/4 mRNA in the foetus is disputed; CYP3A3/4 has not been 
detected in foetal liver at the protein level, however a CYP3A3/4 protein has been 
identified in the liver of a 2-month old infant (Wrighton et ah, 1990; Schuetz et ah, 
1994; Hakkola et ah, 1994).
In one study, the presence of CYP3A5 mRNA was demonstrated in 100% of foetal 
livers tested (Schuetz et ah, 1994), however the protein was only detected in 10% of 
foetal livers in a different study (Wrighton et ah, 1990).
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CYP3A7 mRNA has been detected in all foetal livers tested at similar levels to 
CYP3A5 mRNA; expression is apparently less variable (<2.5 fold) than CYP3A4 
expression in adults (Schuetz et al., 1994).
No gender differences have been observed in the foetal expression of CYP3A5 or 
CYP3A7 mRNA (Schuetz et ah, 1994).
1.4.2.2 CYP3A expression in the kidney
Highly variable CYP3A expression (up to 10-fold) has also been demonstrated in 
human kidney (Haehner, 1994). In a study (Schuetz et al., 1992) CYP3A5 was 
identified as the major CYP3A in five out of seven human kidney samples tested, 
whereas CYP3A3/4 immunoreactive protein was detected in only one of the same 
seven kidney microsome samples tested and CYP3A3/4 mRNA was not detected on 
Northern blot analyses. CYP3A5 may therefore be the major CYP3A enzyme 
expressed in adult kidney.
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1.4.2.3 CYP3A expression in the digestive tract
Isozymes of the CYP3A subfamily account for the majority of cytochrome P450 
present in the human intestine where their expression is reported to vary by greater 
than 10-fold (Kolars et al., 1992; Watkins, 1992; Watkins, 1994). This variation in 
expression does not appear to correlate with the variation in expression of the liver 
CYP3A isoforms (Lown et al., 1994).
Both CYP3 A4 and CYP3A5 have been detected both at the protein level and the 
mRNA level throughout the digestive tract. The major CYP3A protein present in 
jejunum and pancreas appears to be CYP3A4, whereas the major CYP3A protein 
present in the stomach and colon appears to be CYP3A5; CYP3A7 mRNA has not 
been detected in the digestive tract (Kolars et al., 1994; Gervot et al., 1996). 
Throughout the intestine, a zonal distribution of CYP3A expression has been 
demonstrated, with the maximal CYP3A mRNA located at the villus tip (McKinnon 
et al., 1995).
1.4.2.4 CYP3A expression in the placenta and endometrium
CYP3A7 mRNA has been detected in the placenta and endometrium as the only P450 
3 A present; levels in these tissues are highly variable, being considerably influenced 
both by the menstrual cycle and by pregnancy, becoming significantly raised during 
the second trimester of pregnancy (Schuetz et al., 1993). Placenta and endometrium 
carry out steroidogenic biotransformation reactions such as 6p-hydroxylation of 
cortisol. These tissues represent a quantitatively important site for 6p-hydroxylation
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and 16a-hydroxylation of specific steroid precursors, possibly for protection of the 
foetus from the toxic effects of endogenous steroids and foreign substrates.
14.2.5 CYP3A expression in other tissues
Expression of CYP3A has been detected in a number of human brain regions at 
considerably lower levels than those observed in the liver. Expression was reported to 
be highest in the pons region but was also detectable in the cerebellum, frontal lobe, 
occipital lobe, and red nucleus (Farin & Omiecinski, 1993).
Expression of both CYP3A4 and CYP3A5 has been detected in human lung; 
considerable inter-individual variation in expression of both CYP3A4 and CYP3A5 is 
observed, however CYP3A5 appears to be the predominant form (Anttila et al., 1997). 
CYP3A5 was the only P450 3A protein detected in adult human skin examined by 
Western blot analysis (Li et al., 1994)
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1.4.3 CYP3A catalytic activities
The human CYP3A subfamily is capable of catalysing the metabolism of a large 
range of structurally diverse substrates (Table 1-6 & Figure 1-7), including 
endogenous steroids, environmental xenobiotics (e.g. toxins and pesticides), as well as 
an estimated 60% of pharmaceuticals in current use (Cholerton et al., 1992; Jounaidi 
et al., 1994).
Studies on the catalytic selectivity of the individual human CYP3 A isoforms have 
been severely hampered by the lack of probes that specifically recognise a single 
member of these immunochemically related gene products (Schuetz et al., 1994; 
Wrighton et al., 1990), however some studies have demonstrated significant 
differences between the isozymes.
Currently CYP3A4 has exhibited all of the catalytic activities attributed to the CYP3A 
subfamily (Wrighton et al., 1990). Given the minimal differences in the coding 
regions of both mRNAs, it is very likely that the purified proteins P450 3A3 and P450 
3A4 are functionally identical. Indeed, both CYP3A3 and CYP3A4 cDNAs have 
been expressed in heterologous systems and no significant differences in catalytic 
properties have yet been reported (Aoyama et al., 1990; Watkins, 1994).
CYP3A5 appears to catalyse the metabolism of a lower number of substrates with 
lower catalytic rates than CYP3A4. For example CYP3A4 N-demethylates 
erythromycin 10 fold faster than CYP3A5 (Wrighton et al., 1990). CYP3A5 is also 
less efficient in the 6p-hydroxylation of progesterone, cortisol, testosterone and 
androstenedione than P450 3A4, and does not participate in some hydroxylations of 
cyclosporin (Aoyama et al., 1989). CYP3A5 also does not metabolise quinidine, 
17a-ethinylestradiol and aflatoxins (Wrighton et al., 1990). CYP3A5 does however
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catalyse midazolam 1'-hydroxylation more efficiently than CYP3A4 (Wrighton & 
Stevens, 1992; Gorski et al., 1994).
Far less is known about the catalytic activities of CYP3A7, however it appears 
catalytically similar to CYP3A4 in the capacity to activate carcinogenic mycotoxins 
such as aflatoxin Bi and Gi (Hashimoto et al., 1995). CYP3A7 is more efficient than 
other CYP3A isozymes in the metabolism of dehydroepiandrosterone 3-sulfate 
(DHEAs) (Kitada et al., 1987).
Thus different CYP3A isozymes catalyse xenobiotic metabolism with variable rates 
and efficiencies, therefore variations in the rate of metabolism of CYP3A substrates in 
vivo may arise because of inter-individual differences in the expression of each of 
these isozymes.
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Figure 1-7 Structures of a selection of substrates of CYP3A
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1.4.4 Induction of CYP3A
CYP3A isozymes are inducible by a wide range of structurally unrelated compounds 
from varied therapeutic groups (Table 1-7 and Figure 1-8) (Williams et al., 1994; 
Curi-Pedrosaetal., 1994).
Marked differences in response to some of these compounds between different 
species and different experimental systems have been reported (Schuetz et al., 1993; 
Kocarek et al., 1995). For example dexamethasone induces CYP3A isozymes in both 
rat and rabbit liver, however PCN induces only in rat, whereas rifampicin induces 
only in rabbit (Wrighton et al., 1985); this has also been demonstrated in primary 
cultures of rat and rabbit hepatocytes (Guzelian, 1994).
A number of studies have shown that CYP3A5 does not appear to be inducible, either 
in vitro (Guzelian, 1994; Schuetz et al., 1993) or in vivo (Wrighton et al., 1989), 
although a dexamethasone-responsive element has been identified in the 5' flanking 
region of this gene (Schuetz et al., 1996).
CYP3A7 appears to be inducible by the majority of the compounds which induce 
CYP3A4 (Greuet et al., 1996; Guzelian, 1994; Doostdar et al., 1993).
As discussed in Section 1.3.1 xenobiotics may act to induce at a number of different 
loci within the gene regulatory process. To date the exact molecular mechanisms 
involved in the induction of CYP3 A genes remain unclear, however PCN, rifampicin 
and dexamethasone have been shown to act at a transcriptional level (Mills et al.,
1994; Huss et al., 1996). The possible role of the glucocorticoid receptor in the 
induction of the CYP3 A subfamily is still disputed, and is discussed further in Section 
1.7.
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1.4.5 Inhibition and down regulation of CYP3A
The activity of CYP3 A isozymes may be decreased, either by inhibition or by down 
regulation of the enzyme, by a number of structurally diverse compounds (Table 1-7 
and Figure 1-9). Inhibition of enzyme activity can occur via several mechanisms, as 
discussed in more detail in Section 1.3.1.4.
Hepatic drug biotransformation is impaired during inflammation and infection 
(Renton & Knickle, 1990; Morgan, 1993). Total cytochrome P450 content (including 
CYP1A2, CYP2C, CYP2E1, and CYP3A) and P450-associated enzyme activities are 
decreased in parallel (Renton & Knickle, 1990). Cytokines (including interleukin Ip, 
interleukin 6, interferon y and tumour necrosis factor a) can decrease P450 levels, 
both in vivo (Pous et al., 1990) and in hepatocytes (Sujita et al., 1990; Razzak et al., 
1994).
Cytokines and growth factors (EOF and TGFa) have also been shown to block the 
rifampicin-mediated induction of CYP3A4 in human hepatocytes (Muntane-Relat et 
al., 1995). The mechanism(s) by which cytokines down regulate GYP expression is 
(are) not known however they do not appear to affect either the rate of translation of 
CYP mRNAs or the degradation of the P450 proteins in hepatocyte cultures 
(Muntane-Relat et al., 1995).
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Figure 1-8 Structures of a selection of inducers of CYP3A
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Figure 1-9 Structures of a selection of inhibitors of CYP3A
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1.4.6 Clinical significance of CYP3A
The CYP3 A subfamily is of great interest in both the clinical and drug developmental 
situations for a number of reasons.
Metabolism by the CYP3A subfamily can greatly affect the bioavailability of a drug. 
For example orally administered drugs that are substrates for CYP3A may undergo 
extensive first-pass metabolism at the level of the intestine (Watkins, 1994). The 
wide variation in CYP3 A expression can thus lead to highly variable bioavailability 
for a given drug across a population. This is of particular concern when using drugs 
with a low therapeutic index.
CYP3A is also involved in the metabolism of some environmental contaminants 
(Wrighton et al., 1990; Aoyama et al., 1990) and inter-individual variability in 
expression of this enzyme may represent a risk factor for susceptibility to 
environmentally related disease.
CYP3A has also been implicated in aromatic anticonvulsant hypersensitivity 
reactions, occurring with phenytoin, carbamazepine, and phenobarbitone, in which 
anti-CYP3A autoantibodies have been identified (McKinnon & Nebert, 1991).
Due to the wide range of substrates, inducers, and inhibitors of CYP3A isozymes 
there arises the serious complication of drug interactions. These are particularly 
likely to occur in patient populations where the use of polypharmacy is common (for 
example in the elderly, or in the long-term prophylaxis of psychiatric disorders) 
(Ketter et al., 1995). Induction or inhibition of CYP3A activity either by other 
medications or by dietary xenobiotics can cause potentially fatal fluctuations in drug 
levels. Classic examples include the interactions between cyclosporin and inducers 
(such as rifampicin) or inhibitors (for example erythromycin, ketoconazole or 
grapefruit juice), or between terfenadine and inhibitors (Ketter et al., 1995).
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In the case of cyclosporin (an inununosuppressor prescribed to organ transplant 
patients), induced metabolism can lead to graft rejection, whereas decreased 
metabolism can lead to nephrotoxicity (Pichard et al, 1990). Inhibition of terfenadine 
metabolism leads to an increased plasma concentration of terfenadine, causing cardiac 
arrhythmia (Flockhart, 1996); this interaction has caused a number of fatalities, 
leading to the withdrawal of this drug from over-the-counter sales in Britain.
A greater understanding of the induction profiles of the CYP3 A isozymes would 
therefore be of value both clinically and in drug development.
1.4.6.1 Assessment of CYP3A status in vivo
A number of methods involving the use of probe drugs have been proposed for the 
assessment of CYP3A status in individuals. The measurement of the metabolism of 
alfentanil, cortisol, dapsone, dextromethorphan, erythromycin, ethosuximide, 
lignocaine, midazolam and nifedipine have all been proposed as suitable markers 
(Bachmann & Jauregui, 1993; Brockmoller & Roots, 1994; Horsmans et al., 1992; 
Watkins, 1994).
The erythromycin breath test has been used to demonstrate induction of human 
CYP3A4 by glucocorticoids and rifampicin, and inhibition by TAO. In this test, 
radiolabeled erythromycin is administered to the patient and the rate of déméthylation 
(by CYP3 A) assessed by monitoring the rate of production of in the breath 
(Watkins et al., 1989).
All of the tests have some problems, whether it is the administration of undesirable 
test compounds, radioisotopes or invasive administration (Jones et al., 1996). The 
situation is further complicated by the lack of information about the catalytic 
specificities of the individual CYP3A isoforms towards each substrate. With each of
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the tests the possible involvement of extra-hepatic CYP3 A (for example intestinal or 
kidney CYP3A) must also be considered. In a number of studies these different 
methods of assessing the CYP3A status have been reported not to correlate with each 
other, for example both alfentanil clearance, and the urinary dapsone recovery ratio 
have been reported not to correlate with the erythromycin breath test (Krivoruk et al., 
1994).
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1.5 In vitro methods and gene transfection
Drug metabolites are often involved in pharmacological activity and toxicity as well 
as pharmacokinetic processes; it is therefore essential to determine the various 
metabolic pathways early in the development of new drugs. It is also vital to assess 
the activity and toxicity (both acute and chronic) of a drug and its metabolites before 
the first human volunteer studies. During development, metabolism studies are 
routinely performed on various animal species, and drugs are currently tested for 
toxicity in at least one rodent (usually the rat) and one non-rodent species (usually the 
beagle dog). Animal studies are costly, time consuming, create ethical problems for a 
company, and are frequently of questionable validity due to the marked inter-species 
differences in absorption, distribution, metabolism (both metabolic rates and 
pathways) and excretion, which are often observed (Ball et al., 1995). Thus 
extrapolation of in vivo animal data to the human situation can often be misleading.
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1.5.1 In vitro methods in metabolism or toxicology during drug development
There are a variety of reasons for the growing interest in the development of m vitro 
systems. The drug research and development process is becoming more rational as 
development costs are rising exponentially. The animal welfare lobby is a persistent 
problem, raising ethical concerns about current procedures, and the regulatory bodies 
demand increasingly detailed information, particularly in light of the growing 
evidence of the hazards of the extrapolation of metabolism data from animals to man. 
In vitro assays can provide an early appreciation of species-specific metabolism and 
toxicology before a compound reaches the more costly stages of clinical development, 
and can provide a means of assessing aspects of toxicology that cannot be assessed by 
other methods during the drug development process. This approach can lead to 
identification of the most useful animal species for use in the in vivo studies, and can 
provide information allowing more effective targeting of clinical trials.
To be of use in the drug development process an in vitro screen must be valid and 
predictive, reliable and reproducible, practical, quantifiable and cost effective. 
Desirable characteristics are the potential for high throughput, and rapid turnover. 
There are a number of areas of the development process where in vitro screens can be 
of great benefit.
When used for metabolite profiling, in vitro screens can be used to identify 
metabolites in several species (including pharmacologically active or toxic 
metabolites), to identify problem metabolic routes and the sites and rates of 
metabolism. They therefore aid the rational selection of the animal species to be used 
for in vivo metabolism and toxicology studies. They may also be of use in the 
prediction of adverse drug reactions.
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In vitro screens are also useful for identifying which enzymes are responsible for the 
metabolism of a drug (Ball et al., 1995), thus enabling more reliable prediction of the 
potential effects of genetic polymorphisms, and giving an early indication of possible 
bioavailability problems and drug interactions.
In vitro screens may also be used to examine the modulation of enzyme activities to 
identify inhibitory or inductive effects of a developmental compound; they may also 
be used to predict selectivity against therapeutic targets (Ball et al., 1995).
Given the concerns about the extrapolation of animal study data to the human 
situation much work has been done to develop in vitro hepatic human models; these 
include the use of human liver slices, hepatocytes in suspension or primary culture 
and liver microsomes (Cashman, 1996). Human models suffer from a number of 
drawbacks. For ethical, and technical reasons, human material is expensive and in 
short supply, inter-individual variability is marked, the sources of liver are often 
atypical and their drug history often unclear. Cryopreservation techniques have been 
developed in order to establish banks of human hepatocytes, however the reliability of 
thawed hepatocytes is still under investigation (Lacarelle et al., 1991). In systems 
derived from human liver there may be a high background of contributing enzymes 
and some enzymes may expressed at low level in the normal state.
Although microsomal systems have limited use, since they represent only a proportion 
of the total drug-metabolising enzymes present in the cell, they are useful in the study 
of P450-mediated metabolism where enzyme activities can be studies in the presence 
of specific metabolic inhibitors, competitive substrates, and immunoinhibitors and 
thus may provide early detection of potential drug interactions involving enzyme 
inhibition (Miura et al., 1989).
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Another possibility is the use of hepatoma cell cultures to study induction, inhibition, 
metabolism and the hepatotoxicity of xenobiotics; the major disadvantage is that 
transformed cell lines frequently lose much of their differentiation, failing to express 
key enzymes or transcription factors (Ferro et al., 1993).
In vitro animal systems such as rat hepatocyte cultures and co-cultures (Rogiers et al., 
1990) may be used either as a prelude to in vivo animal work, or to further investigate 
species differences and mechanisms.
Another possibility is the use of recombinant expression systems in which cDNAs 
encoding individual P450 enzymes can be expressed either transiently or stably in 
cultured cells. For example catalytically active CYP3A4 has been expressed in yeast 
(Peyronneau et al., 1993), in HepG2 cells (Relling et al., 1993), Caco-2 cells (Crespi 
et al., 1996), human B lymphoblastoid cells (Crespi, 1984) and in Escherichia coli 
(Gillam et al., 1993). The cDNA expressing cell lines may then be studied for their 
metabolic capacity. The major advantage of this approach is that an unlimited supply 
of reproducible material is available for study, and that a particular enzyme activity 
can easily be assigned to the cDNA-expressed P450. However, a potential drawback 
is that not all cell systems are capable of all of the post-translational modifications 
that may be required to produce catalytically active reconstituted enzyme (Sanders, 
1990).
One area of current growth is the development of reporter gene assays (described in 
detail in Section 1.5.3) which have potential for detecting enzyme induction occurring 
at the transcriptional level and also for investigation of the molecular mechanisms 
involved. It is important to note that the transfected unit may not contain all the cis- 
acting sequences involved in xenobiotic-mediated induction. It may also be difficult
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to determine if any trans-dioXmg protein factors required for activation are expressed 
optimally in the cell line used.
Another approach is the development of predictive computer models using data 
gathered on structure activity relations (Cashman, 1996).
A battery of in vitro tests has the potential to rapidly provide useful and detailed 
information about a new chemical entity, however no available in vitro test is capable 
of replicating the complexity of a whole animal system where all of the aspects of the 
ADME factors (described in Section 1.1) play a role in both the pharmacological 
activity and the toxicity of a test compound. In light of this, in vivo studies must still 
be carried out to confirm in vitro findings (Ball et al., 1995).
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1.5.2 Transfection techniques
A variety of methods have been developed to enable the introduction of cloned 
eukaryotic DNAs into cultured mammalian cells (Sambrook et al., 1989; Alam & 
Cook, 1990). DNA introduced into cultured cells does not require integration into 
cellular chromatin in order to be expressed. Expression of introduced DNA may be 
monitored from as early as 12 hours up to 72 hours after transfection, after which time 
the transfected genes are gradually lost; this is referred to as transient expression. 
Integration of introduced DNA into cellular chromatin to form stable transformants 
occurs at a low frequency (0.001-1%) (Chen & Okayama, 1987). It is possible to 
isolate these cells and their resultant clones under selective pressure, thus ensuring 
that a heritable genotype is produced. Stable cell lines may then be manipulated 
without introducing plasmids each time, thereby improving reproducibility and 
reliability. A second advantage is that the transfected DNA is assayed while in a 
natural chromatin environment. This can also be a handicap since both the 
chromosomal integration site and the number of copies may affect transcription 
(Alam & Cook, 1990).
To isolate cells that stably express the transfected gene, and to ensure maintenance of 
the integrated DNA, a gene coding for a selectable marker must also be introduced 
into the cells. Selectable markers are genes whose expression in cells may be 
positively selected. These genes typically code for antibiotic resistance (e.g. 
hygromycin B phosphotransferase) or code for an enzyme that allows survival in a 
nutritionally selective medium (e.g. Xanthine-guanine phosphoribosyl transferase).
The stably selective marker may either be engineered into the same plasmid as the 
gene of interest, or it may be coded for on a second plasmid that is co-transfected with 
the plasmid containing the gene of interest. The advantage of co-transfection is that it
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obviates the need to construct complex recombinants. When co-transfections are 
employed, the plasmid possessing the selectable marker is introduced at a much lower 
molar concentration, generally 10- to 20-fold less. Mammalian cells that are 
competent in taking up DNA import many plasmid molecules, thus selecting for the 
limiting plasmid ensures that the cells will also possess the cotransfected plasmid 
(Wigler et al., 1979).
High variability in transfection efficiency is seen between different cell lines with 
each method of transfection, and thus the method of choice will be dictated by the cell 
line used and whether transient or stable expression is required. The most commonly 
used methods are summarised below.
1.5.2.1 Calcium phosphate precipitation
In this procedure the DNA to be transfected is mixed with a solution of calcium 
chloride, and then added to a solution containing phosphate ions. A DNA-calcium 
phosphate co-precipitate is formed which is then taken up by mammalian cells. The 
exact mechanism of uptake of the precipitate is unclear, but is believed to be by 
endocytosis (Sambrook et al., 1989).
1.5.2.2 Lipofection
In this technique the DNA is either encased in liposomes or coated with a cationic 
lipid. The lipid coating then fuses with the plasma membrane of the cell, introducing 
the DNA into the cell (Feigner et al., 1987).
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1.5.2.3 Electroporation
The application of short, high-voltage electric pulses causes the transient formation of 
nanometer-sized pores in the plasma membrane of cells. The DNA is either taken 
directly into the cell cytoplasm through these pores, or internalised through membrane 
rearrangement during pore closure (Sambrook et al., 1989).
1.5.2.4 Other methods of transfection
Other methods that have been used include polybrene-mediated transfection 
(Sambrook et al., 1989), DEAE-dextran-mediated transfection (Alam & Cook, 1990), 
direct microinjection into nuclei (Graessman & Graessman, 1986) and protoplast 
fusion (Schaffner, 1980).
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1.5.3 Reporter gene technologies
Reporter gene assays have become invaluable in studies of gene regulatory elements. 
Reporter genes code for proteins that are easily distinguishable from the proteins 
produced by the experimental cell line, for example due to unique enzyme activity.
To examine the function of a promoter element, a plasmid construct is created in 
which the test DNA is ligated upstream of the coding region of the reporter gene, thus 
generating a chimeric gene in which the putative regulatory element controls the 
expression of the reporter gene. The construct is introduced into cultured cells by 
transfection, therefore allowing estimation of the transcriptional capability of the test 
DNA either quantitatively from the in vitro activity of the reporter gene product, or 
qualitatively by histochemical staining of intact cells.
Although this approach is an indirect measurement of the transcriptional properties of 
the test DNA, the reporter gene activity is generally directly proportional to 
transcriptional activity (Alam & Cook, 1990).
Sensitive assays are critical for the analysis of low levels of gene expression, 
particularly in cell lines that transfect poorly. The sensitivity of a reporter gene assay 
is a function of several factors including: the detection method, reporter mRNA and 
protein turnover, and endogenous levels of the reporter activity. Both protein 
turnover and levels of endogenous background vary with each reporter protein and the 
cell line used. Commonly used detection techniques include isotopic, colourimetric, 
fluorometric, or luminescent enzyme substrates and immunoassay-based procedures 
with isotopic, colourimetric or chemiluminescent end points.
Commonly used reporter genes are summarised in Table 1-8.
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Table 1-8 Commonly used reporter genes
Reporter Gene Detection method(s)
Chloramphenicol Acetyl Transferase Isotopic
(CAT) ELISA (Colourimetric or luminescence)
P-Galactosidase Colourimetric (ONPG)
Fluorescence (MUG)
Luminescence*
Human Growth Hormone Radioimmunoassay
Luciferase Luminescence
p-GIucuronidase Fluorescence (MUg)
Luminescence*
Secreted Alkaline Phosphatase Colourimetric (PNPP)
Luminescence*
Indirect luciferase assay (Luminescence)
Green fluorescent protein Fluorescence
ELISA: Enzyme linked immunosorbent assay; ONPG: cj-nitrophenyl p-D- 
galactopyranoside; PNPP: p-nitrophenyl phosphate; MUG: 4-methylumbelliferyl p-D- 
galactopyranoside; MUg: 4-methylumbelliferyl P-D-glucuronide.
* : Chemiluminescent assay using 1,2-dioxetane substrate
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1.5.3.1 Bioluminescence and chemiluminescence
The term bioluminescence refers to the light produced in certain creatures (for 
example the firefly) as a result of luciferase- or photoprotein-mediated oxidation 
reactions. This bioluminescence has been utilised in two ways. Genes that produce 
bioluminescent products (such as firefly luciferase) may be directly used as reporter 
genes, or bioluminescent assays may be used for the products of non-bioluminescent 
genes (for example an indirect bioluminescent assay for alkaline phosphatase has 
been reported) (Bronstein et al., 1994).
Chemiluminescence refers to the light generated by the chemical decomposition of a 
destabilised metabolite produced by the reporter protein from a specifically designed 
substrate. Examples of this are seen in the chemiluminescent assays for alkaline 
phosphatase (Figure 2-11), p-galactosidase (Figure 2-9) and in enhanced 
chemiluminesce (ECL and ECL Plus) Western blotting detection systems (Figures 2-6 
and 2-7).
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1.5.3.2 Human secretory placental alkaline phosphatase
Alkaline phosphatase is the generic term used to describe a family of orthophosphoric 
monoester phosphohydrolases that exhibit an alkaline pH optimum. These enzymes 
are relatively stable proteins 'with a high substrate turnover number that display 
affinity for a broad range of substrates. Alkaline phosphatases have been used in 
numerous biochemical, diagnostic, and therapeutic procedures (Alam & Cook, 1990). 
Mammalian alkaline phosphatase is a glycosylated ectoenzyme anchored to the 
plasma membrane by a segment located near the carboxy-terminus of the protein. In 
humans there are three major isoforms of the enzyme, each encoded by distinct genes. 
The liver/bone/kidney alkaline phosphatase is the most ubiquitous isoenzyme, 
whereas the intestinal and placental alkaline phosphatases exhibit a more restricted 
tissue expression. These isoenzymes may be distinguished from each other on the 
basis of certain properties such as thermostability and inhibition by some amino acids 
such as L-phenylalanine and L-homoarginine (Alam & Cook, 1990; Harris, 1981). 
Human placental alkaline phosphatase is of interest as a reporter gene for several 
reasons. Alteration of the coding region for the membrane localisation domain causes 
the enzyme to be secreted from the cell (Berger et al., 1988). Placental alkaline 
phosphatase is also extremely heat stable and resistant to L-homoarginine, and thus 
reporter gene expression may be distinguished from endogenous expression by 
heating of samples to 65°C and/or inclusion of L-homoarginine in the assay buffer 
(Alam & Cook, 1990).
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1.6 The human glucocorticoid receptor
The human glucocorticoid receptor (GR) has been cloned and sequenced (Hollenberg 
et al, 1987); it is a member of the nuclear receptor superfamily, which includes the 
steroid hormone receptors (e.g. the oestrogen, progesterone, testosterone, and 
aldosterone receptors), as well as the vitamin D, thyroid and retinoid receptors 
(McDonnell et al., 1993; Jones & Petkovich, 1996; Evans, 1988).
Two forms, termed hGRa, and hGRp have been identified in humans; hGRp is 
formed by alternative splicing of the GR pre-mRNA, does not bind glucocorticoids 
and is transcriptionally inactive (Bamberger et al., 1995).
The ligand binding domain is located near the carboxy terminus region of the 
molecule; although the sequences required for hormone binding have not been clearly 
defined the ligand binding domain is believed to span 300 amino acids. This region is 
complex, and is also believed to contain regions required for dimérisation, 
transcriptional activation, interaction with heat shock proteins (HSPs) and nuclear 
localisation (McDonnell et al., 1993).
The DNA binding domain is located in the middle of the protein and contains nine 
cysteine residues; this domain is highly conserved amongst the steroid receptor family 
(McDonnell et al., 1993; Evans, 1988). The region folds into a “two-fmger” structure 
stabilised by zinc ions connected to cysteines to form two tetrahedrons; the zinc- 
fingers represent the basic structure by which the DNA-binding domain recognises 
specific nucleic acid sequences (McDonnell et al., 1993; Wingard et al., 1991). These 
specific sites on DNA are referred to as glucocorticoid responsive elements, and are 
short cfr-acting sequences which fimction in a position- and orientation- independent 
fashion and thus behave as transcriptional enhancers (Evans, 1988). The consensus
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sequence for a GRE is GGTACAnnnTGTTCT (Beato, 1989); the GR also recognises 
a consensus TGTTCT half site arranged as a pair in a palindrome; this sequence exists 
in the mouse mammary tumour virus gene (MMTV), and is also recognised by the 
progesterone, testosterone, and aldosterone receptors (McDoimell et al., 1993).
In the absence of ligand binding the receptors are transcriptionally inactive, existing 
within the cell as large oligomeric complexes associated with HSPs; one molecule of 
the receptor is generally associated with two molecules of HSP90, and one each of 
HSP70, HSP56 and HSP 26 (Bamberger et al., 1995). When a ligand binds it induces 
a conformational change which displaces these inhibitory proteins and enables the 
uncomplexed receptor to interact with DNA (McDonnell et al., 1993).
The glucocorticoid receptor can act either to activate, or to down regulate the 
transcription of a gene; the precise molecular mechanisms are still being elucidated 
(McDonnell et al., 1993; Langer & Ostrowski, 1988). In genes that are classically 
induced by glucocorticoids, such as tyrosine amino transferase (TAT), and MMTV, 
glucocorticoids (e.g. dexamethasone) cause transcriptional induction of gene 
expression, while anti-glucocorticoids (e.g. PCN and RU-486) do not induce these 
genes, and also block the induction of these genes by glucocorticoids (Evans, 1988; 
Wright & Paine, 1994; Quattrochi et al., 1995).
The role of the glucocorticoid receptor in the induction of the CYP3A subfamily is 
unclear, and is discussed further in Sections 1.7 and 5.4.
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1.7 In vitro experiments to assess the regulation of the CYP3A subfamily.
A number of recent studies have attempted to examine the molecular mechanisms 
underlying the regulation of the CYP3A genes. Reporter constructs containing DNA 
fragments encoding components of the 5'-flanking regions of the rat, rabbit and 
human CYP3A genes have been transfected into a variety of cell types in attempts to 
elucidate the regulatory mechanisms. For example, the presence of transcriptional 
enhancers and repressors within the CYP3 A4 regulatory region has been 
demonstrated by transfecting reporter constructs containing fragments of the CYP3A4 
5'-flanking region into HepG2 cells (Hashimoto et al., 1993).
Induction of reporter protein production in response to dexamethasone, PCN and 
rifampicin has been demonstrated in reporter constructs containing fragments of the 
5'-flanking regions of rat CYP3A1 and CYP3A23, rabbit CYP3A6 and human 
CYP3A4 (Quattrochi et al., 1995; Burger et al., 1992; Mills et al., 1994; Barwick et 
al., 1996). These responses are species specific; none of the regions respond to 
rifampicin in rat hepatocytes or to PCN in rabbit hepatocytes. In rat hepatocytes, 
simultaneous dosing with dexamethasone and PCN causes synergistic induction 
(Quattrochi et al., 1995; Burger et al., 1992; Huss et al., 1996; Mills et al., 1994; 
Barwick et al., 1996).
CYP3A5 and CYP3A7 have also been investigated using reporter constructs and have 
been shown to contain dexamethasone responsive elements (Schuetz et al., 1996; 
Pickwell et al., 1996).
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The involvement of the glucocorticoid receptor in the induction of members of the 
CYP3A subfamily is still unclear, and is summarised as follows.
The synergistic induction observed with PCN and dexamethasone in combination in 
rat hepatocytes indicates that induction of the CYP3A genes may occur via a different 
mechanism to the induction of classical glucocorticoid-induced genes, such as the 
mouse mammary tumour virus (MMTV) gene, where PCN acts to antagonise the 
effects of dexamethasone (Burger et al., 1992).
Consensus sequences identified in rat CYP3A23, rabbit CYP3A6 and human 
CYP3A4, which were reported to be inducible by dexamethasone, PCN and 
rifampicin (Barwick et al., 1996; Quattrochi et al., 1995), display no sequence identity 
to the classical GRE sequence (GGTACAnnnTGTTCT (Beato, 1989)). In CYP3A23 
a fragment conferring dexamethasone-responsiveness, although not containing a full 
GRE consensus sequence, was shown to contain the motif TGTTCACT (Burger et al., 
1992) which has been shown to bind the glucocorticoid receptor (Danesch et al.,
1987).
Transfection of constructs containing components of the 5'-flanking regions of 
CYP3A7 into a human hepatoma line HuH-7 identified a dexamethasone responsive 
sequence 835bp upstream of the CYP3A7 promoter, however induction was only 
observed upon cotransfection with a plasmid encoding human glucocorticoid receptor 
(Pickwell et al., 1996). The glucocorticoid receptor was also implicated in the 
dexamethasone-mediated induction of a CYP3A5 construct (-891 bp to -1 109bp) for 
a number of reasons. Firstly dexamethasone induction was blocked by the 
antiglucocorticoid RU-486; two GRE half-sites (separated by 160bp) were identified 
within the responsive element, both of which were required to achieve 
dexamethasone-mediated induction, and finally in HepG2 cells, cotransfection with a
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plasmid encoding the glucocorticoid receptor was required to achieve induction 
(Schuetz et al., 1996).
Previously in our laboratory (Williams, 1997) approximately Ikb of the 5'-regulatory 
region of the human CYP3 A4 gene was isolated from genomic DNA by PCR and was 
cloned into a vector carrying the reporter gene for human secreted placental alkaline 
phosphatase (SPAP). During this work the development of a transfection system to 
examine the induction of human CYP3A4 by xenobiotics was started, and a response 
to dexamethasone, phenobarbitone, and pregnenolone 16a-carbonitrile was observed. 
Rifampicin did not appear to cause a response.
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1.8 Aims
In our laboratory a basic system for the in vitro assessment of the induction of the 
human CYP3A4 gene had been developed (Williams, 1997).
The initial aim of the project was to continue this work in an attempt to improve the 
reproducibility and robustness of this system. The ultimate aim of this approach 
would be to modify the system to render it usefiil for the high throughput screening of 
xenobiotics.
Another goal of the project was to attempt to generate a stable cell line expressing the 
alkaline phosphatase reporter gene under the direct control of the CYP3 A4 regulatory 
region. Success in this approach would dramatically reduce problems associated with 
poor reproducibility and would greatly increase the potential for the use of this system 
as a high throughput screen.
The final aim of this project was to use the system to attempt to gain information 
concerning the molecular mechanisms underlying induction of CYP3 A4 by 
xenobiotics.
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CHAPTER 2 - MATERIALS AND METHODS 
2.1 Introduction
The experimental procedures used throughout this project are detailed within this 
chapter. Procedures common to more than one protocol are described in Section 2.3. 
The recipes for the buffers, media and solutions used are listed alphabetically in 
Appendix 1.
2.2 Materials
2.2.1 Chemicals
All chemicals purchased were of the highest purity available, and were supplied by 
the Sigma Chemical Company unless listed below.
Appligene Oncor 
Agarose 
Boehringer Mannheim 
Poly-D-lysine 
Fisher Scientific UK
Sodium chloride
Oxoid
Bacteriological agar (Agar No. 1 )
Phosphate buffered saline (PBS) tablets (Dulbecco ‘A’)
Tryptone 
Yeast extract
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Pharmacia Biotech 
Dextran T70
Scotlab
Bis-acrylamide stock solution 2% w/v 
Acrylamide stock solution 40% w/v 
RU-486 was a gift from Dr. Matthew Wright, University of Southampton.
2.2.2 Enzymes, antibodies and DNA markers
Amersham Life Science
Anti-mouse Ig; biotinylated species-specific whole antibody (from sheep) 
Restriction enzymes: Hind III and Pst I 
Calbiochem
Human placental alkaline phosphatase
Gibco
1 Kb DNA Ladder (Fragment sizes: 12,216; 11,198; 10,180; 9,162; 8,144; 
7,126; 6,108; 5,090; 4,072; 3,054; 2,036; 1,636; 1,018; 516)
High DNA Mass Ladder
Fragment Size Amount of DNA 
in 2pl (ng)
10,000 100
6,000 60
4,000 40
3,000 30
2,000 20
1,000 10
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Promega
6x blue/orange loading dye 
Restriction enzyme: EcoKL, Sail, Seal and Xbal 
Serotech
Mouse anti-human glucocorticoid receptor antibody
Sigma
p-Galactosidase
CYP3A4 and CYP3A5 anti-peptide antibodies were a gift from Dr. Robert Edwards, 
Imperial College School of Medicine, The Hammersmith Hospital, London.
2.2.3 Kits
Amersham
ECL Plus Western blotting detection reagents 
Rat cytochrome P450 3A ECL Western blotting kit 
Boehringer Mannheim
P-Gal Staining Set 
Clontech
CalPhos Maximizer Transfection Kit
Hybaid
Hybaid Recovery -  Quick Flow Maxi Kit
ICN
Aurora Alkaline Phosphatase Chemiluminescent Reporter Gene Assay Kit
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Packard
Cytolite 
Pharmacia Biotech 
FlexiPrep kit 
Primm Labs
Easy-pure plasmid maxi prep kit 
Promega
Wizard Maxipreps DNA purification system 
Wizard Plus Maxipreps DNA purification system 
Wizard Megapreps DNA purification system
Qiagen
Endofree plasmid maxi kit
Tropix
Galactolight plus
2.2.4 Western blotting equipment
Amersham
Hybond -  P: PVDF membrane (a hydrophobic polyvinylidene difluoride 
membrane optimised for protein transfer)
ECL Mini camera
Biorad
Mini-protean II electrophoresis cell and Mini-transblot cell
10 well gel combs (well width 5mm), spacers (1.5mm) and Scotchbrite pads.
Power pack model 200/2
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Jencons
Spiramix Roller mixer
Sigma
Polaroid type 667 black and white positive only film 
Whatman
Cellulose reel
2.2.5 Plasticware & disposables
Beckman
. Polypropylene centrifuge tubes 
Polypropylene centrifuge bottles
Falcon
50ml polypropylene tubes
Flowgen
Electroporation cuvettes (4mm sterile)
Greiner
Transparent microplate sealers 
Sterile inoculating loops 
90mm petri dishes 
Cryovials 
Jencons
Autoclaveable reagent vessels
Kartell
Cuvettes (plastic, 1.5ml)
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Labsystems
Multiframes and breakable microstrips 
Nalgene
0.22pm Filter units 
Nunclon Life Technology
Tissue culture flasks 
6 -well and 24-well tissue culture plates 
Packard
96 well plates: Liteplate (black), Optiplate (white) and View Plate
Scotlab
0.5ml and 1.5ml microcentrifuge tubes
Sigma
Coming cell wells - 96 well flat-bottomed polystyrene cell culture plates 
Cell scrapers 
Whatman
Glass microfibre filters
2.2.6 Instrumentation
All chemiluminescent assays were carried out on a Lumicount plate reader (Packard). 
All spectrophotometric assays were carried out on either a Uvikon 932 
spectrophotometer or a Uvikon 860 spectrophotometer (Kontron).
Electroporation of mammalian cells was carried out using a Gene Puiser (Biorad).
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2.2.7 Cell lines and cell culture reagents
European Collection o f Animal Cell Cultures (ECACC), Porton Down
HepG2 cells - A human hepatocyte carcinoma, originally established from a 15 year
old male Caucasian, supplied as a frozen culture in passage 90.
For the purpose of this project the stock culture in passage 90 was regarded as passage 
zero, and all passage numbers given refer to number of passages from that point. On 
receipt of the frozen culture the cells were grown up in bulk and aliquots were frozen 
in passage 7 to be used as a ‘bank’ for all subsequent work.
H4-II-E-C3 cells- A rat liver hepatoma, derived from the H-35 Reuber hepatoma line, 
supplied as a frozen culture in unknown passage number.
CHO-Kl cells— A sub-clone of the parent line CHO that was derived from the ovary 
of an adult Chinese hamster. These cells were available in the laboratory at the time 
of this project, having been originally supplied by ECACC in unknovm passage 
number.
Clontech
Hygromycin B (50mg.mF^ in PBS)
Gibco BRL Life Technologies
Non-essential amino acids 
Geneticin (50mg.mF^ active geneticin)
Gentamycin (lOmg.mf^ in water)
L-Glutamine 200mM (lOOx)
Cell growth media and supplements
Sigma
0.4% (w/v) Trypan blue solution
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2.2.8 Bacteria and plasmids
The genotypes of the Escherichia coli (E.coli) strains used for the propagation of 
plasmid vectors are shown in Table 2-1.
Clontech
E.coli strains JM109 and DH5a 
Stratagene
E.coli strain XL 1-Blue 
All of the following plasmids carry the ampicillin resistance (amp') gene to enable 
selection for bacteria containing the plasmid during culture.
Clontech
pTK-Hyg Selection vector 
Pharmacia Biotech 
pCHllO
The pSG5-hGR construct was a gift from Zeneca PLC. The pSVNeo plasmid was a 
gift from Dr Claire Scholfield, Nottingham Trent University. The pCMV-cSPAP 
reporter plasmid (referred to as pCMV throughout this project) was a gift from Glaxo 
Wellcome; the p3A4-CMV-SPAP reporter construct (referred to as p3A4 throughout 
this project) was engineered from pCMV-cSPAP in our laboratory by Dr. Janet 
Williams (Williams, 1997).
Restriction maps of the plasmids are given in Figures 2-1 -  2-5.
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Table 2-1 Bacterial strains used for plasmid propagation
E.coli Strain Use of Strain Genotype
DH5a Replication of fwp^44 A/flcU169 (^80 lacZ^M\5) hsdRM recAl
p3A4, pCMV endAX gyrA96 thi-l relAX
JM109 Replication of recAl supE44 end A l hsdRYl gyrA96 relAl thi
pSVNeo, A{lac-proAB)
pSG5-hGR [traD36proAB^ lacE lacZAMlS]
XLl-Blue Replication of supE44 hsdRll recAl end A l gyrA96 thirelAl
pTK-Hyg, lac
pCHllO F’ \proAB* lacï' lacZdM\5TnlO{tef)]
(Sambrook et al., 1989)
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Figure 2-la Functional map of p3A4-CMV-cSPAP
Amp'^
1 (5934)
Spe I (5964)
p3A4-CMV-cSPAP 
7006 bp
SV40 t-intron & poly(A) sites
CYP3A4 (-1087 to -57) 
1(1086)
CMV promoter
SPAP cDNA
I (3284)
Amp‘‘ = ampicillin resistance. SPAP cDNA = Secretory placental alkaline phosphatase gene 
ORI = origin of replication. CMV = Eukaryotic cytomegalovirus promoter.
This construct, referred to as p3A4 throughout this project, was engineered in our laboratory 
(Williams J. 1997) by inserting approximately Ikb of the 5'-flanking region of GYP 3A4 (-1087 to 
57) in the Spel site (5964) of the pCMV-cSP AP plasmid.
Figure 2-1 Functional map of pCMV-cSPAP, an alkaline phosphatase reporter plasmid
Spel (5964)
CMV promoter
Amp’'
(4379)
p C M V -c S P A P  
5976 bp SPAP cDNA
Xbal (2254)
SV40 t-intron & poly (A) sites
Amp’’ = ampicillin resistance. SPAP cDNA = Secretory placental alkaline phosphatase gene 
ORI = origin of replication. CMV = Eukaryotic cytomegalovirus strong promoter 
This plasmid is referred to as pCMV throughout this project.
The CYP3A4 construct, referred to as p3A4 throughout this project, was engineered in our laboratory 
(Williams J. 1997) by inserting approximately Ikb of the 5'-flanking region of GYP 3A4 (-1087 to - 
57) in the Spel site (5964). p3 A4 is 7006bp in size.
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Figure 2-2 Functional map of pCHllO, a P-galactosidase reporter plasmid
SV40 Early promoter
SV40 ORI
pBR322 ORI
lac Z
p C H llO  
7128 bp
Amp’
BamHI(3543)
Amp  ^= ampicillin resistance, lac Z = lac Z gene conferring P-galactosidase activity 
ORI = origin of replication
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Figure 2-3 Functional map of pSG5-hGR, a plasmid encoding the human glucocorticoid receptor
SV40 Promoter
P-globin intron
,T7
p S G 5 -h G R  
7300 bp
POLYA
ORI
hGRcDNA
AMP’’ = ampicillin resistance. hGR cDNA = human glucocorticoid receptor cDNA 
ORI = origin of replication
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Figure 2-4 Functional map of pTK-Hyg, a hygromycin selection vector
Amp’'.
pUC ORI
pTK-Hyg
5066 bp
HS V TK promoter
Amp*^  = ampicillin resistance. Hyg*^  = hygromycin resistance 
ORI = origin of replication
Hind III (1038)
HSVTK polyA
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Figure 2-5 Functional map of pSV-Neo, a neomycin selection vector
Neo^
p S V -N e o  
5736 bp
Amp^
SV40
Amp'' = ampicillin resistance. Neo"" = neomycin resistance
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2.3 General procedures
Methods involved in multiple procedures are described below and will be referred to 
when necessary.
2.3.1 Sterilisation of materials
All materials prepared for use in procedures involving the handling of nucleic acids, 
or bacterial or mammalian cell culture were sterilised using a Rodwell Series 32 
automatic autoclave, unless specified otherwise. Sterilisation was carried out for 2 0  
minutes at 121 °C at a pressure of 151b.in' .^
Where autoclaving was not an appropriate method, solutions were filter sterilised 
(under vacuum through a 0.22pm filter). Some solutions and plasticware were 
purchased pre-sterilised.
2.3.2 Preparation of glycerol stocks
Bacterial cultures, including those containing plasmids of interest, can be stored in 
glycerol at -70°C for many years.
For cultures containing a plasmid coding for ampicillin resistance an overnight culture 
in LB medium containing SOpgmf^ ampicillin was prepared. 150pl of sterile glycerol 
was added to 850pl of bacterial culture in a sterile 1.5ml microcentrifuge tube; the 
tube was vortexed briefly to ensure complete mixing of the contents before fi'eezing 
the stocks at -70°C for storage. For bacterial cultures without plasmids no ampicillin 
was used.
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2.3.3 Growth of bacterial cultures
To grow plasmid-containing bacteria from a glycerol stock a sterile inoculating loop 
was scraped across the surface of a frozen stock, and then streaked on an ampicillin 
(50pgmf^) LB agar plate and incubated overnight at 37°C. A single discreet colony 
was then picked using a sterile loop and inoculated into 10ml of LB medium 
containing ampicillin (SOpgmf^). The mini-culture was then incubated in a rotary 
incubator at 225 rpm overnight; for subsequent maxi-culture, 1ml of mini-culture was 
added per 100ml of LB medium containing ampicillin (50pgmf^) and then incubated 
overnight (12-16 hours) in a rotary incubator at 225 rpm at 37°C.
For bacteria to be used in the production of competent cells no ampicillin was used in 
either the agar plate or the LB medium as the bacteria do not possess plasmids coding 
for ampicillin resistance.
2.3.4 Preparation of competent cells for transformation of plasmids
Plasmids were propagated in strains of E.coli specifically engineered for the purpose. 
Strains used throughout this project were XL 1-Blue, JM109 and DH5a. Plasmid 
DNA was introduced into these strains through a procedure called transformation 
(described in Section 2.3.5); to transform bacteria with plasmid DNA they must first 
be rendered competent.
An overnight culture of host E.coli cells was set up. The following morning 0.5ml of 
the overnight culture was diluted into 30ml of LB medium and grown at 37°C to an 
optical density (at 650nm) of 0.5-0.6. The cells were placed on ice for 20 minutes 
after which they were pelleted by centrifugation at 3500 x g for 5 minutes and 
resuspended in 1 0ml of ice cold 0.1M CaCh. The cells were then repelleted and
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resuspended in 200pl of ice-cold 0. IM CaCL, after which they were left on ice for 30 
minutes before being used for transformation.
2.3.5 Transformation of plasmid DNA into competent cells
Plasmids obtained from commercial sources are often supplied as lyophilised DNA. 
Before such DNA may be used it must be introduced into a suitable host E.coli strain. 
This may be achieved by treating a growing bacterial culture with solutions 
containing divalent cations to make them temporarily permeable to small DNA 
molecules such as plasmids. Selection of the transformed bacteria is achieved by 
growing the bacteria in the presence of an antibiotic (such as ampicillin), resistance to 
which is encoded on the plasmid.
l-5pl DNA (containing 10-20ng DNA) and 3pi DMSO were added to 0.2ml 
competent cells and placed on ice for 30 minutes. The suspension was then heat- 
shocked for 2 minutes at 42°C in a waterbath, and then returned to ice for a further 30 
minutes. 250pl LB medium was then added, and the cells incubated at 37°C in a 
shaking incubator (at 225 rpm) for 1 hour before being spread onto LB agar plates 
containing ampicillin (50pg.mf^). For each transformation 2 plates were prepared; 
50pl of culture were spread on one, and 250pl on the other. A control transformation 
(no DNA) was carried through the same procedure to ensure no contamination 
occurred during the transformation process.
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2.4 Cell culture
For routine culture, cells were grown in 80cm^ (250ml) flasks in 5%C02 at 37°C. 
HepG2 and H4-II-E-C3 cells were grown in flasks with filter lids (vented), whereas 
CHO-Kl cells were grown in non-fllter-lid flasks.
All cell culture media, trypsin and PBS were pre-heated to 37°C in a waterbath prior 
to use in cell culture procedures.
Human HepG2 (human hepatoblastoma) cells were cultured in Minimum Essential 
Medium (MEM, with Earle’s salts) supplemented with 10% (v/v) PCS, 2mM L- 
glutamine, 1% (v/v) gentamycin and 1% (v/v) non-essential amino acids.
Rat H4IIEC3 cells were cultured in the same media conditions as HepG2 cells. 
Chinese hamster ovary (CHO) cells were cultured in Nutrient Mixture F-10 (HAM) 
containing L-glutamine, supplemented with 0.4% (v/v) gentamycin and 10% (v/v) 
FCS.
2.4.1 Subculture of ceils
For routine subculture the cell culture medium was removed from the flask by 
aspiration. The cells were washed in 5ml PBS to remove any dead cells and any 
remaining medium; the PBS was removed by aspiration, and 1ml of 1 x Trypsin- 
EDTA solution was added. The flask was rocked gently until all cells were covered 
and then placed in the cell culture incubator until approximately 80% of cells were 
detached. 10ml of cell culture medium was then added to inactivate the trypsin. The 
required amount of cell suspension was taken and transferred to a new flask; medium 
was added to a flnal volume of 20ml. For routine subculture HepG2 cells were 
normally seeded at a 1 in 4 dilution.
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2.4.2 Cell eounting
For routine counting, a flask of cells was trypsinised and then resuspended in 10ml of 
medium. The number of cells per ml was determined using a haemocytometer.
For more accurate determination of the number of viable cells lOOpl of cell 
suspension was mixed with lOOpl of trypan blue stain (0.4% w/v) prior to counting on 
the haemocytometer.
2.4.3 Storage of cells in liquid nitrogen
A flask of actively growing cells was trypsinised and resuspended in growth medium. 
The cells were pelleted by centrifugation at 80 x g for 5 minutes, and then 
resuspended in growth medium, containing 20% (v/v) FCS and 8% (v/v) DMSO, to a 
flnal concentration of 5x10^ viable cells per ml. This suspension was dispensed into 
cryovials in 1ml aliquots and frozen at -70°C overnight before placing in liquid 
nitrogen for storage.
2.4.4 Recovery of cells from liquid nitrogen
A cryovial was incubated in a waterbath at 37°C for 1 minute, after which the 
contents were poured into a sterile centrifuge tube containing 10ml pre-warmed 
medium. The cells were pelleted by centrifugation at 80 x g for 5 minutes after which 
the pellet was carefully resuspended in 20ml growth medium and transferred to a 
culture flask.
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2.4.5 Charcoal treatment of foetal calf serum
Foetal calf serum (FCS) can contain steroid and hormonal contamination (Jackson et 
al., 1997; Nakama et al., 1995) which could affect the assessment of induction of the 
CYP3A4 fragment. To remove contaminants the FCS was pre-treated with dextran 
coated charcoal (DCC) (Fenske, 1991).
To treat one bottle of FCS (500ml), 500mg activated charcoal and 50mg dextran T70 
were added and the mixture was stirred for 30 minutes. The charcoal was pelleted by 
centrifugation at 1,500 x g for 15 minutes after which the supernatant was filter 
sterilised under vacuum by passage through a 0.22pm filter.
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2.5 Western blotting
Western blotting is a process used to detect the presence of a specific protein in a 
sample. Initially the proteins in the sample are separated by SDS-PAGE, after which 
the proteins are immobilised by electrophoretic transfer to a membrane. Following 
immobilisation the desired protein is detected immunologically.
2.5.1 Cell induction for Western blotting and HepG2 characterisation assays 
Three batches of HepG2 cells were prepared for use in Western blotting and/or 
characterisation assays.
Batch 1 contained cells in passage 10, whereas Batch 2 and Batch 3 contained cells in 
passage 11. For each batch 5 flasks were treated for each of the following 4 treatment 
protocols. Prior to treatment the cells were washed with PBS.
Treatment 1 : DMSO was added to each flask to a final concentration of 0.1%. 
Treatment 2: Dexamethasone (dissolved in DMSO) was added to each flask to give a 
final concentration of IpM dexamethasone and 0.1% DMSO.
Treatment 3: Rifampicin (dissolved in DMSO) was added to each flask to give a final 
concentration of 50pM rifampicin and 0.1% DMSO.
Treatment 4: A 2ml transfection precipitate containing pSG5-hGR (50pg) was made 
up per flask according to the optimised transfection protocol (Section 2.8.1.3), and the 
entire mixture added to the flask.
Treatments 1-3 were repeated daily for 3 days. For treatment 4 the cell culture 
medium was replaced daily for three days following transfection.
Following treatment the cells were lysed as described below (Section 2.5.2)
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2.5.2 Cell extract preparation for Western blotting
Growth medium was removed by aspiration, after which the cells were rinsed twice 
with PBS.
Batch 1 : After removal of the PBS, 2ml lysis solution was added per flask, and the 
cells were detached from the culture flask using a cell scraper 
Batch 2: 2ml lysis solution was added to flask 1, and the cells were detached from the 
culture flask using a cell scraper. The cell suspension was then transferred to flask 2, 
and the process repeated until all five flasks had been lysed. 1ml lysis solution was 
then added to flask 1 to rinse out any remaining debris. It was then transferred 
through the remaining four flasks, and then combined with the initial lysate.
Batch 3: 5ml lysis solution was added per flask and the cells were detached from the 
culture flask using a cell scraper.
For all three batches debris was pelleted by centrifugation of the suspension at 2,000 x 
g for 2 minutes, after which the supernatant was transferred to fresh tubes.
Protein was concentrated in the batch 3 extracts by precipitation with 12.5% ice-cold 
TCA. The protein was pelleted by centrifugation at 2000 x g for 10 minutes, after 
which it was resuspended in 500pl PBS (per treatment) containing IM NaOH.
The extracts were frozen at -70°C for storage.
2.5.3 Western blotting protocol
During this procedure proteins were separated by SDS-PAGE according to a method 
derived from that of Laemmli, (1970). The proteins were then immobilised by 
transfer to membranes by a method modified from that of Towbin et al., (1979).
Prior to assembly of the gel casting apparatus the glass plates were cleaned 
thoroughly in 70% EtOH. The resolving and stacking gels were made according to
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the recipes in Appendix 1. Samples were diluted to appropriate protein 
concentrations in PBS after which an equal volume of loading buffer was added to 
each sample.
The samples were then heated at 95-100°C in a boiling water bath for 5 minutes, after 
which they were allowed to cool; they were then briefly vortex mixed and centriftiged 
for a few seconds.
Following loading of the gel with molecular weight markers, positive control 
microsomes and samples, running buffer was added and the gel was run at 0.04 Amps 
and 120 volts for approximately 1.5 hours.
PVDF membrane was pre-wetted in 100% methanol, followed by a five minute wash 
in distilled water, and then 10 minutes equilibration in transfer buffer. The 
scotchbrite pads and blotting paper were pre-soaked for 10 minutes in transfer buffer. 
Once run the gel was then placed in the transfer cassette, against the membrane. This 
was coated by 2 layers of Whatman grade 3mm Cellulose blotting paper and a 
scotchbrite pad on each side. Transfer buffer was added and protein transfer was run 
overnight at a setting of 0.1 amps and 120 volts.
Primary and secondary antibodies and streptavidin-horseradish peroxidase (HRP)- 
conjugate were diluted in TBS containing membrane-blocking reagent (1%, supplied 
in Amersham kit). The concentrations of each antibody used are given in Table 2-2. 
Following transfer, the membrane was trimmed to size and placed in a 50ml 
polypropylene tube to which 10ml of membrane blocking reagent (5% in TBS) was 
added. The tube was then placed on a roller mixer for 1 hour (and during all 
subsequent incubations and wash steps). Following the blocking incubation the 
membrane was washed in 10ml TBS-tween for one 10 minute wash followed by two 
five minute washes.
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This was followed by an hour incubation with the primary antibody, after which the 
washing protocol was repeated. The membrane was then incubated in the presence of 
the secondary antibody (biotinylated species-specific antibody) for one hour, after 
which the washing protocol was again repeated. This was followed by a 20 minute 
incubation with streptavidin-HRP (5pi in 10 ml TBS with 1% blocking reagent) 
conjugate after which the washing steps were again repeated prior to detection.
The membrane was careftilly removed from the tube using membrane forceps and the 
edge carefully dabbed against a tissue to remove any remaining wash buffer; it was 
then placed protein-side-up in a petri dish and membrane detection reagents were 
added to cover the membrane.
Detection was achieved using either ECL or ECL Plus detection reagents (the 
chemistries of which are illustrated in Figure 2-6 and 2-7; solutions defined in 
Appendix 1). For ECL reagents 1.5ml of solution A was mixed with 1.5ml of 
solution B immediately prior to use. For ECL Plus reagents 2ml of solution A was 
mixed with 50pl of solution B immediately prior to use.
For ECL detection the membrane was incubated with detection reagents for 1 minute; 
excess detection reagents were then drained off and the membrane was placed in the 
camera tray and exposed to film. With ECL Plus the membrane was incubated with 
detection reagents for 5 minutes prior to exposure to film.
For ECL and ECL Plus an initial exposure of 1 minute was carried out, and the timing 
of subsequent exposures adjusted according to signal intensity.
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Table 2-2 Primary and secondary antibodies used in Western blotting
Antibody Source Dilution of Stock
Rabbit anti-rat CYP3A Amersham 1:200 (50pl in 10ml diluent)
Rabbit anti-human CYP3 A4 Dr.R.Edwards* 1:4000 (2.5pl in 10ml diluent)
Rabbit anti-human CYP3A5 Dr.R.Edwards* 1:2000 (5pl in 10ml diluent)
Biotinylated donkey anti-rabbit Ig Amersham 1:2000 (5pl in 10ml diluent)
Mouse anti-human glucocorticoid Serotec 1:1000 (lOpl in 10ml diluent)
receptor
Biotinylated sheep anti-mouse Ig Amersham 1:400 (25pl in 10ml diluent)
School of Medicine, The Hammersmith Hospital, London. The anti-CYP3A5 is mono-specific for 
CYP3A5; the anti-CYP3A4 antibody may also bind to CYP3A7. Diluent = TBS containing 1% 
membrane blocking reagent (Amersham).
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Figure 2-6 Chemilummescent reaction of ECL detection 
reagents (Amersham) with horseradish peroxidase (HRP)
O
NH
NH
Luminol
O
HRP
O
.0
+  N g - h  L i g h t
3-Aminophthalate 
(Taken from Amersham kit protocol)
Figure 2-7 Chemiluminescent reaction of ECL PLUS detection 
reagents (Amersham) with horseradish peroxidase (HRP)
peroxide + HRP
buffer, 
peroxide
Lumigen PS-3 Acridinium ester
L i g h t
* = excited product; (Taken from Amersham kit protocol)
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2.6 Plasmid purification
Procedures such as calcium phosphate mediated transfection or electroporation 
require the use of plasmid DNA that is very pure, free from contaminants such as 
protein, salt, genomic DNA, RNA or silica resin fines used in some purification 
methods. DNA with a spectrophotometrically determined optical density (OD) ratio 
(OD260/OD28 0) of more than 1.85 or less than 1.6 should not be used (Robbins et al., 
1996).
Plasmids have traditionally been purified using caesium chloride gradients, however a 
number of kits are now commercially available for the isolation of plasmid DNA. 
Several kits were used throughout this project; all were derived from an alkaline lysis 
method (Bimboim & Doly, 1979; Ish-Horowicz & Burke, 1981).
All of the following plasmid purification methods extract plasmid DNA from an 
overnight maxi-culture of bacteria in LB medium as described in Section 2.3.3. 
Following purification, plasmid preparations were stored at -20°C.
2.6.1 Wizard Maxiprcp (original protocol )
1) 500ml of bacterial cells in LB medium were pelleted by centrifugation at 5,000 x 
g for 20 minutes at 22-25°C in a room temperature rotor, after which the 
supernatant was discarded and the pellet was completely resuspended in 15ml of 
Cell Resuspension Solution.
2) 15ml Cell Lysis Solution was added, and the solution mixed gently by inversion 
until clear and viscous, after which 15ml Neutralisation Solution was added 
followed immediately by gentle inversion of the centrifuge bottle several times to 
mix components.
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3) The suspension was then centrifuged at 14,000 x g for 20 minutes at 22-25°C in a 
room temperature rotor, after which the cleared supernatant was filtered through 
glass microfibre paper into a clean graduated measuring cylinder.
4) 0.6 volume of room temperature isopropanol was added, and the solution mixed 
by inversion. DNA was pelleted by centriftigation at 14,000 x g for 20 minutes at 
22-25°C in a room temperature rotor, after which the supernatant was discarded 
and the DNA pellet resuspended in 2ml of TE buffer.
5) 10ml of Wizard Maxipreps DNA Purification Resin was added to the DNA 
solution that was then mixed by gentle swirling.
6) The DNA/resin mix was then drawn into a Wizard Maxicolumn using a Vac-Man 
vacuum manifold (Promega). The bound DNA/resin mix was then washed by 
passing 25ml Column Wash Solution through the Maxicolumn under vacuum, 
after which the DNA resin mix was rinsed by the addition of 5ml of 80% ethanol 
which was drawn through the column under vacuum. The vacuum was then 
allowed to draw for an additional 1 minute.
7) Any remaining wash solution and ethanol was then removed by centriftiging the 
Maxicolumn (in a 50ml screw cap tube) using a table top centrifuge with a 
swinging bucket rotor at 1300 x g for 5 minutes, after which a vacuum was drawn 
through the Maxicolumn for an additional 5 minutes to dry the resin to 
completion.
8) 1.5ml of preheated (65-70°C) TE buffer was applied to the Maxicolumn and left 
to stand for 1 minute, after which the DNA was eluted by centriftiging the 
Maxicolunm (in a 50ml screw cap tube) at 1300 x g for 5 minutes in a table top 
centriftige with a swinging bucket rotor.
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2.6.2 Wizard Maxiprep plus (modified maxiprep protocol)
During the project the Wizard Maxiprep kit was modified to the Wizard Maxiprep 
plus kit, the protocol for which was as for (Section 2.6.1) with the following 
adjustments.
In step 4 - 0.5 volumes of isopropanol were used. The reduction in volume was to 
reduce RNA carry-over.
In step 8 — After elution of the DNA from the Maxicolumn it was passed through a 
0.22pm Syringe Filter using a 5ml syringe. This step ensured removal of resin fines 
that might have been present in the eluate.
2.6.3 Wizard Megaprep protocol
The protocol used was identical to the original protocol used for Wizard Maxiprep 
except that all volumes were doubled, including that of the initial bacterial culture.
2.6.4 Qiagcn Endofrcc Maxiprcp protocol
Endotoxins are lipopolysaccharide (EPS) components of the lipid portion of the outer 
layer of the outer membrane of the cell membranes of Gram-negative bacteria such as 
E.coli (Rietschel & Brade, 1992). Each EPS molecule consists of a hydrophobic lipid 
A moiety, a complex array of sugar residues and negatively charged phosphate 
groups, thus possessing hydrophobic, hydrophilic, and charged regions giving it 
unique features with respect to possible interactions with other molecules (Raetz, 
1990, Rietschel & Brade, 1992). Lysis of bacterial cells during plasmid preparation 
leads to the release of large amounts of EPS into the lysate. The physico-chemical 
properties of EPS molecules lead to their co-purification with plasmid DNA.
100
The presence of endotoxins in plasmid preparations can dramatically decrease 
transfection efficiency in sensitive cells (Qiagen kit protocol) (Weber et ah, 1996). 
DNA purified with the Endofree Plasmid Maxi Kit contains only negligible amounts 
of EPS (less than 0.1 endotoxin units per pg plasmid DNA) due to the use of a 
specific endotoxin removal buffer that prevents EPS molecules from binding to the 
resin in the QIAGEN tips (Qiagen Kit protocol). DNA purified by this method can be 
used directly for transfection without the need for ethanol precipitation (Robbins et 
al., 1996).
The bacterial cells were pelleted by centrifugation at 6,000 x g for 15 minutes at 4°C, 
after which the bacterial pellet was resuspended in 10ml buffer PE 10ml buffer P2 
was added and the solution mixed by gentle inversion 4-6 times and incubated at 
room temperature for 5 minutes. 10ml chilled buffer P3 was added to the lysate, and 
mixed immediately but gently by inversion 4-6 times.
The lysate was poured into the barrel of the QIAfilter Maxi Cartridge and incubated at 
room temperature for 10 minutes, after which it was gently pushed through QIAfilter 
Maxi Cartridge using a plunger. The filtrate was collected in a 50ml tube to which 
was added 2.5ml Buffer ER followed by mixing by inversion of the tube 
approximately 10 times. The solution was incubated on ice for 30 minutes.
During this incubation 10ml Buffer QBT was applied to a QIAGEN-tip 500 to 
equilibrate it. The column was allowed to empty by gravity flow.
The cleared lysate was then applied to the QIAGEN-tip and allowed to enter the resin 
by gravity flow, after which the resin was washed 2 x 30ml Buffer QC twice. The 
DNA was then eluted with 15ml Buffer QN.
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10.5ml of room temperature isopropanol was added to the eluted DNA, the solution 
mixed and then centrifuged immediately at 15,000 x g for 30 minutes at 4°C, after 
which the supernatant was discarded.
The DNA pellet was washed with 2.5ml of endotoxin-free, room temperature 70% 
ethanol and centriftiged at 15,000 x g for 10 minutes. The supernatant was careftilly 
discarded and the pellet was air-dried for 5 minutes. After drying, the DNA was 
resuspended in 500pl of endotoxin-free TE Buffer.
2.6.5 Easy-pure plasmid maxiprep
250ml of bacterial cells were pelleted by spinning at 5,000 x g for 5 minutes, after 
which the supernatant was discarded. The bottle was re-spun for 2 minutes and all 
residual media removed using a pipette tip. The pellet was resuspended in 10ml of 
Resuspension solution and left to stand for 5 minutes.
10ml of Lysis solution was added and the contents mixed gently until the cell 
suspension became clear. The suspension was left to stand for approximately 10 
minutes, after which 10ml of Neutralisation solution was added and the contents 
mixed gently. 0.1ml of RNAse solution was then added and the contents were mixed. 
The mixture was centriftiged at 14,000 x g for 15 minutes, after which the supernatant 
was filtered through glass microfibre paper into a 50ml polypropylene tube.
0.6 volume of room temperature isopropanol was added to the supernatant, mixed by 
inversion and left to stand in ice for 10 minutes, after which the mixture was 
centrifuged for 10 minutes at 14,000 x g. The supernatant was discarded and the 
pellet was dissolved in 3ml of TE. 12ml of resin was added, and the tube mixed for 5 
minutes by tube inversion after which the slurry was transferred directly into the 
purification colunrn.
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The slurry was drawn into the column under vacuum and the DNA/resin mix was 
washed twice using 5ml of Ethanol Wash. After removal of the wash under vacuum 
3ml of 80% ethanol was added and drawn through under vacuum. The vacuum was 
left to draw for an additional 5 minutes following removal of the ethanol to dry the 
resin.
2ml of preheated TE (60°C) was added to the column and left to stand for 5 minutes. 
The DNA was eluted by centriftigation for 5 minutes at 1500 x g. If white resin fines 
were visible in the eluted DNA they were removed by spinning the DNA in a clean 
microcentriftige tube, after which the supernatant was transferred to a ft-esh tube.
2.6.6 FlexiPrep
The FlexiPrep kit presents a protocol that may be adapted to process a wide range of 
culture volumes. The following protocol was used on a 100ml bacterial culture. 
Bacterial cells were pelleted by centriftigation at 7700 x g for 10 minutes, after which 
the supernatant was discarded. The pellet was resuspended in 20ml of ice-cold STE 
buffer by pipetting, and then repelleted as above and the supernatant discarded. The 
pellet was then resuspended in 10ml of solution I by pipetting. 500pl of freshly 
prepared lysozyme (lOmg.mf^) was added to the solution that was then mixed and 
placed on ice for 5 minutes.
10ml of solution II was then added and the tube inverted 4 times to mix the contents, 
after which it was left to stand at room temperature for 5 minutes.
10ml of solution III was added and the tube mixed by inversion, after which it was 
placed on ice for 10 minutes. The suspension was then centriftiged at 12,000 x g for 
15 minutes at room temperature, after which the supernatant was decanted into a clean 
centriftige tube.
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21ml of room temperature isopropanol was added to the supernatant, mixed well and 
then incubated for 10 minutes at room temperature, after which the DNA was pelleted 
by centrifugation at 12,000 x g for 20 minutes to pellet the plasmid DNA. The 
supernatant was discarded.
10ml of Sephaglass FP suspension was added to the DNA pellet that was then 
dissolved by gentle vortexing for one minute. The DNA suspension was incubated at 
room temperature for 10 minutes, during which the sample was mixed by vortexing 
every 2 minutes to keep the Sephaglass in suspension.
The Sephaglass was pelleted by centrifugation at 1,000 x g for 2 minutes in a tabletop 
centrifuge, and the supernatant discarded. 10ml of Wash Buffer was added to the tube 
that was then vortexed gently to resuspend the pellet, after which it was centrifuged as 
above. The supernatant was discarded. The pellet was then resuspended by vortexing 
in 10 ml of 70% ethanol, after which it was repelleted by centriftigation as above.
The supernatant was discarded, and the tube was re-centrifuged without a cap at 1,000 
X g for 1 minute, after which any residual ethanol was removed with a pipette.
The tube was tapped to partially disperse the Sephaglass pellet that was then allowed 
to air dry for 20-30 minutes at room temperature.
To elute the bound DNA from the Sephaglass, 1ml of TE buffer was added and the 
pellet was resuspended by vortexing. The tube was then incubated for 10 minutes at 
room temperature, vortexing occasionally to keep the Sephaglass in suspension.
The Sephaglass was pelleted by centrifugation at 1,000 x g for 5 minutes and the 
supernatant transferred to a clean centrifuge tube.
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2.6.7 Hybaid Recovery -  Quick flow maxiprep kit protocol
30ml column equilibration solution was added to the purification column before the 
preparation of a cleared lysate. The column was allowed to empty by gravity flow. 
100ml bacterial cells were pelleted by centrifugation at 5,000 x g for 20 minutes. The 
supernatant was discarded and all traces of medium removed. The pellet was 
resuspended in 10ml Resuspension Solution, after which 10ml Cell Lysis Solution 
was added and the tube inverted 5 times. The mixture was incubated at room 
temperature for 5 minutes, after which 10ml Neutralisation Solution was added and 
the contents mixed immediately by gentle inversion 5 times. The mixture was 
centriftiged at 20°C and 15,000 x g for 10 minutes.
The supernatant was added to the equilibrated column, and the lysate allowed to run 
by gravity flow. The column was washed through with 60ml Column wash, emptying 
by gravity flow.
DNA was eluted from the column by the addition of 15ml Elution solution, and 
collected as the column emptied by gravity flow.
0.7 volume of room temperature isopropanol was added to the DNA which was 
pelleted by centrifugation at 4°C and 15,000 x g for 30 minutes, after which the pellet 
was washed with 70% ethanol and re-centriftiged. The pellet was air-dried for 10 
minutes and then re-dissolved in 500pl TE.
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2.6.8 Ethanol precipitation of plasmid DNA
Ethanol precipitation was used as a means to purify and/or concentrate samples of 
plasmid DNA prior to transfection.
Plasmid 450pl
Sodium Acetate (3M) 45pi
100% Ethanol 1ml
The above components were added to a sterile microcentrifuge tube and placed at - 
20°C overnight (volumes were scaled up or down as required). The DNA was 
pelleted by centrifugation in a microcentrifuge at 12,000 x g at 4°C for 12 minutes, 
after which the supernatant was discarded. The pelleted DNA was washed in 70% 
ethanol and the sample re-spun in a microcentrifuge at 12,000 x g at 4°C for 2 
minutes, after which the supernatant was again discarded. The pellet was then air- 
dried for 5 minutes after which it was resuspended in 200pl 0.1 x TE.
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2.7 Analysis of plasmid DNA
When using DNA in procedures such as transfection it is important to be able to 
accurately estimate the concentration and purity of a plasmid preparation. Some 
contaminants can affect the accuracy of spectrophotometric determination of DNA 
concentration thus the plasmid preparation was assessed by both UV analysis and 
agarose gel electrophoresis.
2.7.1 UV analysis of plasmid DNA
The purity and concentration of a plasmid DNA preparation was determined by 
measuring the UV absorbance of a diluted aliquot over the wavelength range of 200- 
300nm. Samples were diluted in MilliQ water and were measured against a water 
blank in matched quartz cuvettes. The purity and DNA concentration of the 
preparation were determined as described by Sambrook et al., (1989).
DNA purity = ratio Abs^ ^® : Abs^ ^®
DNA concentration (pg/pl) = Abs^^^x 1 absorbance unit (us.ml'h x D
1,000
Where Abs^^  ^ = absorbance reading at 260nm
1 absorbance unit (Abs^ ^®) = SOpg.ml'  ^dsDNA
D = dilution factor
1,000 = conversion factor to pg.pl"^
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A pure plasmid DNA sample gives a symmetrical peak at 260nm and a 260/280 ratio 
of approximately 1.8. Impurities such as protein, salt, RNA or silica resin fines will 
affect the purity ratio and the observed concentration; this becomes apparent when the 
concentration determined by UV analysis does not correlate with the concentration 
upon electrophoretic analysis.
2.7.2 Restriction enzyme digests of plasmid DNA
Restriction endonucleases are enzymes that cut double stranded DNA molecules at 
specific sequences.
Restriction digests were set up as follows
Standard restriction digest incubation mixture
DNA Iftg
Enyzme 10 units*
lOx Restriction enzyme buffer 2pl
MilliQ water To 20pl
1 unit of restriction enzyme activity is defined as the amount of enzyme 
required to completely digest 1 pg of substrate DNA in sixty minutes.
Reactions were incubated at 37°C for a minimum of 1 hour. Restriction enzymes 
used in this study are detailed in Table 2-3.
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Table 2-3 Restriction enzymes used in this study, 
and their recognition sequences.
Enzyme Recognition Sequence
EcdKl G^AATTC
Hindlll A^AGCTT
Pstl CTGCA^G
Sali GTTCGAC
Seal AGT^ACT
Xbal T^CTAGA
The symbol (^) denotes the site at 
which the enzyme cuts DNA.
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2.7.3 Agarose gel electrophoresis
Agarose gel electrophoresis is a procedure commonly used in the analysis of DNA. 
The rate of migration of DNA through an agarose gel matrix is dependent on a 
number of factors including the molecular size of the DNA, the conformation of the 
DNA (superhelical circular, nicked circular, and linear migrate at different rates), the 
concentration of the agarose, the applied voltage, the presence of intercalating dyes 
and the composition of the electrophoresis buffer (Sambrook et al., 1989). When 
standard markers are run alongside a DNA sample it is possible to estimate both the 
size and the concentration of the plasmid sample.
Agarose gel electrophoresis of DNA was carried out according to the standard 
protocol described by Sambrook et al., (1989). Agarose gels of 0.8-1.2% w/v 
(depending on the sizes of the DNA to be separated) were prepared in TAB buffer. 
For staining of the DNA, ethidium bromide was included in the gel (O.Spg.mT^). 
Samples were mixed with 6x loading dye prior to running, and the gels were run at 
2.5V.cm"\ DNA markers of appropriate size were run along side the samples in 
order to estimate the size of the DNA molecules.
Although not as sensitive as UV analysis this technique does highlight situations 
where contaminants in the plasmid sample are falsely elevating the apparent DNA 
concentration.
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2.7.3.1 Visualisation of DNA in agarose gels
DNA in agarose gels was visualised by staining with ethidium bromide followed by 
exposure to UV light using a transilluminator (Model TM20, Genetic Research 
Instrumentation Ltd.). Ethidium bromide is a fluorescent dye that intercalates into 
nucleic acid molecules, absorbing UV radiation at SOOnm and emitting at 590nm in 
the visible spectrum. Thus DNA in the gel was visualised as red/orange bands upon 
exposure to UV light.
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2.8 Transfection methods
DNA may be introduced into cultured mammalian cells by a number of different 
methods (as described in Section 1.5.2). One of the most widely used methods is 
calcium phosphate precipitation as it is cheap, can achieve an acceptable transfection 
efficiency, and may be applied to many different cell lines (Graham & Van Der Eb, 
1973); other commonly used methods include lipofection (Feigner et al., 1987) and 
electroporation (Alam & Cook, 1990).
2.8.1 Calcium phosphate transfection
In this technique the uptake of DNA by cells in culture is enhanced by presenting the 
DNA as a calcium phosphate-plasmid co-precipitate. Depending on the cell line used 
up to 20% of a population of cultured cells can be transfected at any one time 
(Sambrook et al., 1989).
The calcium phosphate precipitation method requires detailed optimisation before 
reproducible and acceptable transfection efficiencies may be achieved. A number of 
variations on the basic method are possible, depending on whether transient or stable 
transfection was required, and on the nature of the cell line.
Table 2-4 shows an overview of timing of the basic steps in a transient transfection 
assay.
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Table 2-4 The timescale of calcium phosphate transfection experiments
Basic protocol Xenobiotic induction assay Transfection efficiency assay
Day 1 Seed cells
Day 2 Change medium 
Transfect cells
Day 3
Change medium
Assay medium 
Dose cells
Day 4 Assay medium
Day 5 Assay medium
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2.8.1.1 Cell seeding protocol
The following seeding protocol was used for all methods of calcium phosphate 
transfection with the exception of transfection in suspension (Section 2.8.1.4) in 
which the cells are transfected prior to seeding.
A flask of actively growing cells (50-80% confluent) was selected. The cell culture 
medium was removed by aspiration, the cells were washed in PBS that was also 
removed by aspiration, and the cells were then harvested by trypsinisation in 1ml 
trypsin-EDTA. 9ml of growth medium was added to the cells and a small aliquot of 
cells was taken and counted. For standard seeding protocol the cells were then diluted 
in growth medium to a concentration of 6x10^ cells per ml. HepG2 cells frequently 
grow in clumps, making both accurate counting and seeding difficult. In the cases 
where the trypsinised cells appeared to be clumping badly the clumps were broken up 
by gently passing the cells through a sterile 0.8mm-bore needle with a syringe. 
Excessive force during this stage resulted in poor cell viability, so was avoided when 
possible; this problem was not encountered with the H4-II-E-C3 cells or with the 
CHO-Kl cells.
For cell seeding in a six well culture plate 2ml of pre-warmed medium was added per 
well, and then 1ml of cell suspension added per well. For cell seeding in a 24 well 
culture plate 400pl of pre-warmed medium was added per well, and then 200^1 of cell 
suspension added per well. For cell seeding in a 96 well culture plate 80pl of pre- 
warmed medium was added per well, and then 40pl of cell suspension added per well. 
The plates were placed in humidified containers in the cell culture incubator at 37°C 
for 24 hours. After this time the growth medium was removed. For six well and 24 
well plates the medium was removed by aspiration, but for 96 well plates the medium
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was removed using a multi-channel pipette. The cells were washed with PBS (1ml 
for 6 well plates, 40pl for 96 well plates), which was also removed.
For all methods of calcium phosphate transfection using pre-seeded cells the cell 
culture medium was removed and replaced with fresh medium 1 hour prior to 
transfection. With the exception of the CalPhos Maximizer protocol, 2ml of pre- 
warmed culture medium was added per well to six well plates, 400pl to 24 well plates 
and 80pl to 96 well plates. In the CalPhos Maximizer protocol (carried out only in 6 
well plates) 3ml medium was added. The cells were then returned to the incubator for 
an hour during which time transfection mixtures were prepared.
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2.8.1.2 Original method for calcium phosphate transfection
The following method, derived from a method described by Sambrook et al., (1989), 
was used in our laboratory for the initial work involving calcium phosphate 
transfection (Williams, 1997).
Reagents were allowed to warm to room temperature. The following incubation 
mixture was then made up (sufficient for 1 well of a six well plate -  volumes were 
scaled up in proportion where required).
Standard incubation mixture
DNA (40ng m r‘ in O.lx TE) 220pl
2xHBS 250pl
To initiate precipitate formation
CaCl2(2M) 30pl
To initiate precipitation 30pl CaCli was added dropwise to the standard incubation 
mixture while gently swirling the tube. The mixture was then allowed to stand for 20 
minutes, to allow formation of the precipitate, after which it was slowly added to the 
wells, while mixing by gentle rocking of the plate.
For transfection in 96 well plates 20pl of precipitate mixture was added per well.
2.8.1.3 Optimised method for calcium phosphate transfection
Previous work in our laboratory (Sarah Giddings, personal communication) has 
shown that higher transfection efficiencies can be obtained by modifying the 
parameters of the original precipitation reaction (Section 2.8.1.2), as was seen with
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the following procedure which is a modification of a procedure detailed by (Jordan et 
al, 1996).
All reagents used in this procedure were kept on ice while the incubation mixes were 
prepared, as the transfection mix temperature is critical in precipitate formation 
(Jordan et al., 1996).
For the standard optimised procedure 2ml of precipitate was usually prepared, 
although this may be adjusted up or down depending on the experimental 
requirements. A standard DNA concentration of 25pg.ml'^ precipitate was used.
For 2ml precipitate
2M CaCl2 lOOpl
DNA (dissolved in TE buffer) 50|ag
O.lxTE To 1ml
To initiate precipitation reaction
2xHBS 1ml
To terminate precipitation reaction
Cell culture medium 4.6ml
The precipitation mixture was prepared on ice. To initiate the precipitation reaction 
1ml 2xHBS was added rapidly and mixed in by pipetting. The precipitate was 
allowed to form during a 1 minute incubation on ice. The precipitation reaction was 
terminated by the addition of 4.6ml of pre-warmed cell culture medium. The reaction 
mixture was quickly mixed by tube inversion, after which it was added to the cells. 
For 6 well plates 1ml of reaction mixture (equivalent to 300pl precipitate or 7.5pg 
DNA) was added per well. For 96 well plates 40pl of reaction mixture (equivalent to 
I2[il precipitate or 0.3pg DNA) was added per well. For 24 well plates 200pl of
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reaction mixture (equivalent to 60pl precipitate or 1.5pg DNA) was added per well.
The plates were placed in humidified containers and then returned to the cell culture 
incubator.
2.8.1.4 Calcium phosphate-mediated transfection of adherent cells in suspension
The precipitate was formed exactly as specified in Section 2.8.1.2.
While the precipitate was forming, cells were harvested by trypsinisation, 
resuspended in medium, counted and divided into aliquots containing 10^  cells. The 
cells were pelleted by centrifugation at 80 x g for 5 minutes at 4°C, after which the 
supernatant was discarded. The cell pellets were each resuspended in 0.5ml of the 
calcium phosphate-DNA suspension and incubated for fifteen minutes at room 
temperature, after which add 5.5ml of pre-warmed medium was added to each aliquot. 
3ml was added per well to a six well plate.
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2.8.1.5 Modified calcium phosphate-mediated transfection procedure
This method has been reported to be a highly efficient method for obtaining stable 
transformation of mammalian cells with supercoiled plasmid DNA; linear DNA is 
reported to give low efficiency with this method (Sambrook et al., 1989).
In this method the cells were seeded according to the standard protocol.
For 2mls precipitate
DNA (2ng.nr‘ in O.lxTE) 25pl
2.5M CaCl2 975pl
To initiate precipitate formation
2xBES 1ml
The reaction mixture was prepared as above, and the precipitation reaction initiated 
by the addition of 2xBES, after which the mixture was left to incubate for 20 minutes 
at room temperature. Following incubation 4.6ml of pre-warmed cell culture medium 
was added to the tube. The reaction mixture was mixed by tube inversion, after which 
it was added to the cells. For 6 well plates 1ml of reaction mixture (equivalent to 
300pl precipitate or 7.5pg DNA) was added to the cells. For 96 well plates 40pl of 
reaction mixture (equivalent to 12|l i 1 precipitate or 0.3pg DNA) was added to the 
cells. The plates were returned to the incubator in humidified containers, and 
incubated overnight at a CO2 concentration of 4%. Under conditions of low pH the 
calcium phosphate-DNA co-precipitate forms very slowly, gradually precipitating 
onto the cells.
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2.8.1.6 CalPhos Maximizer transfection protocol
The cells were seeded according to normal seeding protocol, and the medium was 
changed 1 hour prior to transfection, as described above.
For each transfection, solution A and solution B were prepared in separate sterile 
tubes.
Solution A
DNA (4pg diluted in sterile water) 2-4pg (lOOpl final volume)
CalPhos Maximizer 5-30pl
2M Calcium 12.4 |l i 1
Solution B
2xHBS lOOpl
Solution B was gently vortexed while slowly adding solution A dropwise, to initiate 
the precipitation reaction, after which the solution was incubated at room temperature 
for 20 minutes. The transfection solution was then gently vortexed and added 
dropwise to the cells (200pl transfection solution per well of a 6 well plate) while 
gently rocking the culture plate to ensure even distribution. The plates were then 
incubated in humidified containers for 6 hours in the cell culture incubator, after 
which the medium was removed by aspiration, and the cells washed with PBS. The 
medium was then replaced and the cells returned to the incubator.
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2.8.1.7 Shock treatment of transfected cells with DMSO or glycerol
Shock treatment of cells post-transfection, with either glycerol or DMSO, can 
enhance the transfection efficiency (Sambrook et ah, 1989).
16 hours post-transfection the cell culture medium was removed and the cells were 
washed in PBS (80pl per well of a 96 well plate). Following removal of the PBS the 
cells were treated with either a glycerol or DMSO shock.
For glycerol shock treatment, 80pl glycerol shock solution (15% v/v glycerol in 
IxHBS warmed to 37°C) was added per well. The cells were incubated at room 
temperature for 1 minute, after which the shock solution was removed.
For DMSO shock treatment, 80pl DMSO shock solution (10% v/v DMSO in PBS 
warmed to 37°C) was added per well. The cells were incubated at room temperature 
for 2 minutes, after which the shock solution was removed.
After removal of the shock solutions the cells were washed twice in PBS. Fresh cell 
culture medium was then added and the cells were returned to the cell culture 
incubator.
2.8.2 Electroporation
The efficiency of transfection by electroporation may be influenced by a range of 
factors including the strength of the applied electric field, the length of the electric 
pulse, the temperature of the cell culture medium, the conformation and concentration 
of the DNA, the ionic composition of the medium, and cell density and growth phase 
(Sambrook et al., 1989).
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A flask of cells (approximately 80% confluent) was harvested by trypsinisation, and 
an aliquot was counted. The cells were pelleted by centrifugation at 80 x g for 5 
minutes and resuspended in fresh growth medium to a concentration of 5 x 10^  cells 
per ml. 0.8ml cell suspension was placed in a sterile electroporation cuvette, to which 
8pl DNA (Ipg.pT^ in O.lxTE, either linearised or supercoiled) was added. The 
cuvette was sealed and the electric field applied.
Experiments to optimise applied voltage and capacitance settings were carried out as 
described in Section 3.11.1. For stable transfections the cells were electroporated at 
400 volts at a capacitance of 25pFD.
Immediately following electroporation the cells were resuspended in fresh medium to 
9ml total volume for optimisation experiments or 10ml for stable transfections. For 
optimisation experiments 3ml was seeded per well of a 6 well plate. For stable 
experiments the 10ml was placed in a 25cm^ cell culture flask. Cell culture medium 
was replaced 24 hours post-transfection to remove the large numbers of dead cells 
generated by this procedure.
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2.8.3 Xenobiotic addition to transfected cells
l,000x Stocks of the xenobiotic inducers were dissolved in suitable solvents. The 
solvent of choice was DMSO, however a few chemicals proved to be extremely 
poorly soluble in DMSO. In these cases the next solvent of choice was absolute 
ethanol. Unless otherwise stated, drug solutions and solvent controls were added to 
cell culture medium to give a final concentration of 0.1% solvent.
Those compounds dissolved in absolute ethanol were as follows: clotrimazole, 
phenobarbitone and phenytoin.
All solutions were freshly prepared on the day of dosing.
2.8.4 Poly-D-Iysine coating
Previous work in our laboratory has demonstrated that coating of cell culture plates 
with poly-D-lysine can enhance the transfection efficiency of HepG2 cells (Sarah 
Giddings, personal communication).
For 6 well plates SOOpl of poly-D-lysine solution (O.lmg.mF^) was added per well; for 
96 well plates 20pl was added per well. The plates were rocked gently to ensure 
complete coverage of the surface and were then incubated at room temperature for 5 
minutes, after which the poly-D-lysine was removed. The wells were then washed 
with sterile PBS (1ml per well for 6 well plates and 40pl for 96 well plates) which 
was then removed and the plates were left to dry overnight. Coated plates were stored 
in sterile conditions at room temperature until required.
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2.9 Reporter gene assays
As described in Section 1.5.3, reporter genes code for proteins that may easily be 
distinguished from the normal proteins expressed by the host cell. In the case of both 
P-galactosidase and secreted placental alkaline phosphatase the reporter protein is 
distinguishable by measurement of its catalytic activity, which is separable from 
similar host cell catalytic activities by the use of carefully defined reaction conditions. 
Throughout this project these reporter assays were used either as a measure of 
transfection efficiency, or to report on the level of transcriptional activation of the 
fragment of CYP3A4 regulatory DNA under investigation.
2.9.1 Assays for p-galactosidase activity
The p-galactosidase reporter gene is derived from the lacZ gene of E.coli, it exhibits 
maximal activity at neutral to alkaline pH (optimum pH 7.0-7.5), allowing 
discrimination from endogenous mammalian p-galactosidase (optimal pH 3.0-6.0) 
(MacGregor et al., 1987).
2.9.1.1 Colourimetric p-galactosidase assay
The chemistry of this reaction is detailed in Figure 2-8.
Cell culture medium was removed, and the cells washed twice with 500pl PBS. After 
removal of the PBS 500pl of lysis buffer was added per well, and the plate rocked 
gently to ensure complete cell coverage. The plate was incubated at room 
temperature for 5 minutes and then the lysis buffer was collected for assay.
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700pl of Z buffer was added to lOOpl of lysate, and incubated at 37°C for 5 minutes. 
Following this incubation 140pl of a-nitrophenyl-p-D-galactopyranoside (ONPG) 
solution (2mg.mF^ in Z buffer) was added and the mixture was incubated at 37°C 
until the solution turned yellow. The amount of time taken for this step varied greatly 
depending on the level of p-galactosidase expression in the transfected samples, 
varying from 1 hour to overnight. The reaction was stopped by the addition of 400pl 
Na2C0 3  (IM) and the incubation time in the presence of ONPG was recorded. The 
absorbance of the solution was then measured at 420nm, against a reagent blank.
Calculation of activity of p-galactosidase:
1 unit uF^  hr'  ^= 1,000 x Abs"^ ^^
v x t
where Abs"^ ®^ = absorbance at 420nm 
V = sample volume (pi) 
t = incubation time (hours)
2.9.1.2 Chemiluminescent assay for P-galactosidase
The chemistry of this reaction is detailed in Figure 2-9.
The chemiluminescent assay for p-galactosidase (Galacto-Light Plus, Tropix) has a 
wide dynamic range enabling detection from 2fg to 20ng of detectable P- 
galactosidase (Jain & Magrath, 1991).
Sufficient reagents for the assay were removed from storage and allowed to 
equilibrate to room temperature.
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Cells were rinsed twice with PBS (40pl per well of a 96 well plate) after which lysis 
solution was added (50pl per well). The plate was rocked gently for 1 minute to 
ensure complete coverage of the cells. 20pl lysate per well (in duplicate) was 
transferred to a 96 well optiplate.
70pl reaction buffer was added per well and the plate was incubated at room 
temperature for 1 hour. lOOpl accelerator solution was added per well and the plate 
immediately assayed for light emission.
2.9.1.3 Staining for p-galactosidase
The histochemical staining of cells demonstrating p-galactosidase activity may be 
used to determine the percentage of transfected cells, thus allowing the estimation of 
the transfection efficiency of a particular method.
The cells were washed once with PBS, which was then removed by aspiration. 
Fixative solution (2ml per well of a 6-well culture plate) was then added and the plate 
rocked gently to ensure that the surface was covered. Following incubation for 15 
minutes at room temperature the fixative was removed by aspiration and the cells 
were washed 3 times with PBS. Staining solution (1ml per well of a 6-well culture 
plate) was added and the plate was incubated for 0.5-3 hours at 37°C until blue 
staining of some cells was apparent. The staining solution was removed by aspiration 
and the cells washed three times with PBS. The cells were analysed in PBS under a 
light microscope without phase contrast. To determine the transfection efficiency the 
numbers of stained and non-stained cells in 3 random viewing fields per well on the 
plate were counted, and the percentage of stained cells in the total cell population was 
calculated.
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Figure 2-8 The colourimetric assay for p-galactosidase activity
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Figure 2-9 The chemiluminescent assay for p-galactosidase activity
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2.9.2 Assays for alkaline phosphatase activity
As described in more detail in Section 1.5.3.2, human secretory placental alkaline 
phosphatase may be readily distinguished from similar host cell activities by the use 
of heat deactivation of samples or the inclusion of inhibitors of endogenous alkaline 
phosphatase in the reaction buffers. Heat deactivation is used in the colourimetric and 
chemiluminescent assays described below, however selective inhibitors are included 
only in the chemiluminescent protocol.
2.9.2.1 Heat deactivation of media samples for alkaline phosphatase assay 
For the colourimetric assay, samples in microcentrifuge tubes were incubated for 30 
minutes at 65°C in a water bath, following which they were allowed to cool to room 
temperature prior to assay.
For samples in microplates (96 well), the plates were sealed with a plastic strip, and 
then incubated for 1 hour at 65°C in an oven.
2.9.2.2 Colourimetric alkaline phosphatase assay
The chemical basis of this assay is illustrated in Figure 2-10.
The samples to be analysed were aliquotted into cuvettes (lOOpl per cuvette), to 
which 1ml of freshly prepared PNPP (5mM in DEA buffer) was then added.
The samples were then incubated at 37°C in the dark until the development of yellow 
colour, after which the absorbance of the samples was measured at 405nm against a 
reagent blank. The incubation time with PNPP was recorded.
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The concentration of SPAP in the original medium (units mf^) could then be 
calculated as follows:
[SPAP] in medium = Abs 405
t  X 18.5 X V
where Abs"^ ®^  = Optical density at 405nm (must be within linear range<1.5) 
t = PNPP reaction time in minutes 
V = volume of medium assayed (ml)
1 SPAP unit = hydrolysis of 1 pmole of PNPP per minute
2.9.2.S Chemiluminescent alkaline phosphatase assay
The chemical basis of the Aurora chemiluminescent alkaline phosphatase assay is 
illustrated in Figure 2-11.
Sufficient Assay Buffer and Reaction Buffer (both stored at 4°C) for the assay was 
allowed to equilibrate to room temperature. 25pl of heat deactivated sample was used 
per well of a 96 well optiplate. To each well 75pi of dilution buffer was added. 
lOOpl of Assay Buffer was then added per well and the plate was incubated at room 
temperature for 5 minutes. lOOpl of Reaction Buffer was then added per well. The 
plate was then incubated at room temperature for 20 minutes.
5 minutes prior to measurement the plate was placed inside the luminometer (in the 
dark) to reduce the effect on the assay of background phosphorescence from the white 
plate. Following incubation, light emission from the plate was measured.
On each plate some wells were used as reagent blanks, the average of which was 
subtracted from the results before analysis. On single plate assays the gain and
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photomultiplier settings were automatically determined by the machine to ensure 
maximum sensitivity of readings. During assays in which more than one plate was 
required some wells on each plate were also used to contain a positive control (a 
known amount of alkaline phosphatase calculated to produce slightly brighter light 
emission than the brightest sample). The ideal gain and photomultiplier settings were 
determined on the first plate only and were then fixed at those values so that all plates 
in the series were assayed under identical conditions. The average of the positive 
control values per plate was then used to normalise the readings between all the plates 
of the series prior to data analysis.
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Figure 2-10 The colourimetric assay for alkaline phosphatase activity
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Figure 2-11 The chemiluminescent assay for alkaline phosphatase activity
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2.10 Cytolite cytotoxicity assay
The basis of the Cytolite assay is illustrated in Figure 2-12. The cationic 
chemiluminogenic probe (CLP^^) binds to the cell membrane of all intact cells. Upon 
contact it is transformed into a univalent radical state (CLP^ ). Unbound CLP remains 
in the CLP^  ^state and does not participate in the reaction process further. The 
amplifier solution contains a reduced coenzyme, formulated with a carrier component 
that facilitates its uptake by the cells. The coenzyme drives a series of electron 
transferring reactions resulting in the generation of reactive oxygen species (ROS), 
which diffuse out of the cell and react with the CLP^ on the cell membrane. The 
product formed from this spontaneously decomposes, emitting light in the process 
(Packard Cytolite kit protocol).
Growing cells were prepared in a 96 well view plate. Prior to assay the cells were 
washed twice with PBS (50pl per well). Two variants of the method were tried. In 
the first case lOOpl of fresh cell culture medium was added to the cells; this medium 
should not contain amino-glycoside antibiotics (such as gentamycin) as these act as 
radical scavengers and interfere with the chemiluminescent reaction. 25pi activator 
solution was then added per well. This approach did not work with HepG2 cells. In 
the second case no fresh medium was added and the activator solution was added 
directly onto the cells. 125pl per well of amplifier solution was then added.
The optiplate was then placed inside the plate reader and incubated in the dark for five 
minutes. Luminescence was then measured for 0.02 minutes per well.
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2.11 General assays
This section describes the assays used in the characterisation of the HepG2 cells.
2.11.1 Modified Miller protein assay
The following protocol is a modification of the procedure described by Miller, (1959). 
lOOpl of either sample or protein standard (BSA 0-400pg per lOOpl) was added to a 
test tube and diluted to 1ml with MilliQ water.
1ml of solution A was then added to each tube and the tubes were left to stand for 
exactly 10 minutes at room temperature. 3mis of solution B was then added per tube 
and the tubes were immediately mixed by vortexing after which they were incubated 
at 50°C in a waterbath for 10 minutes to allow colour to develop. The tubes were 
then cooled after which the absorbance was read at 650nm.
2.11.2 Cytochrome P450
Total cytochrome P450 in cell lysates and in microsomal samples was determined 
according to the method of Omura and Sato, (1964).
The sample to be examined was diluted with O.IM phosphate buffer pH 7.4. A few 
granules of sodium dithionite were added and the sample was mixed and then divided 
equally between two cuvettes. A scan between 400 and 500nm was then recorded. 
Carbon monoxide was then bubbled gently through the test cuvette for approximately 
30 seconds, after which a difference spectrum between the test and reference cuvettes 
between 400 and SOOnm was obtained. Cytochrome P450 was expressed as the 
difference in optical density between 450 and 490nm.
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The molar extinction coefficient for cytochrome P450, for the wavelength couple 450- 
490, is 91mM'^cm’  ^(Omura & Sato, 1964).
2.11.3 Erythromycin N-demethylase
The déméthylation of erythromycin is followed by measuring the formaldehyde 
formed from the methyl group during incubation; the formaldehyde is trapped as 
acetylacetone semicarbazone and measured by the colourimetric procedure of Nash, 
based on the Hantzsch reaction (Nash, 1953).
The incubation mixture was prepared in test tubes and comprises
Standard incubation mixture
Potassium phosphate buffer 0.1ml
(0.05 M), pH 7.25
MgCli (0.15 M) 0.4ml
Erythromycin (0.01 M) 0.1ml
Glucose-6-phosphate (0.15 M) 0.1ml
Sample (cell lysate) 0.2ml
Total Volume 0.9ml
To initiate reaction
NADP (12.5 mM) 0.1ml
Samples were incubated for 10 minutes at 37°C in a shaking waterbath and the 
reaction was terminated by the addition of 12.5% (w/v) ice-cold TCA (0.5ml).
Protein was then removed by centrifugation (2,000 x g for 10 minutes) and an aliquot 
of the supernatant (1.0ml) was added to 1.0ml of freshly prepared Nash Reagent. The 
mixture was incubated for 40 minutes at 37°C in a shaking waterbath to allow the
135
colour to develop, following which the absorption was read at 412nm against a 
reagent blank. A control containing O.Spmoles of formaldehyde was carried through 
the same procedure.
2.11.4 NADPH-cytochrome c reductase
This enzyme (also known as NADPH-cytochrome P450 reductase) functions as a 
component of the microsomal mixed function oxidase system. The activity was 
measured according to the method of Williams & Kamin, (1962).
Two cuvettes were set up as follows:
Incubation mixture Test Reference
Potassium phosphate buffer (0.05M), 850pl 900pl
pH7.6 containing ImM KCN
Cytochrome c (O.lmM) 500pl 500pl
Sample* lOOpl lOOpl
To initiate reaction
NADPH (0.03M)
.  „  1 ^  _ 1 - 1  r  * _ 1
50pl -
phosphate buffer, 0.05M, pH7.6); cell lysates used undiluted.
A baseline was recorded and the reaction was initiated by the addition of the NADPH 
to the test cuvette and the reaction was followed at 550nm for 2 minutes. The initial 
velocity of the reaction was taken as the measure of cytochrome c reduction.
The activity was calculated using the molar extinction coefficient at 550nm of 
18.5 mM’^ cm'^  (Williams & Kamin, 1962).
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CHAPTER 3 - METHOD DEVELOPMENT
3.1 Introduction
Previous work in our laboratory (Williams, 1997) involved the use of transfected 
HepG2 cells for the assessment of xenobiotic induction of human CYP3A4. Cells 
were transiently transfected using calcium phosphate precipitation (original method 
described in Section 2.8.1.2) in six well plates, with either the pCMV or p3A4 
alkaline phosphatase reporter constructs. The reporter gene assays used were 
colourimetric, and a P-galactosidase plasmid (pCHl 10) was co-transfected with the 
alkaline phosphatase plasmid constructs to allow normalisation for transfection 
efficiency. The effect of xenobiotics on the control plasmid was not routinely tested. 
The plasmid purification method used was the Wizard maxiprep (described in Section 
2 .6.1).
One of the initial aims of this project was to develop this system into a high 
throughput screen capable of robustly and reproducibly detecting xenobiotic induction 
of human cytochrome P450 3A4. It was therefore decided that each aspect of the 
system would be examined for possible improvements.
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3.2 Reporter gene assays
During preliminary work on this project the use of colourimetric assays for the 
detection of reporter gene activity was frequently found to be inadequate. If reporter 
gene expression was low due to poor transfection efficiency, reporter protein activity 
often proved difficult to detect; problems arising from this are discussed in Section 
3.2.1.
In the colourimetric alkaline phosphatase assay (Section 2.9.22) the substrate was 
light sensitive which made screening of large numbers of samples difficult and 
unreliable. Also both the alkaline phosphatase and p-galactosidase colourimetric 
assays were carried out in cuvettes thus making an extremely time consuming process 
which would limit the use of this technique in high throughput screening. Another 
disadvantage of the p-galactosidase colourimetric assay (Section 2.9.1.1) was that 
samples had to be left until a yellow colour was visible. This could take minutes, but 
could take as long as an overnight incubation, meaning that the assay had to be 
monitored constantly. Both of these latter disadvantages would limit the use of this 
technique in high throughput screening.
During my project the purchase of a chemiluminescent plate reader enabled the 
examination of chemiluminescent assays for reporter gene activity. It was thus 
decided to compare the alkaline phosphatase and p-galactosidase chemiluminescent 
assays with the colourimetric assays, as described in Sections 3.2.2 and 3.2.3 
respectively.
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3.2.1 Assessment of the use of P-galactosidase to normalise data for variation in 
transfection efficiency
In the case of P-galactosidase, the activity was frequently so low that results were 
often below the level of expression in untransfected cells (despite the assay pH 
difference to allow differentiation from endogenous expression) thus making 
normalisation for variation in transfection efficiency impossible in those transfections 
in which this occurred; this problem is illustrated by the results of the following 
transfection.
HepG2 cells in passage 12 were seeded according to standard cell seeding protocol 
(Section 2.8.1.1) in 6 well plates and were transfected using the original method of 
calcium phosphate precipitation (Section 2.8.1.2).
3 wells of cells were not transfected. 6 wells were transfected with 5 pig p3A4 and 
5 pig pCHl 10 per well; of these 6, 3 wells were dosed with dexamethasone (5pM in 
DMSO) as described in Section 2.8.3. At 72 hours post-transfection, the medium was 
taken for colourimetric SPAP assay (Section 2.9.2.2) and the cells were lysed for 
colourimetric p-galactosidase assay (Section 2.9.1.1).
For both SPAP (Figure 3-1) and P-galactosidase (Figure 3-2) activities the relative 
levels of the reporter genes in the samples are represented by absorbance values. It is 
technically possible to calculate activities from this but with absorbance values of 
0.0016-0.232 for SPAP after a 16 hour incubation and 0.012-0.169 after a 15.5 hour 
incubation for p-galactosidase, any such calculations are inaccurate, particularly at the 
lower absorbance values. Absorbance values are around the limits of detection for 
these assays and little confidence can be placed in them.
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As can be seen from Figure 3-1 the SPAP activity was higher in transfected cells, and 
higher still in those dosed with dexamethasone. To ensure that this result was due to 
dexamethasone and not variation in transfection efficiency or cell seeding it was 
necessary to normalise the SPAP data against p-galactosidase values.
However, as can been seen from Figure 3-2 the observed p-galactosidase activity was 
lower in cells transfected with a p-galactosidase plasmid than in those that were not 
transfected at all. This therefore makes normalisation impossible for this experiment; 
this situation was observed on many occasions and was clearly far from ideal.
Possible solutions to this problem included increasing the sensitivity of detection 
(discussed in Sections 3.2.2 and 3.2.3), increasing the transfection efficiency 
(discussed in Section 3.7) and using an alternative method of data normalisation 
(discussed in Section 3.2.4).
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Figure 3-1 Alkaline phosphatase activity in HepG2 cells co-transfected with p3A4 and pCHllO
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HepG2 cells in passage 12. Absorbance values at 405nm following colourimetric assay of 
alkaline phosphatase activity. Data shown as MEAN+/-SEM, where n=3.
Figure 3-2 p-galactosidase activity in HepG2 cells co-transfected with p3A4 and pCHllO
0.16 1
0.14 -
0.12  -
I
§ 0.1 -
8 0.08 -
-G
S 0.06 - 
0.04 -
0.02 -
Untransfected Untreated 
Cell treatment
Dexamethasone (5|aM)
HepG2 cells in passage 12. Absorbance values at 420nm following colourimetric assay of 
P-galactosidase activity. Data shown as MEAN+/-SEM, where n=3.
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3.2.2 A comparison of assays for alkaline phosphatase activity
Initially the chemiluminescent assay was examined to determine the optimum time to 
read plates using this assay protocol (Figure 3-3). Purified alkaline phosphatase was 
added to cell culture medium to a concentration of 2ng.mf^ (equivalent to 2.06x10’^  
units of active enzyme). Alkaline phosphatase activity was assayed according to the 
standard protocol (Section 2.9.2.3); light emission from the well was recorded every 
20 seconds immediately following addition of the reaction buffer.
On the basis of this experiment it was determined that alkaline phosphatase activity 
should be assessed between 20 and 30 minutes after the addition of reaction buffer 
when using this protocol.
To examine the linearity and detection limits of the colourimetric and 
chemiluminescent assays, serial dilutions of alkaline phosphatase were made in cell 
culture medium and the assays were carried out according to the protocols (Sections 
2.9.2.2and2.9.2.3).
As can been see from Figures 3-4 and 3-5 the minimum amount of detectable alkaline 
phosphatase in the colourimetric assay was approximately 1500pg and in the 
chemiluminescent assay was approximately 5pg. The colourimetric assay was linear 
up to approximately 25,000pg (absorbance 1.36) and the chemiluminescent assay was 
linear up to the maximum concentration tested (100,000pg).
The chemiluminescent alkaline phosphatase assay was examined in the presence and 
absence of phenol red, to ensure that phenol red would not quench light emission. 
Thus the chemiluminescent assay for alkaline phosphatase activity was shown to have 
a greater sensitivity and linear range than the colourimetric assay. The 
chemiluminescent assay was therefore used for all subsequent work.
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Throughout the project, all cells transfected with SPAP constructs were found to 
exhibit activity detectable above background with this assay.
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Figure 3-3 Kinetics of the chemiluminescent alkaline phosphatase assay
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RLUs = Relative light emission during chemiluminescent SPAP assay. 
Curve = polynomial fit (Microsoft Excel 97); n=l.
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Figure 3-4 Linearity of the colourimetric alkaline phosphatase assay
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Figure 3-5 Linearity of the chemiluminescent alkaline phosphatase assay
70000
= 0.9992
—  Without Phenol red R  ^= 0.9961
—  With Phenol red
60000
50000
40000
30000
20000
10000
20000 40000 60000 80000
Alkaline phosphatase (pg)
100000
RLUs = Light emission following chemiluminescent SPAP assay 
Data shown as Mean+/-SEM, where n=3. Line fit = linear trendline (Microsoft Excel 97).
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3.2.3 A comparison of assays for p-galactosidase activity
To examine the linearity and detection limits of the colourimetric and 
chemiluminescent assays, serial dilutions of p-galactosidase were made in Z buffer 
and the assays were carried out according to the protocols described in Sections
2.9.1.1 and 2.9.1.2 respectively.
As can been see from Figures 3-6 And 3-7 the minimum amount of detectable p- 
galactosidase in the colourimetric assay was approximately 1500pg and in the 
chemiluminescent assay was approximately 12pg. The colourimetric assay was linear 
throughout the range tested up to 100,000pg (corresponding to an absorbance of 2.0) 
and the chemiluminescent assay was also linear throughout the tested range.
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Figure 3-6 Linearity of the colourimetric P-galactosidase assay
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Line fit = Linear trendline (Microsoft Excel 97); n = 1.
Figure 3-7 Linearity of the chemiluminescent p-galactosidase assay
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3.2.4 Normalisation of data to account for variation in transfection efficiency
Although SPAP activity could generally be detected by the colourimetric assay post 
transfection, the p-galactosidase activity frequently could not, rendering the currently 
used method of normalisation very unreliable. It was therefore decided that a new 
method of normalisation should be developed.
Transfection is a highly variable process. Differences in cell seeding density and 
transfection efficiency can both affect the levels of reporter gene activity observed. In 
xenobiotic induction experiments to ensure that any perceived changes are due to the 
effects of the xenobiotic it is necessary to find a method of normalisation to account 
for any variation due to cell seeding and variation in transfection efficiency. The use 
of reporter genes relies on the assumption that, in the absence of inducing or 
repressing stimuli, the levels of reporter expression measured are directly proportional 
to the product of cell number and transfection efficiency. The use of two plasmids co­
transfected relies on the assumption that both plasmids are transfected with equal 
efficiency. Because traditionally used reporter genes such as P-galactosidase, CAT 
and more recently luciferase all rely on the lysis of the transfected cells this method 
has been the only available means of normalising for the above factors. However, 
with the development of reporter genes such as green fluorescent protein and SPAP, 
which may both be measured repeatedly over several days from the same transfected 
sample, an alternative method of normalisation is possible. Reporter gene activity is 
measurable approximately 8-12 hours after transfection, providing the detection 
method is sufficiently sensitive. For control plasmids (i.e. pCMV) levels of activity at 
this stage (i.e. prior to xenobiotic dosing) will be in direct proportion to transfection 
efficiency and cell seeding in all samples. For test plasmids (i.e. p3A4) the level of 
expression may also be influenced by inducing or repressing effects of endogenous
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substances. In the standard transfection protocol the culture medium is changed 24 
hours post-transfection, prior to the addition of drugs where appropriate. It is possible 
to take medium from all transfected samples at this stage, as well as 72 hours post­
transfection (48 hours post-drug dosing) allowing normalisation for transfection 
efficiency despite the use of only one plasmid. For this system to be of use reporter 
activity must be detectable by the assay procedure 24 hours post-transfection.
A comparison of normalisation methods is illustrated in Figures 3-8 to 3-11.
HepG2 cells in passage 12 were seeded in 96 well plates (n=8) according to the 
standard cell seeding protocol (Section 2.8.1.1). Cells were transfected using the 
optimised calcium phosphate transfection protocol (Section 2.8.1.3). Transfection 
mixtures contained Qiagen-prepared pCHl 10 (Abs^^ /^Abs^^° = 1.78) at a 
concentration of 12.5pg.mf^ precipitate with Qiagen preparations of either pCMV 
(Abs^^ /^Abs^^  ^= 1.80) or p3 A4 (Abs^^ /^Abs^^  ^= 1.84), also at a concentration of 
12.5pg.mf^ precipitate.
At 24 hours post-transfection, levels of SPAP expression were determined using a 
chemiluminescent assay as described in Section 2.923. The results of this are 
displayed in Figure 3-8. The transfected cells were then dosed with either DMSO or 
dexamethasone (5pM) as described in Section 2.8.3. At 72 hours post-transfection, 
levels of SPAP expression were determined using a chemiluminescent assay (Figure 
3-9); the cells were then lysed and the levels of P-galactosidase were also determined 
using a chemiluminescent assay as described in Section 2.9.1.3 (Figure 3-10). The 
final levels of SPAP expression (72 hours post-transfection) were then normalised 
against the SPAP values obtained 24 hours post-transfection (Figure 3-11) and against 
the p-galactosidase values (Figure 3-12). When the data is normalised using 24 hour 
and 72 hour SPAP activities the fold induction by dexamethasone is 1.97; when the
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data is normalised against p-galactosidase activity the fold induction by 
dexamethasone is 1.54. Calculation of fold induction values is discussed in Section 
3.9.
In the initial work co-transfection of two plasmids (i.e. SPAP construct and pCHl 10) 
was observed to cause greater intra-transfection variability than the transfection of a 
SPAP construct alone. Since fold induction values in the experiment described above 
were of the same order between normalisation methods, and since intra-transfection 
variability is a major problem associated with this transient transfection assay, it was 
decided that the method of 24:72 hour SPAP normalisation would be used for this 
project.
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Figure 3-8 Alkaline phosphatase activities 24 hours post-transfection
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HepG2 cells in passage 12. RLUs = relative light units emitted following a 
chemiluminescent assay for alkaline phosphatase activity 
* = Cells to be treated with DMSO; # = cells to be treated with Dexamethasone (5pM). 
Data shown as MEAN+/-SEM, where n=8.
Figure 3-9 Alkaline phosphatase activities 72 hours post-transfection
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HepG2 cells in passage 12. RLUs — relative light units emitted following a chemiluminescent 
assay for alkaline phosphatase activity. Data shown as MEAN+/-SEM, where n=8.
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Figure 3-10 p-galactosidase activities 72 hours post-transfection
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assay for p-galactosidase activity. Data shown as MEAN+/-SEM, where n=8.
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Figure 3-11 Normalisation of alkaline phosphatase activity at 72 hours post-transfection 
against alkaline phosphatase activity at 24 hours post-transfection
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HepG2 cells in passage 12. RLUs — light emission from alkaline phosphatase assay (72 hours post­
transfection) normalised against alkaline phosphatase activity (24 hours post-transfection).
Data shown as MEAN+/-SEM, where n=8.
Figure 3-12 Normalisation of alkaline phosphatase activity at 72 hours post­
transfection against P-galactosidase activity
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HepG2 cells in passage 12. RLUs = light emission from alkaline phosphatase assay (72 hours 
post-transfection) normalised against P-galactosidase activity (72 hours post-transfection).
Data shown as MEAN+/-SEM, where n=8.
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3.3 Choice of cell line
In addition to the HepG2 cells previously used for the transient transfection assays 
(Williams, 1997) 2 other cell lines were available in the laboratory. To determine 
whether Rat H4-II-E-C3 cells or Chinese hamster ovary (CHO-Kl) cells were 
potentially useful for the transient transfection assays the transfection efficiency was 
assessed in each cell type.
Cells were seeded in 96 well plates (n=6) according to standard cell seeding protocol 
(Section 2.8.1.1) and were transfected using the optimised calcium phosphate 
transfection protocol (Section 2.8.1.3) with pCMV (Wizard Plus maxiprep, 
Abs^ ^^ /Abs^ ^® = 1.63). The HepG2 cells were in passage 12; the H4-II-E-C3 and the 
CHO-Kl cells were of unknown passage number. Levels of alkaline phosphatase 
activity were assayed 48 hours post-transfection using a chemiluminescent assay 
(Section 2.9.2.3). As can be seen from Figure 3-13 the levels of alkaline phosphatase 
expression were extremely low in the CHO-Kl and H4-II-E-C3 cell lines; it was 
therefore concluded that these cell lines would not be suitable for use.
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Figure 3-13 A comparison of transfection efficiency in 3 cell lines using pCMV
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HepG2 cells in passage 12; H4-II-E-C3 and CHO-Kl in unknown passage number. 
RLUs = relative light units emitted following a chemiluminescent assay for alkaline 
phosphatase activity. Data shown as MEAN+/-SEM, where n=6.
Cell seeding density = 6.4 x 10"^  cells per cm  ^growth area.
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3.4 Characterisation of HepG2 cells
On the basis of the comparison of cell lines (Section 3.3) it was determined that 
HepG2 cells were the cell line of choice for the project. HepG2 cells are a human 
hepatocyte carcinoma line, originally established from a 15 year old male Caucasian 
(Aden et al., 1979). Being a transformed cell line HepG2 cells display a number of 
abnormal properties compared to normal liver cells, including immortalisation 
(infinite lifespan), loss of contact inhibition (which allows them to be cultured 
indefinitely), and a number of other phenotypic alterations. Changes in structure 
include a modified actin cytoskeleton and the loss of cell surface-associated 
fibronectin (Freshney, 1994). Many functions normally lost in culture are maintained 
by HepG2 cells such as the ability to synthesise and secrete major plasma proteins 
such as a2-plasmin inhibitor and insulin-like growth factor carrier protein (Dawson et 
al., 1985). HepG2 cells are reported to be capable of a number of phase one and 
phase two metabolic activities such as benzo[a]pyrene activation, ethoxyresorufin O- 
dealkylation (EROD), pentoxyresorufin 0-dealkylation (PROD), and 
benzyloxyresorufm 0-dealkylation (BROD), UDP-glucuronyltransferase and 
sulphotransferase (Doostdar et al., 1993; Dawson et al., 1985; Diamond et al., 1980). 
Of these activities a number have been reported to be inducible by xenobiotics 
(Dawson et al., 1985; Doostdar et al., 1993). At the mRNA level HepG2 cells have 
been shown to express CYPlAl (constitutive expression, inducible by 
3-methylcholanthrene), CYP1A2 (following treatment with 3 -methylcholanthrene) 
and CYP3A3 (constitutive and inducible by dexamethasone) (Fukuda et al., 1992). 
However, a more recent study (Schuetz et al., 1993) has reported that of the CYP3A 
subfamily, only CYP3A7 is present in HepG2 cells at the mRNA or the protein level,
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and that it is inducible at the protein level by dexamethasone, rifampicin, TAO, 
erythromycin and phenobarbitone, and at the mRNA level by dexamethasone, 
phenobarbitone, rifampicin, phenytoin and lovastatin. HepG2 cells express the Ah 
receptor (Roberts et a l, 1990) and the glucocorticoid receptor (Raddatz et al., 1996). 
The HepG2 cells therefore maintain at least some of the factors required for the 
induction of P450 and would appear to be the most suitable of the available cell lines 
for studying the regulation and induction of CYP3 A. Many cell lines are reported to 
lose expression of differentiated functions such as enzyme production as rapidly as 
from one passage to the next (Freshney, 1994).
It was therefore decided that work should be carried out to examine the profile of the 
HepG2 cells with respect to the expression of endogenous CYP3 A and the 
glucocorticoid receptor.
3.4.1 Loss of dexamethasone induction at high passage
Some preliminary work indicated that HepG2 cells lose the response to 
dexamethasone after repeated subculture (Dr. Janet Williams, personal 
communication).
To test this, cells in passage 16 were seeded in six well plates according to the 
standard seeding protocol (Section 2.8.1.1).
Cells were transfected with Qiagen preparations of either pCMV (Abs^ ^^ /Abs^ ^® = 
1.71) or p3A4 (Abs^ ^^ /Abs^ ^® = 1.73) as described in (Section 2.8.1.3). Cells were 
then dosed (3 wells per condition), according to the protocol described in Section 
2.8.3, with DMSO, dexamethasone (IpM) or rifampicin (lOpM or lOOpM). Alkaline 
phosphatase activity was assayed using a chemiluminescent assay (Section 2.9.2.3)
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immediately prior to dosing and 48 hours after dosing and normalised as described in 
Section 3.2.4.
It can be seen from the results of this transfection (Figure 3-14) that by passage 16 
these cells have lost all responsiveness to dexamethasone, however they still appear to 
be induced by rifampicin.
This is important for two reasons. Firstly, to be considered valid, all transfections 
must be carried out within a carefully defined passage number. Secondly, the 
differences between inducers highlight a possible difference in their molecular 
mechanisms of induction.
In light of this, a new batch of HepG2 cells was purchased from EC ACC and a bank 
grown and then frozen down in the lowest possible passage number (7 passages from 
the received stock) so that all subsequent work could be carried out at a passage 
below 14.
The assumption that loss of responsiveness to dexamethasone was solely due to the 
passage number of the cells was observed to be incorrect during subsequent work.
In the absence of co-transfected glucocorticoid receptor plasmid (pSG5-hGR), cells 
appeared to be responsive to dexamethasone in only approximately 50% of cases; this 
response did not appear to be passage dependent. This variation was noted even in 
cells of the same batch at the same passage number, transfected with the same 
plasmid preparations at the same time, and dosed with the same stock of 
dexamethasone. When the pSG5-hGR plasmid was co-transfected with the SPAP 
reporter constructs some activation of the p3 A4 reporter construct was observed on 
every occasion, although the level of response was found to vary greatly.
The reasons for the variation in responsiveness of the HepG2 cells are unclear. 
Possible factors involved might include the degree of cell to cell contact or the growth
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phase of the cells. Variation in the levels of contaminating steroids or hormones in 
the FCS might also exert some effect although this would not account for intra-batch 
variation.
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Figure 3-14 Loss of dexamethasone induction of CYP3A4-dependent reporter gene
expression in high passage HepG2 cells
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HepG2 cells in passage 16. Data shown as MEAN+/-SEM, where n=3.
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3.4.2 Sample preparation for characterisation assays
To prepare samples for use in subsequent characterisation assays, 3 batches of HepG2 
cells (prepared by different methods) were induced and then lysed according to the 
protocols described in Sections 2.5.1 and 2.5.2 respectively.
The protein concentrations of the samples, determined using a modified Miller protein 
assay (Section 2.11.1), are given in Table 3-1. Protein concentrations are also given 
for liver microsomes from an untreated rat, a dexamethasone treated rat and a human.
Table 3-1 Protein concentrations (mg.ml^) in cell lysates and microsomal 
samples used for Western blotting and cell characterisation assays
Cell lysates Batch 1 Batch 2* Batch 3*
DMSO treated 4.12 6.17 20.83
Transfected cells 1.89 4.46 17.24
Dexamethasone treated 3.27 6.02 25.12
Rifampicin treated 3.03 7.90 26.47
Liver Microsomes Human Untreated rat Dexamethasone treated rat
13.68 17.8 21.42
The methods used to induce and lyse each batch of cells are described in Sections 
2.5.1 and 2.5.2, where each batch represents a different protocol for the preparation of 
the cell lysates; each treatment within each batch represents the combined contents of 
5 flasks of cells.
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3.4.3 Total cytochrome P450
The total cytochrome P450 content of the samples was determined as described in 
Section 2.11.2. The levels of cytochrome P450 in the cell lysates were below the 
detectable limit. The total cytochrome P450 content of the untreated rat microsomes 
was 0.24 nmol.mg'^ protein, and of the dexamethasone treated rat microsomes was 
0.36 nmol.mg'^ protein.
3.4.4 NADPH-cytochrome c reductase
NADPH-cytochrome c reductase activity was assessed in the cell lysates using the 
protocol described in Section 2.11.4 and the results are illustrated in Table 3-2. All of 
the samples showed measurable cytochrome c reductase activity, although activity in 
the cell lysates was not as high as in the microsomal samples. Values presented are 
the result of a single determination.
Table 3-2 NADPH cytochrome c reductase activity of cell lysates 
and microsomal samples
Cell lysates Activity (nmol/min/mg protein)
DMSO treated 2.52
Transfected 3.56
Dexamethasone treated 1.38
Rifampicin treated 1.89
Rat liver microsomes
Untreated 6.01
Dexamethasone treated 10.99
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3.4.5 Erythromycin N-demethylase
Erythromycin N-demethylase activity is a measure of the activity of the CYP3A 
family (Watkins et al., 1989). Samples were assayed in triplicate according to the 
protocol detailed in Section 2.11.3. The results are given in Table 3-3.
Table 3-3 Erythromycin N-demethylase activity of cell lysates
Cell lysates Mean activity (pmol/min/mg protein)
DMSO treated 126.7+/-31.3
Transfected 310.1 +/- 44.6
Dexamethasone treated 347.4+/-61.2
Rifampicin treated 158.9+/-13.4
Data shown as MEAN+/-SEM, where n=3.
Although activities are calculable it should be noted that absorbance values were as 
low as 0.005. Such values are only just above baseline levels; the lack of sensitivity 
of colourimetric assays makes it difficult to make accurate comparisons between 
samples based on this data. It is clear from this data that the cell lysates express very 
little CYP3A, either constitutively or after treatment with inducers.
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3.4.6 Western blotting for CYP3A
HepG2 cells have previously been shown to express inducible CYP3A7 (Schuetz et 
ah, 1993). To confirm that the HepG2 cells in our laboratory did not express either 
CYP3A4, or CYP3A5, the cell lysates (described in Section 3.4.2) were examined by 
Western blotting (as described in Section 2.5.3). 3 primary antibodies were used on 
subsequent blots. The first antibody was an anti-rat CYP3A antibody (Amersham) 
that was reported to react weakly with CYP3A4, and moderately with CYP3A5 
(Amersham); with this antibody, a blot was carried out against cell lysates from batch 
1, using liver microsomes from a dexamethasone-treated rat (supplied in kit) as a 
positive control. ECL reagents (Amersham) were used for detection; this blot is 
shown in Figure 3-15. The second and third antibodies used were anti-peptide anti- 
CYP3 A4 and anti-CYP3A5 respectively. The peptide sequence used to produce the 
anti-CYP3A4 antibody is also present in CYP3A7; it is therefore likely that the anti- 
CYP3A4 antibody will bind to CYP3A7, although this has not been tested. The 
peptide sequence used to produce the anti-CYP3A5 antibody is specific to CYP3A5; 
this antibody does not bind to CYP3A4, and is therefore believed to be mono-specific 
for CYP3A5 (Anttila et al., 1997). These anti-peptide antibodies were used against 
lysates from batch 2 (loaded at llOpg protein per well) and from batch 3 (loaded at 
420pg per well); human liver microsomes loaded at 15pg per well were also 
examined. ECL Plus detection (Amersham) was used for these blots (Data not 
shown).
In each case the molecular weight markers were visible, indicating successful 
blotting, but no bands were visible for any of the cell lysates examined; Figure 3-15 
(using the Amersham anti-rat CYP3A antibody) is shown as a representative blot.
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The human microsomes were found to contain CYP3A4, reacting strongly with the 
anti-peptide anti-CYP3A4 antibody.
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Figure 3-15 Western blotting for CYP3A in HepG2 cells
58100
39800
1. Molecular weight markers^
2. Dexamethasone-treated lysate^
3. Rifampicin-treated lysate^
4. DMSO-treated lysate^
J. GR-transfected lysate^
6. Dexamethasone-treated lysate^
7. DMSO-treated lysate^
8. Kit positive control
Supplied in Amersham anti-CYP3A kit; positive control — liver microsomes from a dexamethasone- 
treated rat. ^Protein loading = 30pg per well; ^Protein loading = 60pg per well; ^Protein loading -  5pg 
per well. Expected band size of human CYP3A4 = 51 kDa.
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3.4.7 Western blotting for the human glucocorticoid receptor
As described in Section 3.4.1 the HepG2 cells appear to lose the ability to induce 
reporter gene expression in response to dexamethasone at high passage. As described 
in Section 1.7, some workers have reported the possible involvement of the 
glucocorticoid receptor in the molecular mechanism of dexamethasone induction of 
CYP3 A. It was therefore decided that an attempt should be made to detect the 
glucocorticoid receptor in low passage cells; the aim being that if the glucocorticoid 
receptor could be sensitively detected in low passage cells, then an attempt could be 
made to screen subsequent passages for glucocorticoid receptor expression.
Western blots using a mouse anti-human glucocorticoid receptor antibody were 
carried out on cell lysates from all batches (described in Section 3.4.2) to determine 
whether HepG2s in this passage express detectable amounts of the human 
glucocorticoid receptor, and whether any expression of this is inducible. Blotting was 
carried out according to the protocol described in Section 2.5.3 using ECL Plus 
detection (Amersham).
The antibody is reported to cross-react with both the alpha and beta subtypes of the 
human glucocorticoid receptor, leading to 2 bands between 94 and 96kD which it 
should be possible to resolve on a sensitive system; the antibody has previously been 
used to detect expression of the glucocorticoid receptor in HepG2 cells (Serotec, 
product information).
Figure 3-16 shows a Western blot carried out against cell lysates from batch 1, and 
Figure 3-17 shows a blot carried out against lysates from batches 2 and 3; no positive 
control for the human glucocorticoid receptor was available. Liver microsomes from 
a dexamethasone-treated rat (Amersham) were run on each blot.
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In both blots the bands appear to be of approximately the correct molecular weight 
although this is difficult to assess due to poor resolution and over exposure of the 
markers. From these blots a band is visible for cells treated only with DMSO, thus 
illustrating that in cells of this passage expression of the glucocorticoid receptor is 
detectable. The brightest band appears for cells transfected with the plasmid pSG5- 
hGR (which encodes the human glucocorticoid receptor), thus confirming that 
transfection with this plasmid increases the expression of the glucocorticoid receptor 
within these cells. The lack of resolution of these blots was such that it was not 
possible to determine whether one or both subtypes of the human glucocorticoid 
receptor were expressed in the samples. From these blots it was concluded that this 
technique would not be sufficiently sensitive to determine with certainty any loss of 
expression of the glucocorticoid receptor with repeated passage.
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Figure 3-16 Western blotting for the human glucocorticoid receptor in HepG2 ceils
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1. Molecular weight markers*
2. Dexamethasone-treated lysate^
3. Rifampicin-treated lysate^
4. DMSO-treated lysate^
5. GR-transfected lysate^
6. Dexamethasone-treated lysate^
7. DMSO-treated lysate^
8. Liver microsomes from a 
dexamethasone-treated rat*’"*
'Supplied in Amersham anti-CYP3A kit. ^Protein loading = 30pg per well; ^Protein loading = 
60pg per well; ‘'Protein loading = 5pg per well.
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Figure 3-17 Western blotting for the human glucocorticoid receptor in HepG2 cells
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1. Liver microsomes from a 
dexamethasone-treated rat*’^
2. Dexamethasone-treated lysate^
3. DMSO-treated lysate^
4. Rifampicin-treated lysate"*
5. GR-transfected lysate"*
6. Dexamethasone-treated lysate"*
7. DMSO-treated lysate"*
8. Molecular weight markers*
'Supplied in Amersham anti-CYP3A kit.  ^Protein loading -  5pg per well.  ^Batch 2 cell lysates, 
protein loading = 1 lOpg per well; " Batch 3 cell lysates, protein loading = 420pg per well. 
Expected band size for human GR = 94-96kDa.
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3.5 Culture plate size
The initial work in our laboratory had been carried out in 6 well plates, using 
colourimetric reporter gene assays. The switch to the use of the chemiluminescent 96 
well plate reporter gene assays ensured that assay speed was no longer the limiting 
factor in terms of throughput.
Transfection assays carried out in six well plates require large amounts of plasmid, 
thus very few experimental conditions can be examined in a single transfection 
without pooling several plasmid preparations -  this increases this risk of including a 
plasmid preparation which contains sufficient impurities to adversely affect the 
transfection efficiency.
Transfections carried out in 6 well plates are time consuming to set up and to harvest, 
and require large amounts of incubator space. Thus the use of six well plates greatly 
limits the potential for high throughput screening.
It was therefore decided that an attempt should be made to carry out the transfections 
in a more suitable plate size to enable greater volumes of work to be processed. Both 
24 well and 96 well plates were assessed. HepG2 cells in passage 13 were seeded 
according to normal seeding protocol (Section 2.8.1.1) and were transfected with 
pCMV (Qiagen maxiprep, Abs^ *^*/Abs^ °^ = 1.81) using the optimised calcium 
phosphate transfection protocol (Section 2.8.1.3). Levels of alkaline phosphatase in 
the transfected cells were assayed using a chemiluminescent assay 48 hours post­
transfection (Section 2.9.2.3). As can be seen from Figure 3-18 transfection 
efficiency was approximately equal in all plate types.
Both the 24 well and 96 well plates were far easier to work with manually allowing 
processing of far more samples. Also both required far less DNA than transfections
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in 6 well plates. In addition to the reduction in DNA usage, 96 well plates have a 
number of other advantages. The most notable include the increase in the number of 
experimental conditions and replicates that may easily be assessed in a single 
transfection and the fact that all manipulations may be carried out using multi-channel 
pipettes which allows a great saving in experimental time, and increases the 
reproducibility of the experiment.
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Figure 3-18 The transfection efficiency of pCMV into HepG2 cells in 
different sizes of culture plate
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96 well 24 well 6 well
Plate size
HepG2 cells in passage 13. RLUs = relative light units emitted following a chemiluminescent 
assay for alkaline phosphatase activity. Data shown as MEAN+/-SEM, where n=6.
Cell seeding density = 6.4 x 10^  cells per cm  ^growth area.
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3.6 Choice of plasmid preparation method and the effect of ethanol precipitation
The quality of plasmid DNA is a major factor influencing transfection efficiency 
(Robbins et al., 1996). For the initial experiments the method of plasmid preparation 
used was the Wizard maxiprep Kit (Promega), however transfection efficiencies were 
frequently either poor or highly variable, even following ethanol precipitation, with 
purity ratios (Abs^^°/Abs^^°) varying between 1.3 and 2.2 indicating contamination.
In light of these problems it was decided that several of the commercially available 
plasmid preparation kits should be compared. The effect of ethanol precipitation on 
the transfection efficiency of each maxiprep was also examined.
A large LB maxi culture (2 litres) of pCHl 10 was grown according to the standard 
protocol (Section 2.3.3). Each plasmid preparation method was then carried out on an 
aliquot of the same culture according to the recommended protocols as described in 
Sections 2.6.1 to 2.6.7. 250p,l of each plasmid preparation was ethanol precipitated 
overnight and resuspended in 125pi O.lxTE according to the protocol detailed in 
Section 2.6.8.
The concentration and purity (Abs^^ /^Abs^ °^) of each plasmid preparation was 
determined by UV analysis (Section 2.7.1), and is given in Table 3-4.
HepG2 cells in passage 11 were seeded in 96 well plates (n=8) according to the 
standard protocol (Section 2.8.1.1) and were transfected with the plasmid preparations 
according to the optimised calcium phosphate transfection protocol as outlined in 
Section 2.8.1.3.
48 hours post-transfection cells were assayed for p-galactosidase activity using the 
chemiluminescent assay described in Section 2.9.1.2. The p-galactosidase activities 
of cells transfected with each method are shown in Figure 3-19.
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Measurable reporter activity was observed with all kits tested. In most cases the 
transfection efficiency was enhanced by ethanol precipitation. The highest 
transfection efficiency was obtained using the Qiagen endotoxin free maxi 
preparation.
For the later part of the project the kit of choice was the Endofree Maxi Kit (Qiagen) 
as it was suspected that endotoxin contamination of the plasmid preparations was 
responsible for much of the variation in transfection efficiency observed. Also DNA 
prepared by this method was useable without the need for ethanol precipitation.
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Table 3-4 The concentration and purity of DNA prepared using commercial 
plasmid preparation kits, before and after ethanol precipitation
Kit
Before ethanol precipitation After ethanol precipitation
Concentration Purity
(Abs^ (^)/Abs^ (^))
Concentration Purity
(Abs^^°/Abs^^°)
Easy Pure 0.61 1.35 0.47 1.46
FlexiPrep 0.38 1.54 0.22 1.52
Quick Flow 0.85 2.05 0.55 1.83
Wizard Maxi 1.96 2.01 3.09 1.97
Wizard Mega 8.245 1.78 1.39 2.00
Qiagen 0.73 1.82 0.45 1.76
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Figure 3-19 A comparison of the transfection efficiencies of pCHllO preparations,
purified by a variety of methods
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Maxi Mega Endofree
Plasmid purification kit
HepG2 cells in passage 11. RLUs = relative light units emitted following a chemiluminescent 
assay for p-galactosidase activity. Data shown as MEAN+/-SEM, where n=8.
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3.7 Optimisation of the transfection protocol
Once it had been established that transfection in 96 well plates was a viable option, 
the possibilities for the use of this system as a screening method were improving. The 
next major concern was to address the factors causing the variability in transfection 
efficiency in order to render the system more robust and reproducible.
Since the initial work with this transactivation system (Williams, 1997) much work 
had been done in our laboratory to optimise the transfection conditions for 6 well 
plates (Sarah Giddings, personal communication). All of the factors that had been 
observed to affect transfection efficiency in 6 well plates were then examined for their 
effects on transfection efficiency in 96 well plates.
For the optimisation of transfection efficiency the ethanol precipitated Wizard 
maxiprep (because it had been used for previous optimisation work in the laboratory) 
was compared with the Qiagen Endofree maxiprep (which had given the highest 
transfection efficiency in the comparison of plasmid purification methods as described 
in Section 3.6).
3.7.1 The use of staining to determine transfection efficiency
HepG2 cells in passage 11 were seeded in 6 well plates at a density of 6 x 10^  cells 
per well. The cells were transfected with either Wizard maxiprep (ethanol 
precipitated, Abs^^°/Abs^^° = 1.67) or Qiagen (Abs^^°/Abs^^° =1.82) preparations of 
the pCHl 10 plasmid by a number of different methods according to the protocols 
described in Sections 2.8.1.2 to 2.8.1.6. 48 hours post-transfection the cells were 
stained for p-galactosidase activity using the p-galactosidase staining set (Section
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2.9.1.3) and the percentage of transfected cells was determined by attempting to count 
3 random fields of view in each of 3 wells.
It proved impossible to choose completely random fields of view -  the cells in this 
experiment clumped greatly, making counting in some view fields impossible and 
thus preventing accurate determination of the transfection efficiency. Table 3-5 
contains estimations of the efficiency of each method.
Table 3-5 p-Galactosidase staining for the estimation of transfection efficiency
Transfection method Wizard maxiprep Qiagen maxiprep
Original «1% 1-9%
Optimised 1-5% 5-15%
Suspension «1% very coarse precipitate and cells extensively clumped
BBS «1% 1-2%
The problems of cell clumping are illustrated in Figures 3-20 and 3-21, and the 
staining of cells is illustrated in Figures 3-21 and 3-22; these figures demonstrate the 
degree of variation in cell seeding within the same batch of cells at the same seeding 
density.
Although staining allows an estimation of the percentage of cells transfected by a 
particular method, it would be more useful to use total reporter gene expression, as 
determined by a chemiluminescent assay, to more accurately compare the relative 
efficiencies of different methods.
179
Despite the wide variability in this method of determination it was clear that the 
highest transfection efficiency was obtained using the Qiagen endotoxin free plasmid 
preparation, transfected with the optimised calcium phosphate transfection protocol.
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Figure 3-21 Cells stained for p-galactosidase activity within a clump of HepG2
cells
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Figure 3-22 Staining of HepG2 cells for p-galactosidase activity
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3.7.2 The use of different transfection methods
On the basis of the results presented in Section 3.7.1, it was decided that the 
efficiencies of several different methods of transfection should be compared using 
chemiluminescent detection of reporter gene expression to assess efficiency.
HepG2 cells in passage 11 were seeded according to the standard protocol (Section
2.8.1.1), in 96 well plates (n=8). Cells were transfected with either Wizard maxiprep 
(ethanol precipitated, Abs^^°/Abs^^° = 1.67) or Qiagen (Abs^^°/Abs^^° =1.82) plasmid 
preparations of pCHl 10. Each transfection method was carried out according to the 
methods detailed in Sections 2.8.1.2 to 2.8.1.6. The cells were lysed 48 hours post­
transfection and assessed for P-galactosidase activity using the chemiluminescent 
assay as described in Section 2.9.1.2.
The results are displayed in Figure 3-23.
It can be clearly seen from these results that the Qiagen endotoxin-ffee plasmid 
preparation is transfected more efficiently than the Wizard plasmid preparation by all 
methods examined. The most efficient methods were the optimised calcium 
phosphate transfection and the CalPhos Maximizer protocol. Of the two, the 
optimised calcium phosphate precipitation method would be the method of choice for 
further investigations as it is far cheaper and is more easily applied to large scale 
transfections.
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Figure 3-23 A comparison of the efficiency of different methods of transfection of pCHllO 
by calcium phosphate precipitation in HepG2 cells
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□  Qiagen DNA1400 -
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BBS Original Optimised Calphos Maximiser
HepG2 cells in passage 11. RLUs — relative light units emitted following a chemiluminescent assay 
for p-galactosidase activity. Data shown as MEAN+/-SEM, where n=8.
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3.7.3 The effect of poly-D-lysine coating
The coating of the culture plate surface with poly-D-lysine has been previously found 
to enhance transfection efficiency in six well plates in our laboratory (Sarah Giddings 
and Dr. Janet Williams, personal communication). When HepG2 cells are grown on 
poly-D-lysine coated culture surfaces they spread out across the growth surface rather 
than growing in clumps. It is possible that the mechanism of increased transfection 
efficiency might be due to the exposure of a greater surface area to the calcium 
phosphate precipitate.
The effect of poly-D-lysine coating on 96 well plates was investigated. 96 Well 
plates were coated with poly-D-lysine according to the method outlined in Section 
2.8.4.
HepG2 cells in passage 11 were seeded according to normal seeding protocol (Section
2.8.1.1) into uncoated and poly-D-lysine-coated 96 well plates (n=8). The cells were 
transfected with pCHl 10 plasmid preparations (Wizard maxiprep, ethanol 
precipitated, Abs^ ^^ /Abs^ ^® = 1.67 or Qiagen maxiprep, Abs^^ /^Abs^^  ^= 1.82) using 
the optimised method of calcium phosphate precipitation (Section 2.8.1.3). The levels 
of p-galactosidase activity were determined 48 hours post-transfection by 
chemiluminescent assay (Section 2.9.1.2).
As can be seen from Figure 3-24 the use of poly-D-lysine to pre-coat the plates did 
not appear to have any significant effects on the transfection efficiency of either the 
Wizard or the Qiagen plasmid preparations. Poly-D-lysine coating was therefore not 
used during this project.
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Figure 3-24 The effect of poly-D-lysine coating on the transfection efficiency
of pCHllO in HepG2 cells
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Not coated Poly-D-lysine coated
HepG2 cells in passage 11. RLUs = relative light units emitted following a chemiluminescent 
assay for P-galactosidase activity. Data shown as mean RLUs +/- SEM, where n=8.
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3.7.4 The effect of cell seeding density
The effect of cell density on transfection efficiency of Wizard maxiprep and Qiagen 
plasmid preparations was investigated. A flask of HepG2 cells in passage 10 was 
trypsinised and resuspended in growth medium; the number of cells was counted, and 
serial dilutions made from this stock. The cells were seeded into a 96 well plate (n=8) 
according to normal cell seeding protocol (Section 2.8.1.1) and then transfected the 
following day with either Wizard maxiprep (ethanol precipitated, Abs^ ^^ /Abs^ ^® =
1.67) or Qiagen (Abs^^ /^Abs^^  ^= 1.82) pCHl 10 plasmid preparations using the 
optimised calcium phosphate transfection protocol (Section 2.8.1.3). The levels of P- 
galactosidase were determined 48 hours post transfection using a chemiluminescent 
assay (Section 2.9.1.2).
The results are displayed in Figures 3-25. It is clear from these results that whereas 
cell density does have some effects on transfection efficiency there is quite a degree 
of leeway with acceptable transfection efficiencies obtained at all cell densities 
examined. On the basis of this data a cell seeding density of 24,000 cells per well was 
used for all transfections.
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Figure 3-25 The effect of cell seeding density on the transfection efficiency
of pCHllO in HepG2 cells
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HepG2 cells in passage 10. RLUs = relative light units emitted following a chemiluminescent 
assay for p-galactosidase activity. Data shown as mean RLUs +/- SEM, where n=8.
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3.7.5 The effect of DNA concentration on transfection efficiency
DNA concentration is a factor reported to be critical in precipitate formation during 
calcium phosphate precipitation (Jordan et al., 1996).
The effect of DNA concentration on transfection efficiency was determined for both 
Wizard maxiprep (ethanol precipitated, Abs^^ /^Abs^^  ^=1.71) and Qiagen 
(Abs^^ /^Abs^^  ^= 1.78) pCHl 10 plasmid preparations. HepG2 cells in passage 10 
were seeded in 96 well plates (n=8) according to standard cell seeding protocol 
(Section 2.8.1.1). Cells were transfected using the optimised calcium phosphate 
transfection protocol (Section 2.8.1.3) however the amount of DNA was adjusted. 
Reporter gene activity was determined by chemiluminescent assay 48 hours post­
transfection (Section 2.9.1.2) and the results are displayed in Figure 3-26.
With Qiagen prepared DNA, good transfection efficiency was achieved with the 
standard concentration of 25 pg DNA per ml of precipitate. With the Wizard 
maxiprep the maximal efficiency was attained at a concentration of lOOpg.ml"  ^
precipitate. It appears from these results that a maximal level of efficiency is attained; 
this suggests that within a population of cells only a percentage of that population 
may be transfected.
It is interesting to note that the same maximal transfection efficiency appears to be 
attained with smaller quantities of the Qiagen prepared DNA than with the Wizard 
DNA. This is an important advantage of this method of plasmid preparation as it 
allows more transfections to be carried out on the same plasmid preparations, 
reducing cost, and inter-transfection variability.
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Figure 3-26 The effect of DNA concentration on the transfection efficiency
ofpCH110inHepG2 cells
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HepG2 cells in passage 10. RLUs = relative light units emitted following a chemiluminescent 
assay for p-galactosidase activity. Data shown as mean RLUs +/- SEM, where n=8.
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3.7.6 The effect of precipitate amount on transfection efficiency
In light of the fact that DNA concentration appeared to be a critical factor in 
transfection efficiency (as described in Section 3.7.5) the effect of the amount 
precipitate added was investigated.
HepG2 cells in passage 11 were seeded in 96 well plates (n=8) according to normal 
seeding protocol (Section 2.8.1.1). In this standard protocol, prior to transfection, the 
medium on seeded cells was changed and a reduced volume of fresh medium was 
added. To facilitate the addition of different amounts of precipitate to the wells this 
volume of medium was adjusted accordingly so that the total volume of medium post­
transfection remained the same in each well.
Cells were transfected with either Wizard maxiprep (ethanol precipitated, 
Abs“ “/Abs“  = 1.62) or Qiagen (Abs“ ‘’/Abs“ ‘’ -  1.85) pCHl 10 plasmid preparations. 
Transfection was carried out using the optimised calcium phosphate precipitation 
protocol (Section 2.8.1.3) but the amount of precipitate added to the cells was 
adjusted. Reporter gene activity was determined by chemiluminescent assay 48 hours 
post-transfection (Section 2.9.1.2).
Results are displayed in Figure 3-27.
It would appear from the results that the use of 12pl precipitate is optimal for both 
Wizard and Qiagen plasmid preparations. Any increase over this by the use of 
increasing precipitate is not sufficient to justify the amount of extra DNA consumed.
It appears that large amounts of precipitate either reduce the transfection efficiency or 
adversely affect the cells.
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Figure 3-27 The effect of precipitate amount on the transfection efficiency
ofpCHllO in HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units emitted following a chemiluminescent 
assay for p-galactosidase activity. Data shown as mean RLUs +/- SEM, where n=8.
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3.7.7 The effects of glycerol and DMSO shocks on transfection efficiency
Both glycerol and DMSO shock treatment have been reported to increase transfection 
efficiency (Lopata et al., 1984; Lewis et al., 1980). Work in our laboratory has 
previously shown that shock treatment does not appear to affect transfection 
efficiency in six well plates (Sarah Giddings, personal communication).
HepG2 cells in passage 12 were seeded in 96 well plates (n=8) according to the 
standard protocol (Section 2.8.1.1.), and were transfected with either Wizard (ethanol 
precipitated, Abs^ ^^ /Abs^ ^® = 1.62) or Qiagen (Abs^ ^®/Abs^ °^ = 1.85) pCHl 10 plasmid 
preparations using the optimised calcium phosphate protocol (Section 2.8.1.3). Post­
transfection cells were treated with either DMSO or glycerol shock treatment as 
described in Section 2.8.1.7. 48 hours post-transfection levels of reporter gene 
activity were determined using chemiluminescent assay (Section 2.9.1.2). Results are 
displayed in Figure 3-28.
Rather than enhancing transfection efficiency it would appear from these results that 
the use of shock treatment decreases transfection efficiency. As both forms of shock 
treatment are toxic in excess this may be due to overexposure, however the use of 
shorter exposure times would be difficult in 96 well plates, hence no further 
optimisation of exposure times was attempted.
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Figure 3-28 The effects of glycerol and DMSO shock treatments on the transfection
efficiency of pCHllO in HepG2 cells
8000 1
□  Qiagen 
S  Wizard
7000 -
6000 -
5000 -
6^4000 -
3000 -
2000 -
1000  -
Normal Glycerol DMSO
HepG2 cells in passage 12. RLUs = relative light units emitted following a chemiluminescent 
assay for p-galactosidase activity. Data shown as mean RLUs +/- SEM, where n=8.
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3.8 Optimisation of the culture medium
Batches of PCS can be contaminated with steroids, hormones and other factors, the 
levels of which can vary greatly from batch to batch. (Jackson et al., 1997; Nakama 
et al., 1995). Given that CYP3A4 is glucocorticoid inducible (Schuetz et al., 1992), 
the presence of unquantified, unidentified and variable steroids in the cell culture 
medium is of concern.
To investigate the possible effects of this, cells were cultured and transfected in 
different media conditions. 3 flasks of HepG2 cells in passage 10 were cultured in 
normal media conditions until 24 hours prior to seeding. The medium was then 
replaced. In flask 1 standard culture medium containing PCS was used. In flask 2 
cell culture medium containing DCC-treated PCS (Section 2.4.5) was used. In the 
third flask culture medium containing no PCS was used. The cells were then seeded 
in a 96 well plate according to standard seeding protocol (Section 2.8.1.1) and were 
transfected with Qiagen preparations of pCMV (Abs^^ /^Abs^^  ^= 1.79) or p3A4 
(Abs^^ /^Abs^^  ^=1.86) using the optimised calcium phosphate precipitation protocol 
(Section 2.8.1.3). Each set of cells was maintained in the media conditions described 
above.
At 24 hours post-transfection (day 3), the levels of alkaline phosphatase expression 
were assayed, and some of the cells were dosed with dexamethasone (5pM in DMSO 
as per Section 2.8.3). At 72 hours post-transfection (day 5), the levels of alkaline 
phosphatase expression were assayed again.
As can be seen from Pigures 3-29 and 3-30, levels of alkaline phosphatase expression 
in cells transfected with the pCMV plasmid were approximately equal in all media 
conditions at day 3. Levels of alkaline phosphatase in cells transfected with p3A4
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were dramatically higher in those cells cultured in the presence of untreated PCS, 
indicating that factors were present in this batch of PCS that appeared to be capable of 
the induction of human CYP3A4.
As can be seen from Pigure 3-31, levels of alkaline phosphatase expression in cells 
transfected with the pCMV plasmid were still approximately equal in all media 
conditions at day 5. The cells in serum free culture produced slightly lower amounts 
of alkaline phosphatase and they did not appear to be growing as rapidly as cells in 
the other media conditions under microscopic examination. Levels of alkaline 
phosphatase in cells transfected with p3 A4 were still high in those cells cultured in the 
presence of untreated PCS, but were also markedly raised in all cells treated with 
dexamethasone.
After normalisation (Pigure 3-32) it can be seen that the highest observed induction 
occurred in the cells maintained in medium containing DCC-stripped PCS.
It was therefore decided that cells should be routinely cultured in normal media 
conditions, however 24 hours prior to seeding for transfection the medium should be 
replaced with medium containing DCC-treated PCS, which would then be used 
throughout the transfection.
Other workers have demonstrated that PCS can contain factors that inhibit the 
induction of CYP3A in rat hepatocytes (Jackson et al., 1997). It is likely that a 
variety of factors, such as steroids and hormones, capable of influencing reporter 
expression from the CYP3A are present in PCS, and that their concentration may vary 
greatly from batch to batch. Por use in high throughput screening, and other 
situations where inter-transfection comparisons are required it would be advisable to 
ensure that all transfections were carried out using the same batch of PCS.
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Figure 3-29 The effect of media conditions on SPAP activity
in transfected HepG2 cells (Part 1)
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HepG2 cells in passage 10. RLUs = relative light units emitted following a 
chemiluminescent assay for alkaline phosphatase activity 24 hours post-transfection. 
Data shown as MEAN+/-SEM, where n=8.
Figure 3-30 The effect of media conditions on SPAP activity 
in transfected HepG2 cells (Part 2)
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HepG2 cells in passage 10. RLUs = relative light units emitted following a chemiluminescent
assay for alkaline phosphatase activity 24 hours post-transfection.
* = Samples to be dosed with 5pM dexamethasone. Data shown as MEAN+/-SEM, where n=8.
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Figure 3-31 The effect of media conditions on SPAP activity
in transfected HepG2 cells (Part 3)
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HepG2 cells in passage 10. RLUs = relative light units emitted following a 
chemiluminescent assay for alkaline phosphatase activity 72 hours post-transfection. 
Dex = 5pM dexamethasone. Data shown as MEAN+/-SEM, where n=8.
Figure 3-32 The effect of media conditions on SPAP activity 
in transfected HepG2 cells (Part 4)
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HepG2 cells in passage 10. RLUs = relative light units of alkaline phosphatase activity following
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection.
Dex = 5pM dexamethasone. Data shovm as MEAN+/-SEM, where n=8.
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3.9 Data analysis and experimental design
In previous work (Williams, 1997) the experimental controls had been as follows.
The control plasmid pCMV was transfected into one plate and not dosed. The test 
plasmid, p3 A4 was transfected into all other plates. Controls included one sample left 
undosed. Initial work was carried out according to this experimental design, however 
a test experiment was carried out to confirm that drugs would have no effect on the 
levels of the control plasmid. This assumption was shown to be incorrect and it was 
found that test drugs could be seen to have a number of different effects on both the 
control and test plasmids. It is thought that these effects might be due to either 
proliferative or cytotoxic effects of the drugs used.
The following two experiments illustrate how results obtained with this system might 
lead to mistaken conclusions if a control plasmid were not included for each 
xenobiotic concentration tested.
In two separate experiments, HepG2 cells in passage 14 (experiment 1) and passage 
16 (experiment 2) were seeded according to normal seeding protocol (Section 
2.8.1.1.) in 6 well plates and were transfected with Wizard Plus maxipreps of either 
pCMV (ethanol precipitated, Abs^ ^^ /Abs^ ^® = 1.67) or p3 A4 (ethanol precipitated, 
Abs^^ /^Abs^^  ^= 1.64) using the optimised calcium phosphate protocol (Section
2.8.1.3). In the first experiment cells were dosed with dexamethasone (1 pM), 
phenylbutazone (ImM) or carbamazepine (lOpM, lOOpM or ImM) according to 
standard dosing protocol (Section 2.8.3). In the second experiment cells were dosed 
with either dexamethasone ( 1 pM) or PCN ( 1 pM).
Levels of alkaline phosphatase activity were assessed using a chemiluminescent assay 
24 hours and 72 hours post-transfection, and the results normalised as detailed in
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Section 3.2.4. The results of the experiments are displayed in Figures 3-33 and 3-34 
respectively.
In Figure 3-33 reporter expression in the cells transfected with the p3A4 plasmid 
construct does not appear to have been induced by any of the xenobiotics. However 
reporter expression in the cells transfected with pCMV has dropped. Thus there is a 
change in the relative reporter expression of the two plasmids caused by the drug. It 
is possible that the drug has induced reporter expression from the p3 A4 plasmid but 
has also had some cytotoxic effects decreasing total cell protein production, thus 
masking the increase in reporter protein production.
In Figure 3-34, if the levels of expression from p3A4 are considered it appears that 
both dexamethasone and PCN have caused induction, however SPAP activity in cells 
transfected with pCMV has risen by the same degree. Thus neither compound has 
caused a change in the relative reporter expression of the two plasmids. The observed 
increase in reporter gene expression from both plasmids must be due to some other 
effect (possibly proliferative) of the drug on the cells; this was not further 
investigated.
Thus the various controls that should be included:
1. For alkaline phosphatase assays some medium from untransfected cells should be 
carried through the heat deactivation and assay procedures to ensure that heat 
deactivation is adequate (values should be no different to the reagent blank).
2. Cells that are transfected but not dosed will highlight any differences in basal 
expression between p3 A4 and pCMV.
3. A solvent control should be included to ensure that the solvents have no inducing 
effect on the regulatory region.
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4. Control plasmid (pCMV) should be included at every dose of test compound, for 
the reasons outlined above.
Figure 3-35 illustrates that neither solvent (DMSO or ethanol) used throughout this 
project has any significant effect on reporter gene expression. In this experiment, 
HepG2 cells in passage 11 were seeded in a 96 well plate according to the standard 
protocol (Section 2.8.1.1), with 8 replicates per experimental condition, and were 
transfected with Qiagen purified DNA (pCMV or p3 A4, +/-pSG5-hGR) using the 
optimised calcium phosphate transfection protocol (Section 2.8.1.3). Where 
appropriate pSG5-hGR was added to the transfection mixture at a concentration of 
12.5pg.mF^ precipitate (equivalent to 0.15pg per well of a 96 well plate). Solvents 
were added as described in Section 2.8.3. SPAP activity was measured using the 
chemiluminescent SPAP assay (Section 2.9.2.3) and data was normalised according to 
the procedure outlined in Section 3.2.4. These results are typical of the results 
obtained throughout the project, and thus for the purpose of clarity, in Chapter 4, only 
the solvent control is presented with the results of xenobiotic induction studies.
Another concern is the method of data analysis. The easiest way of comparing 
induction by xenobiotics in this system is in terms of fold induction; there are 
however several ways in which this could be calculated from the available data.
The first method would be to compare the levels of expression from p3 A4 in the 
presence and absence of xenobiotic; this could be statistically assessed using analysis 
of variance. As can be seen from Figures 3-33 and 3-34, use of this method would 
increase the occurrence of false positives and false negatives in the system, which is 
obviously undesirable in a high through-put screen.
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A second method would be to compare the levels of expression from the p3 A4 
construct with those from the pCMV construct in the presence of the xenobiotic; this 
could again be statistically analysed by analysis of variance. Although this method 
would prevent many of the false positives and false negatives negative that could 
occur using the system outlined above, it does not account for any difference in 
expression between p3 A4 and pCMV in the presence of solvent alone, thus any fold 
induction values calculated by this method may be falsely high or low.
In order to take account of all of the factors outlined above it is necessary to calculate 
fold induction values as follows:
Ratio of SPAP tp3 A4) to SPAP tnCMVf in the presence of xenobiotic 
Ratio of SPAP (p3 A4) to SPAP (pCMV) in the presence of solvent
where SPAP (p3A4) and SPAP (pCMV) represent normalised SPAP expression from 
cells transfected with p3A4 and pCMV respectively.
Fold induction values calculated in this way thus reflect the change in the relative 
expression of p3A4 with respect to pCMV caused by treatment with a xenobiotic. 
Data generated by this means may be analysed for statistical significance using one­
way analysis of variance (ANOVA) with Duncan’s multiple range post-hoc test. This 
latter method of data analysis has been routinely used throughout this project. The 
computer software (SPSS, version 6.1.2) used for these analyses can only test for 
significance at a level of p<0.05; the data analysed may therefore contain results that 
would pass this test at higher levels of significance, but this could not be extracted 
from the software used.
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Figure 3-33 The requirement for xenobiotic dosing of cells 
transfected with a control plasmid
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HepG2 cells in passage 14. RLUs = relative light units following normalisation of alkaline 
phosphatase activity at 72 hours post-transfection against activity at 24 hours post­
transfection. Data shown as MEAN+/-SEM, where n=6.
Figure 3-34 The requirement for xenobiotic dosing of cells 
transfected with a control plasmid
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Figure 3-35 Solvent controls for the assessment of xenobiotic induction of 
CYP3A4-dependent reporter gene expression in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase aetivity 
following normalisation of aetivity 72 hours post-transfection against activity 24 hours 
post-transfection. Data shown as MEAN+/-SEM, where n=8.
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3.10 Development of a system for the assessment of cytotoxicity
In addition to effects on the regulation of reporter gene expression, a compound may 
also affect the viability of the cells, either altering the total number of viable cells, or 
producing cellular toxicity, leading to reduced growth or protein production. This 
reduction can be the cause of increased variability and may mask increased reporter 
gene induction. It was therefore decided that it would be of use to identify a 
cytotoxicity assay capable of detecting alterations in cell number during transfection 
and xenobiotic treatment.
There were found to be several major obstacles to this. Firstly, insufficient culture 
medium remained after sampling for SPAP for any assays based on the measurement 
of the leakage of cellular enzymes into the cell culture medium (such as measurement 
of lactate dehydrogenase). Secondly, the HepG2 cells did not grow in a monolayer, 
but grew in clumps. Finally these cells were also coated with calcium phosphate 
precipitate which proved resistant to removal even after repeated washing with PBS. 
Given these problems a new chemiluminescent cytotoxicity assay (Cytolite from 
Packard) was evaluated.
HepG2 cells in passage 12 were harvested by trypsinisation and counted (Section 
2.4.2). Serial dilutions were made from this cell suspension and were seeded across 
two 96 well view plates in replicates of 8 wells per cell concentration per plate. One 
plate was transfected with a Wizard maxiprep of pCHl 10 (Abs^^ /^Abs^^  ^= 1.66) 
using the optimised calcium phosphate transfection protocol (Section 2.8.1.3), to 
provide a precipitate. The cells were grown for 24 hours and then assayed using the 
Cytolite assay as described in Section 2.10.
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This system was capable of detecting increasing cell number across a plate, however 
the results became extremely variable in those cells that had been transfected.
In a second experiment HepG2 cells in passage 13 were seeded in a 96 well view 
plate according to standard cell seeding protocol (Section 2.8.1.1). Half of the cells 
were transfected with a Wizard maxiprep of pCHl 10 (Abs^^ /^Abs^^  ^= 1.66) using the 
optimised calcium phosphate transfection protocol (Section 2.8.1.3), to provide a 
precipitate. 24 Hours after cell seeding, the medium was changed and the cells were 
dosed with carbon tetrachloride (CCI4 IpM, 50pM, 500pM and 50mM). The cells 
were grown for a further 24 hours and then assayed using the Cytolite assay (Section 
2.10). The cells were also examined under a microscope for visual signs of toxicity. 
Visually the cells appeared adversely affected at all concentrations of CCI4, and large 
numbers of dead cells were floating in the growth medium at concentrations of 50pM 
and above. The results of the Cytolite assay were extremely variable (data not 
shown); this system was unable to show a significant difference between those cells 
treated with CCI4, and those left untreated. This may be due to the clumping nature of 
HepG2 cells that may prevent the chemiluminogenic probe from reaching the 
membranes of many of the viable cells. The presence of cellular debris and the 
calcium phosphate precipitate may also interfere with the assay.
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3.11 Electroporation
Transient transfections are a highly variable and labour intensive procedure.
For use in high throughput screening it would be of great value to establish a cell line 
which stably expressed the alkaline phosphatase reporter gene under the direct control 
of the CYP3 A4 regulatory region.
Initial attempts to achieve this involved the co-transfection of HepG2 cells with the 
p3A4 and the pTK-Hyg plasmids in a 20:1 ratio respectively, using calcium 
phosphate precipitation methods (Sections 2.8.1.2 to 2.8.1.5). All of these attempts 
failed. One of the major problems encountered was that the calcium phosphate 
precipitate coated the cells and proved difficult to remove. Under the precipitate the 
cells failed to spread across the growth surface and proved extremely resistant to 
harvesting by trypsinisation. It was therefore decided that a more suitable approach 
might be to use electroporation (described in Sections 1.5.2.3 and 2.8.2).
3.11.1 Optimisation of the electroporation protocol
As with other methods of transfection, electroporation requires optimisation for the 
cell line under investigation. HepG2 cells in passage 10 were harvested and 
electroporated with a Qiagen pCMV plasmid preparation (Abs^^ /^Abs^^  ^=1.87) as 
described in Section 2.8.2.
Voltage and capacitance were varied as is illustrated in Figure 3-36 to attempt to 
determine optimal parameters for the transfection of HepG2 cells. A more complete 
optimisation was not possible due to time constraints.
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Figure 3-36 Optimisation of the parameters for the transfection of pCMV into HepG2
cells by electroporation
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HepG2 cells in passage 10. RLUs = relative light units emitted following a chemiluminescent 
assay for alkaline phosphatase activity. Data shown as MEAN+/-SEM, where n=3.
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3.11.2 Antibiotic kill curves
When using an antibiotic for the selection of stably transformed cell lines, it is 
important to determine the minimum lethal concentration. 10 culture flasks (80cm^) 
were each seeded with an 2.5 x 10^  HepG2 cells in passage 10 and left for two days to 
allow the cells to begin growing actively; antibiotic was added to each flask, over a 
range of concentrations. This was carried out for both hygromycin and G418. The 
medium was changed every two days to remove dead cells, and the antibiotic 
replaced. After 14 days the cells were trypsinised, and an aliquot diluted in trypan 
blue for counting as described in Section 2.4.2. From the results (Figure 3-37) it can 
be seen that total cell death is achieved with a concentration of 400pg.ml'^ for 
hygromycin and 800pg.ml'^ for G418.
3.11.3 Electroporation for the establishment of stable cell lines.
HepG2 cells in passage 10 were transfected by electroporation as described in Section 
2.8.2 with either p3A4 and pTK-Hyg (20:1) or p3A4 and pSV-Neo (10:1). For both 
plasmid combinations, 2 flasks were set up with the plasmids in supercoiled form and 
2 flasks were set up with the plasmids linearised by restriction enzyme digest 
(described in Section 2.7.2). 24 Hours post-transfection selective medium was 
applied (Hygromycin 400pg.ml'^ or G418 800pg.ml'^). The medium was changed 
every two days. Control cells, transfected with just p3A4, were also carried through 
the selection procedure to ensure that total killing of non-resistant cells was achieved. 
After selection, only two colonies of cells were growing. Both were growing under 
hygromycin selection, one colony in each flask transfected with linearised plasmids. 
The cells were harvested by trypsinisation and were grown for 10 days without 
selective medium, after which the cells derived from each colony were divided into
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two batches. The first batch from each colony was grown in normal growth medium 
for two days; the second batch was grown in medium containing dexamethasone 
(5pM in 0.1% DMSO) for two days. The medium was then assayed for SPAP using 
the chemiluminescent SPAP assay (Section 2.9.2.3). No alkaline phosphatase was 
present in any of the samples indicating that the p3 A4 plasmid had not been integrated 
into the cell genome in a ftinctional position in cells from either colony.
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CHAPTER 4 -  RESULTS
4.1 Introduction
Previously in our laboratory, a system for the in vitro assessment and detection of 
xenobiotic induction of the human CYP3 A4 gene was developed, and this system was 
shown to be capable of detecting induction by known inducers of CYP3 A4 (Williams, 
1997). Dexamethasone was observed to induce CYP3A4-dependent reporter gene 
expression in a concentration-dependent fashion; PCN and phenobarbitone were also 
reported to induce. TAG and rifampicin did not cause statistically significant 
induction.
Chapter 3 detailed the further development and refinement of this transient 
transfection reporter gene assay, both in terms of experimental procedure and in data 
normalisation and statistical analysis. This chapter investigates the effects of a 
number of known in vivo inducers of the CYP3A subfamily, presenting the results 
obtained whilst using the optimised transient transfection system for the assessment of 
xenobiotic induction of human CYP3A4.
4.2 The standard experimental format for the assessment of xenobiotic induction 
of CYP3A4-dependent reporter gene expression
For each experiment detailed in this chapter the HepG2 cells were seeded in 96 well 
plates according to the standard protocol (Section 2.8.1.1), with 8 replicates per 
experimental condition, and were transfected with Qiagen purified DNA using the 
optimised calcium phosphate transfection protocol (Section 2.8.1.3). In some of the 
experiments the plasmid pSG5-hGR, which encodes the human glucocorticoid
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receptor (GR), was co-transfected with the reporter constructs to enable assessment of 
the involvement of the GR in induction of CYP3 A4 by xenobiotics. Where 
appropriate, pSG5-hGR was added to the transfection mixture at a concentration of 
12.5pg.ml'^ precipitate (equivalent to 0.15pg per well of a 96 well plate).
All xenobiotic dosing was carried out as described in Section 2.8.3 with the exception 
of investigations in which dexamethasone was combined with other inducers 
(described in Section 4.15 and Section 4.16); in these experiments higher 
concentrations of solvent were used (0.2% DMSO or 0.1% DMSO + 0.1% ethanol). 
SPAP activity was measured using the chemiluminescent SPAP assay (Section
2.9.2.3) and data was normalised according to the procedure outlined in Section 3.2.4, 
and analysed and tested for statistical significance as described in Section 3.9.
Results are listed by compound. Each experiment has been assigned an experimental 
reference number (ERN) so that comparisons between compounds may be made.
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4.3 Effect of dexamethasone on CYP3A4-dependent reporter gene expression
Dexamethasone is a synthetic glucocorticoid, used as an anti-inflammatory and 
immunosuppressive agent, particularly in cases where water retention is undesirable 
such as cerebral oedema; it is also the drug of choice for suppression of 
adrenocorticotrophic hormone production (Rang et al, 1996; Wingard et al., 1991). 
Dexamethasone is an inducer of the CYP3 A subfamily in several species including 
the rat, rabbit and man both in vivo and in vitro (Barwick et al., 1996; Burger et al., 
1992; Eliasson et al., 1994; Kocarek et al., 1995; Thummel et al., 1994b). 
Dexamethasone has been demonstrated to induce CYP3A23 (rat), CYP3A6 (rabbit) 
and CYP3A4 (human) at the transcriptional level (Barwick et al., 1996), and has been 
shown to induce CYP3A3 mRNA (Fukuda et al., 1992), and CYP3A7 mRNA and 
protein in HepG2 cells (Schuetz et al., 1993). Dexamethasone has also been shown to 
cause induction of rat CYP3A1 through mRNA stabilisation (Simmons et al., 1987; 
Telhada et al., 1992).
Dexamethasone has previously been used in our laboratory as a typical inducer of 
CYP3A4 during the development of the in vitro transactivation system (Williams, 
1997), and was therefore used to test the responsiveness of the modified system.
The concentration dependence of the induction of CYP3 A4-dependent reporter gene 
expression by dexamethasone, in the presence and absence of the human GR, was 
investigated using the standard experimental format as described in Section 4.2. The 
results are displayed in Figure 4-1, and fold induction values are displayed in 
Table 4-1.
Dexamethasone was observed to cause a concentration-dependent increase in 
CYP3 A4-dependent reporter gene production. In the absence of the GR, the
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minimum concentration at which induction was observed was IpM (1.55 fold, 
p<0.05), and the concentration at which the maximal induction was observed was 
50pM (3.70 fold, p<0.05). In the presence of the GR, which enhanced induction by 
dexamethasone, the response was also concentration dependent. The minimum 
concentration at which induction was observed was 0.1pm (1.99 fold, p<0.05), and 
the concentration at which the maximal induction was observed was lOOpM (9.46 
fold, p<0.05). A degree of cytotoxicity may be occurring at a concentration of 
lOOpM dexamethasone, because slightly lower total reporter gene expression from 
both the pCMV and the p3 A4 reporter constructs is observed at this concentration. 
Throughout the course of my project, dexamethasone was frequently used as a 
positive control for induction assessment experiments. During these experiments, the 
fold induction of reporter expression by dexamethasone appeared to be variable, but 
this variation was not analysed statistically. Table 4-2 lists fold induction values 
obtained in other experiments to illustrate this variation. In many experiments 
dexamethasone failed to induce. Two main causes of this were identified. Firstly, as 
described in Section 3.4.1, dexamethasone induction was lost in cells of passage 16 or 
higher; this was solved by creating a large bank of HepG2 cells in lower passage. 
Secondly the presence of contaminants, presumably steroids, in some batches of FCS 
strongly induced reporter expression from the p3 A4 construct obscuring any 
subsequent induction by dexamethasone. As described in Section 3.8 this was 
avoided by the pre-treatment of FCS with dextran-coated charcoal to strip out any 
contaminants. Despite addressing these problems dexamethasone still failed to induce 
in several experiments. The reasons for this remain unclear, however in experiments 
where the GR was co-transfected, if induction was not present in the absence of GR it 
was always restored by the presence of GR.
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Figure 4-1 The influence of the glucocorticoid receptor on the induction of CYF3A4- 
dependent reporter gene expression by dexamethasone in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-1 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by dexamethasone
Dexamethasone
concentration
0.1 pM IpM 5pM lOpM 50pM lOOpM
Fold increase (-GR) 0.88 1.55* 1.54* 2.82* 3.70* 3.60*
Fold increase (+GR)
* . . . . .
1.99* 2.42* 5.08* 6.26* 8.78* 9.46*
DMSO (p<0.05). ERN: 1
Table 4-2 Further experiments on the influence of the glucocorticoid receptor on 
the induction of CYP3A4-dependent reporter gene expression by dexamethasone
ERN
HepG2 
passage no.
Dexamethasone
concentration
Fold increase 
(-GR)
Fold increase 
(+GR)
2 11 5pM 1.06 2.97*
3 11 5pM 1.24* 2.36*
4
*
11 5pM 1.19* 2.59*
control, DMSO (p<0.05).
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4.4 Effect of rifampicin on CYP3A4-dependent reporter gene expression
Rifampicin is an antibiotic used mainly in the treatment of tuberculosis; it is also 
occasionally used to treat other infections by both Gram-positive and Gram-negative 
organisms including staphylococci and bacteroides. Rifampicin is excreted in the bile 
and is occasionally used to treat biliary infections (Wingard et ah, 1991; The 
Pharmaceutical Codex, 1988). Rifampicin acts by inhibiting the DNA-directed RNA 
polymerase of mycobacteria and other micro-organisms by binding to the p-subunit of 
the polymerase, forming a stable drug-enzyme complex, leading to suppression of 
initiation of chain formation in RNA synthesis (Wingard et al., 1991; Gilman et al., 
1991).
Rifampicin is an inducer of the CYP3 A subfamily in several species including the 
rabbit, dog and man both in vivo and in vitro (Barwick et al., 1996; Jackson et al.,
1997; Jones et al., 1996; Kocarek et al., 1995; Kolars et al., 1992; Watkins et al.,
1989), however it does not induce in the rat (Wrighton et al., 1985b; Barwick et al., 
1996). It induces CYP3A6 and CYP3A4 at the transcriptional level, and has been 
shown to induce a CYP3A23 reporter construct transfected into rabbit hepatocytes 
demonstrating that its failure to induce CYP3A23 in vivo in the rat and in primary 
culture of rat hepatocytes must be due to the lack of species specific cellular factors 
(Barwick et al., 1996). Rifampicin has been reported to induce both CYP3A4 and 
CYP3A7 mRNA in primary human hepatocyte cultures (Greuet et al., 1996) and 
CYP3A7 mRNA and protein in HepG2 cells (Guzelian, 1994).
In a previous experiment using the CYP3A4 transactivation system developed in this 
laboratory it was observed that rifampicin did not appear to induce CYP3A4- 
dependent reporter gene expression (Williams, 1997).
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The concentration dependence of the induction of CYP3 A4-dependent reporter gene 
expression by rifampicin, in the presence and absence of the human GR, was 
examined using the standard experimental format as described in Section 4.2. The 
results are displayed in Figure 4-2, and fold induction values are displayed in 
Table 4-3.
Rifampicin increased CYP3 A4-dependent reporter gene production. In the absence of 
the GR, a response was observed at a concentration of IpM (1.33 fold, p<0.05); 
responses were also observed at lOOpM (1.41 fold, p<0.05) and ImM (1.39 fold, 
p<0.05) but no response was observed at concentrations in between (5pM, lOpM and 
50pM). The presence of the GR enhanced the response with induction observed at 
concentrations of 1 pM (1.35 fold, p<0.05) and above, reaching a maximum induction 
at a concentration of lOOpM (3.89 fold, p<0.05).
Throughout the course of the project rifampicin was frequently used as a positive 
control for induction assessment experiments. During these experiments, the fold 
induction of reporter expression by rifampicin appeared to be variable, but this 
variation was not analysed statistically. Table 4-4 lists fold induction values obtained 
in other experiments to illustrate this variation. In contrast to dexamethasone the 
HepG2 cells did not appear to lose their responsiveness to rifampicin, although the 
presence of co-transfected GR always appeared to enhance induction.
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Figure 4-2 The influence of the glucocorticoid receptor on the induction of CYP3A4- 
dependent reporter gene expression by rifampicin in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-3 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by rifampicin
Rifampicin concentration IpM 5pM lOpM 50pM lOOpM ImM
Fold increase (-GR) 1.33* 1.00 1.02 0.92 1.41* 1.39*
Fold increase (+GR) 
* .
1.35* 2.79* 2.72* 3.22* 2.93* 3.89*
DMSO (p<0.05). ERN:2
Table 4-4 Further experiments on the influence of the glucocorticoid receptor on 
the induction of CYP3A4-dependent reporter gene expression by rifampicin
ERN
HepG2 
passage no.
Rifampicin
concentration
Fold increase 
(-GR)
Fold increase 
(+GR)
1 11 50pM 2.43* 4.55*
3 11 50pM 1.24* 2.42*
4
*
11 50pM 1.37* 2.72*
control, DMSO (p<0.05).
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4.5 Effect of pregnenolone 16a- carbonitrile (PCN) on CYP3A4-dependent 
reporter gene expression
PCN is a synthetic antiglucocorticoid that has been widely used experimentally in the 
study of glucocorticoid-inducible genes. It is an inducer of the CYP3 A subfamily in 
several species including the rat and man both in vivo and in vitro (Barwick et al., 
1996; Burger et al., 1992; Kocarek et al., 1995; Gonzalez et al., 1985). It induces 
CYP3A23 and CYP3A4 at the transcriptional level (Barwick et al., 1996), and has 
previously been used in our laboratory as an inducer of CYP3A4 during the 
development of the in vitro transactivation system (Williams, 1997). PCN was 
reported not to induce CYP3A7 in HepG2 cells (Guzelian, 1994; Schuetz et al.,
1993); in human hepatocytes it has been shown to induce CYP3A in some but not all 
cultures (Kocarek et al., 1995). PCN has also been shown to cause induction of rat 
CYP3A1 through mRNA stabilisation (Simmons et al., 1987).
The concentration dependence of the induction of CYP3 A4-dependent reporter gene 
expression by PCN, in the presence and absence of the human GR, was examined 
using the standard experimental format as described in Section 4.2. The results are 
displayed in Figure 4-3, and fold induction values are displayed in Table 4-5.
PCN was observed to cause an increase in CYP3A4-dependent reporter gene 
production. In the absence of the GR, a response was observed at a concentration of 
0.1 pM (1.24 fold, p<0.05); the maximal response was observed at a concentration of 
lOpM (1.63 fold, p<0.05). In the presence of GR, induction was observed at 
concentration of 5pM (1.51 fold, p<0.05); the maximal response was observed at a 
concentration of lOpM (2.13 fold, p<0.05).
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The presence o f the GR enhanced induction at doses of 5pM, lOpM and 50pM but
not at concentrations above or below.
Interestingly no induction was seen with or without the GR at a dose of lOOpM; at 
this dose the cells appeared to be adversely affected by PCN, exhibiting altered 
morphology, and there was an increase in cell debris in the culture medium, but a 
drop in total reporter gene expression was not observed. It is possible that any 
toxicity may have been slow acting, but the lack of any induction remains 
unexplained.
Throughout the course of the project PCN was occasionally used as a positive control 
for induction assessment experiments. During these experiments, the fold induction 
of reporter expression by PCN appeared to be variable, but this variation was not 
analysed statistically. Table 4-6 lists fold induction values obtained in other 
experiments to illustrate this variation. As with dexamethasone the HepG2 cells 
appeared to lose their responsiveness to PCN in some experiments, although the 
presence of co-transfected GR always appeared to restore induction.
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Figure 4-3 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by PCN in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs — relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-5 Influence of tbe glucocorticoid receptor on tbe induction of
CYP3A4-dependent reporter gene expression by PCN
PCN concentration 0.1 pM IpM 5fiM lOfiM 50pM lOOpM
Fold increase (-GR) 1.24* 1.36* 1.23* 1.63* 1.45* 0.83
Fold increase (+GR) 1.22 1.20 1.51* 2.13* 1.91* 0.81
DMSO (p<0.05). ERN:3
Table 4-6 Further experiments on tbe influence of tbe glucocorticoid receptor on 
tbe induction of CYP3A4-dependent reporter gene expression by PCN
ERN
HepG2 
passage no.
PCN
concentration
Fold increase 
(-GR)
Fold increase 
(+GR)
1 11 5pM 1.78* 4.59*
2 11 5pM 1.41* 2.52*
4
*
11 5pM 0.93 2.76*
control, DMSO (p<0.05).
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4.6 Effect of phenobarbitone on CYP3A4-dependent reporter gene expression
Phenobarbitone is a barbiturate and has been used as a sedative in a variety of 
disorders such as nervous and anxiety states, chorea and thyrotoxicosis, however this 
use has been largely replaced by other sedatives; it has also been used in the treatment 
of migraine (The Pharmaceutical Codex, 1988). Its main use is as an anti-seizure 
agent either alone or in combination therapy (Wingard et al., 1991).
Phenobarbitone has been shown to induce CYP3 A in vivo and in vitro in several 
species including rat, primates, dog and human (Thummel et al., 1994a; Ciaccio & 
Halpert, 1989; Jones et al., 1992; Kocarek et al., 1995; Pichard et al., 1990). 
Phenobarbitone has been shown to induce CYP3A7 mRNA and protein expression in 
HepG2 cells (Schuetz et al., 1993). As well as members of the CYP3A subfamily, 
phenobarbitone has also been reported to induce isozymes of the 2B and 2C 
subfamilies in several species including rats and primates (Shaw et al., 1993; Jones et 
al., 1992) and has also been shown to induce forms of P450 in bacteria (Liang et al.,
1995).
To investigate whether the current system was capable of detecting induction of 
CYP3 A4-dependent reporter gene expression by phenobarbitone an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-4, and fold 
induction values are displayed in Table 4-7.
In the absence of co-transfected GR, phenobarbitone appeared to induce at a 
concentration of lOpM (1.39 fold). In the presence of GR, induction was observed at 
all concentrations tested.
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Figure 4-4 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by phenobarbitone in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-7 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by phenobarbitone
Phenobarbitone concentration IpM lOpM lOOpM
Fold increase (-GR) 0.94 1.39* 1.20
Fold increase (+GR)
* . . . .
1.36* 1.39* 2.11*
to the solvent control ethanol (p<0.05). ERN:4
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4.7 Effect of metyrapone on CYP3A4-dependent reporter gene expression
Metyrapone is an inhibitor of steroid 1 ip-hydroxylase activity, which is required for 
the formation of cortisone and hydrocortisone from their precursors; it is used 
clinically as a diagnostic agent to investigate the frmction of the anterior lobe of the 
pituitary gland and in the investigation and treatment of Cushing’s syndrome (The 
Pharmaceutical Codex, 1988; Reynolds, 1993).
Metyrapone is a transcriptional inducer of CYP3A expression in human hepatocytes 
(Wright et al., 1996) and in rats and rat hepatocytes (Wright & Paine, 1994a; Wright 
et al., 1994b), possibly acting independently of the GR (Wright et al., 1996).
To investigate whether the current system was capable of detecting induction of 
CYP3 A4-dependent reporter gene expression by metyrapone an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-5, and fold 
induction values are displayed in Table 4-8.
In the absence of co-transfected GR, metyrapone appeared to induce CYP3A4 at all 
concentrations tested. In the presence of GR, induction was observed at 
concentrations of lOpM and lOOpM but not at ImM. The presence of co-transfected 
GR did not enhance induction of CYP3 A-dependent reporter gene expression.
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Figure 4-5 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by metyrapone in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-8 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by metyrapone
Metyrapone concentration lOpM lOOpM ImM
Fold increase (-GR) 1.74* 1.40* 2.18*
Fold increase (+GR)
* .. . . .
1.91* 1.48* 1.10
to the solvent control, DMSO Q)<0.05). ERN:4
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4.8 Effect of carbamazepine on CYP3A4-dependent reporter gene expression
Carbamazepine is one of the most frequently prescribed antiepileptic drugs, used in 
the treatment of partial and tonic-clonic epileptic seizure; it is also used in the 
treatment of trigeminal neuralgia and psychiatric disorders, particularly bipolar 
depression (Spina et al., 1996; Gilman et al., 1991; The Pharmaceutical Codex, 1988). 
Carbamazepine induces CYP3A in humans (Tomlinson et al., 1996; Spina et al.,
1996) and has been shown to increase levels of CYP3 A-dependent catalytic activity 
(assessed by measurement of oxidation of cyclosporin A) in primary cultures of 
human hepatocytes (Pichard et al., 1990).
To investigate whether the current system was capable of detecting induction of 
CYP3A4-dependent reporter gene expression by carbamazepine an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-6, and fold 
induction values are displayed in Table 4-9.
In the absence of co-transfected GR, carbamazepine caused induction of reporter 
expression at concentrations of lOOpM and ImM. In the presence of GR, enhanced 
induction was observed at all concentrations tested.
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Figure 4-6 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by carbamazepine in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs — relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-9 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by carbamazepine
Carbamazepine concentration lOpM lOOpM ImM
Fold increase (-GR) 0.97 1.37* 1.21*
Fold increase (+GR)
*
2.13* 1.98* 1.83*
to the solvent control, DMSO (p<0.05). ERN:4
234
4.9 Effect of sulfinpyrazone on CYP3A4-dependent reporter gene expression
Sulfinpyrazone is a uricosuric agent used in the treatment of chronic gout (Reynolds, 
1993); it is also a competitive inhibitor of platelet cyclooxygenase (blocking the 
synthesis of thromboxane A2) and is thus used to reduce platelet adhesiveness in some 
vascular disorders (Wingard et al., 1991; The Pharmaceutical Codex, 1988). 
Sulfinpyrazone has been shown to increase levels of CYP3 A-dependent catalytic 
activity (assessed by measurement of oxidation of cyclosporin A) in primary cultures 
of human hepatocytes (Pichard et al., 1990).
To investigate whether the current system was capable of detecting induction of 
CYP3A4-dependent reporter gene expression by sulfinpyrazone, an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-7, and fold 
induction values are displayed in Table 4-10.
In the absence of co-transfected GR, sulfinpyrazone induced reporter expression at 
concentrations of lOpM and lOOpM. In the presence of GR, induction was observed 
at all concentrations tested.
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Figure 4-7 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by sulfinpyrazone in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-10 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by sulfinpyrazone
Sulfinpyrazone concentration lOpM lOOpM ImM
Fold increase (-GR) 1.81* 2.10* 1.15
Fold increase (+GR)
* . _ _
1.22* 1.59* 1.39*
to the solvent control, DMSO (p<0.05). ERN:4
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4.10 Effect of triacetyloleandomycin (TAO) and erythromycin on CYP3A4-
dependent reporter gene expression
TAO and erythromycin are macrolide antibiotics which act by binding reversibly to 
the 50S subunit of the bacterial ribosome, resulting in blockage of the transpeptidation 
or translocation reactions, inhibition of protein synthesis, and hence inhibition of cell 
growth; they thus exhibit a primarily bacteriostatic action against a broad range of 
bacteria (Rang et ah, 1996; Reynolds, 1993). TAO is used in the treatment of 
respiratory tract infections caused by Group A beta-haemolytic streptococci and 
pneumococcal pneumonia, and to eradicate streptococci from the nasopharynx; it is 
also used in combination with methylprednisolone in the treatment of 
hypereosinophilic syndrome (Gennaro et al., 1990). Erythromycin is mainly used in 
patients allergic to penicillin and infections caused by penicillin-resistant 
staphylococci; it is also used in conditions such as diphtheria, pertussis, legionnaires 
disease, and other respiratory tract infections, as well as being used as an alternative 
to tetracyclines in chlamydial infections and some other conditions (Gilman et al.,
1991; The Pharmaceutical Codex, 1988).
TAO induces CYP3A protein in humans (Watkins et al., 1985); both TAO and 
erythromycin also induce CYP3A in rats (Wrighton et al., 1985a). TAO and 
erythromycin have been shown to increase the levels of detectable CYP3A in human 
hepatocytes, while decreasing CYP3 A-dependent enzyme activities (cyclosporin A 
oxidation) (Pichard et al., 1990) and both have been reported to increase levels of 
CYP3A7 protein in HepG2 cells (Schuetz et al., 1993). Both TAO and erythromycin 
have been shown to act at the post-transcriptional level, inhibiting protein degradation 
(Eliasson et al., 1994; Watkins et al., 1986).
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The effects of erythromycin and TAO on CYP3A4-dependent reporter gene 
expression were investigated in an experiment carried out according to the standard 
experimental format (Section 4.2), in the presence and absence of the GR.
The results are displayed in Figure 4-8, and fold induction values are displayed in 
Table 4-11. It can be seen from the results that erythromycin and TAO do not induce 
CYP3 A4-dependent reporter gene expression.
4.11 Effect of clotrimazole on CYP3A4-dcpcndcnt reporter gene expression
Clotrimazole is a broad-spectrum imidazole antifungal and trichomonacidal agent that 
interferes with amino acid transport into the organism by an action on the cell 
membrane (Rang et al., 1996). It is used in the treatment of dermatomycoses, 
leucorrhoea and vaginitis caused by infections with Candida and Trichomonas species 
(The Pharmaceutical Codex, 1988).
Clotrimazole has been reported to be a potent inducer or CYP3A1 in vivo (Hostetler et 
al., 1988; Khan et al., 1989), acting post-transcriptionally by inhibition of protein 
degradation (Eliasson et al., 1994). Clotrimazole has also been shown to induce 
CYP3A mRNA levels in primary cultures of human hepatocytes and also CYP3A 
mRNA and protein in rat leukocytes (Mahnke et al., 1996) and in primary cultures of 
rat, but not rabbit, hepatocytes (Kocarek et al., 1995).
The effects of clotrimazole on CYP3A4-dependent reporter gene expression were 
investigated in an experiment carried out according to the standard experimental 
format (Section 4.2), in the presence and absence of the GR.
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The results are displayed in Figure 4-9, and fold induction values are displayed in 
Table 4-11. It can be seen from the results that clotrimazole does not induce 
CYP3A4-dependent reporter gene expression.
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Figure 4-8 The influence of the glucocorticoid receptor on the effect of erythromycin and TAO on
CYP3A4-dependent reporter gene expression in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours 
post-transfection. Data shown as MEAN+/-SEM, where n = 8.
Figure 4-9 The influence of the glucocorticoid receptor on the effect of clotrimazole on 
CYP3A4-dependent reporter gene expression in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours 
post-transfection. Data shown as MEAN+/-SEM, where n = 8.
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Table 4-11 Influence of the glucocorticoid receptor on the effect of TAO,
erythromycin and clotrimazole on CYP3A4-dependent reporter gene expression
TAO lOOpM Erythromycin lOOpM Clotrimazole
lOOpM
Fold increase (-GR) 0.93 0.96 0.66
Fold increase (+GR) 0.96 1.12 0.77
ERN:4
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4.12 Effect of phenylbutazone on CYP3A4-dependent reporter gene expression
Phenylbutazone is potent non-steroidal anti-inflammatory drug used mainly to relieve 
symptoms of rheumatic disorders (Rang et al., 1996; The Pharmaceutical Codex, 
1988).
Phenylbutazone has been shown to increase levels of CYP3 A-dependent catalytic 
activity (assessed by measurement of oxidation of cyclosporin A) in primary cultures 
of human hepatocytes (Pichard et al., 1990).
To investigate whether the current system was capable of detecting induction of 
CYP3A4-dependent reporter gene expression by phenylbutazone an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-10, and fold 
induction values are displayed in Table 4-12.
Phenylbutazone induced C YP3 A4-dependent reporter gene expression at all 
concentrations tested, and in each case this was enhanced by the presence of the GR.
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Figure 4-10 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by phenylbutazone in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-12 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by phenylbutazone
Phenylbutazone concentration lOpM lOOpM ImM
Fold increase (-GR) 1.30* 1.23* 1.40*
Fold increase (+GR) 1.78* 2.29* 1.65*
to the solvent control, DMSO (p<0.05). ERN:4
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4.13 Effect of phenytoin on CYP3A4-dependent reporter gene expression
Phenytoin has been used for more than 50 years in the treatment of epilepsy, and is 
effective against all types of partial and tonic-clonic seizures but not absence seizures; 
it is frequently used in conjunction with phenobarbitone (Griffin, 1996; The 
Pharmaceutical Codex, 1988).
Phenytoin has been shown to induce CYP3 A in vivo in rats and humans (Thummel et 
al., 1994a; Ghosal et al., 1996; Tomlinson et al., 1996).
It also been reported to increase levels of CYP3A-dependent catalytic activity 
(assessed by measurement of oxidation of cyclosporin A) in primary cultures of 
human hepatocytes (Pichard et al., 1990), and to increase expression of CYP3A7 
mRNA in HepG2 cells (Schuetz et al., 1993).
To investigate whether the current system was capable of detecting induction of 
CYP3 A4-dependent reporter gene expression by phenytoin, an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-5, and fold 
induction values are displayed in Table 4-13.
Phenytoin induced CYP3A4-dependent reporter gene expression at all concentrations 
tested, and in each case this was enhanced by the presence of the GR.
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Figure 4-11 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by phenytoin in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-13 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by phenytoin
Phenytoin concentration lOpM lOOjiM ImM
Fold increase (-GR) 1.31* 1.37* 1.31*
Fold increase (+GR) 1.98* 1.46* 1.86*
to the solvent control, ethanol (p<0.05). ERN:4
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4.14 Effect of spironolactone on CYP3A4-dependent reporter gene expression
Spironolactone is a synthetic hormone used clinically as a potassium sparing diuretic; 
it exerts a diuretic effect by antagonising the action of aldosterone in the distal tubule 
(Rang et al, 1996). It is mainly used in the treatment of refractory oedema in patients 
with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis (Reynolds, 
1993).
Spironolactone has been shown to induce CYP3A in rats in vivo (Heuman et al., 
1981); it has also been shown to induce CYP3A mRNA levels in primary rat and 
human hepatocyte cultures but not in rabbit (Kocarek et al., 1995).
To investigate whether the current system was capable of detecting induction of 
CYP3 A4-dependent reporter gene expression by spironolactone an experiment was 
carried out according to the standard experimental format (Section 4.2), in the 
presence and absence of the GR. The results are displayed in Figure 4-5, and fold 
induction values are displayed in Table 4-14.
In the absence of co-transfected GR, spironolactone did not induce reporter 
expression. In the presence of GR, induction was observed at concentrations of lOpM 
and lOOpM.
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Figure 4-12 The influence of the glucocorticoid receptor on the induction of CYP3A4-
dependent reporter gene expression by spironolactone in transfected HepG2 cells
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HepG2 cells in passage 11. RLUs = relative light units of alkaline phosphatase activity following 
normalisation of activity 72 hours post-transfection against activity 24 hours post-transfection. Data 
shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent control (p<0.05).
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Table 4-14 Influence of the glucocorticoid receptor on the induction of
CYP3A4-dependent reporter gene expression by spironolactone
Spironolactone concentration lOpM lOOpM ImM
Fold increase (-GR) 1.03 0.99 1.03
Fold increase (+GR) 
*
1.71* 1.44*, 0.85
to the solvent control, DMSO ^<0.05). ERN:5
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4.15 Effect of RU-486 on dexamethasone induction of CYP3A4-dependent
reporter gene expression
RU-486 (also known as mifepristone) is a synthetic potent progesterone antagonist 
that also exhibits some antiglucocorticoid activity (Wingard et al., 1991). It is used as 
an abortifacient in some countries, and has been used in the treatment of Cushing’s 
syndrome in clinical trials (Rang et al., 1996). It binds to the progesterone receptor, 
preventing binding by endogenous progesterone, while avoiding the usual hormone 
response; it also binds weakly to the androgen receptor and tightly to the GR (with 
greater affinity than dexamethasone) (Wingard et al., 1991).
RU-486 has been shown to induce GYPS A mRNA in primary cultures of rat, rabbit 
and human hepatocytes (Kocarek et al., 1995), but it has also been reported to inhibit 
dexamethasone induction of CYP3A7 mRNA in HepG2 cells (Schuetz et al., 1993). 
Dexamethasone-dependent induction of a CYP3A5 reporter construct transfected into 
primary cultures of rat hepatocytes was blocked by the addition of RU-486 (Schuetz 
et al., 1996). In rat hepatoma cells (FAO) RU-486 was reported not to inhibit 
dexamethasone induction of CYP3A (Waziers et al., 1992), however it has been 
reported to block phenobarbitone induction of rat CYP2C6 mRNA, and to block 
induction of reporter gene expression from CYP2B1 and CYP2B2 reporter constructs 
transfected into these cells (Shaw et al., 1993).
To investigate the effects of RU-486 on CYP3A4-dependent reporter gene expression, 
and on the induction of expression by dexamethasone, an experiment was carried out 
according to the standard experimental format (Section 4.2), in the presence of the 
GR, and the presence and absence of dexamethasone (lOpM). To obtain the 
appropriate concentrations of both compounds 0.2% DMSO was used.
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The results are displayed in Figures 4-13 and 4-14, and fold induction values are 
displayed in Table 4-15.
It can be seen from Figure 4-13 that RU-486 does not induce CYP3A4-dependent 
reporter gene expression. It may also be seen from this figure that RU-486 may tend 
to decrease the expression of the p3 A4 construct relative to the expression pCMV at 
concentrations of 10|iM and lOOpM, however there is no statistically significant 
difference in these data, and it appears that cytotoxicity may be occurring at these 
concentrations. Figure 4-14 clearly illustrates that RU-486 blocks dexamethasone- 
dependent induction of CYP3A4-dependent reporter gene expression at all doses of 
RU-486 (IjLiM, lOpM and lOOpM, p<0.05).
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Figure 4-13 Effect of RU-486 on CYP3A4-dependent reporter gene expression in 
transfected HepG2 cells, in the presence of the glucocorticoid receptor
I
I
2000  -  
1800 - 
1600 
1400 
1200 
1000 
800 
600 
400 
200 
0
□ pCMV + GR 
^p3A 4 + GR
r T
DMSO RU486
IpM
RU486
lOpM
RU486
lOOpM
HepG2 cells in passage 12. RLUs = relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours 
post-transfection. Data shown as MEAN+/-SEM, where n = 8.
Figure 4-14 Blockade of dexamethasone induction of CYP3A4-dependent reporter gene expression by 
RU-486 in transfected HepG2 cells, in the presence of the glucocorticoid receptor
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HepG2 cells in passage 12. Dex -  Dexamethasone. RLUs = relative light units of alkaline phosphatase 
activity following normalisation of activity 72 hours post-transfection against activity 24 hours post­
transfection. Data shown as MEAN+/-SEM, where n = 8. * = significant induction compared to solvent 
control (p<0.05); + = significant block of dexamethasone-dependent induction (p<0.05).
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Table 4-15 Blockade of dexamethasone induction of CYP3A4-dependent 
reporter gene expression by RU-486, in the presence of the glucocorticoid 
receptor
Dexamethasone RU-486 RU-486 RU-486
lOpM IpM lOpM lOOpM
Fold increase 1.97* 1.08 0.55 0.54
Fold increase (+Dex lOpM)
* . . ...........................
- 0.48^ 0.46^ 0.54+
significantly different to dexamethasone alone ^<0.05).
ERN:5
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4.16 Effect of dexamethasone in combination with other xenobiotics on CYP3A4-
dependent reporter gene expression
Previously in the literature it has been reported that the use of other inducers in 
combination with dexamethasone may affect the levels of induction compared to 
dexamethasone alone. In studies of a CYP3A1 reporter gene construct in primary 
cultures of rat hepatocytes, PCN was observed to synergistically increase 
dexamethasone-dependent induction of reporter gene expression (Quattrochi et al., 
1995). However PCN has been reported to inhibit dexamethasone induction of 
CYP3A7 mRNA in HepG2 cells (Schuetz et al., 1993).
To investigate the effects in this system, transfected cells were dosed with 
dexamethasone in combination with other xenobiotics, in the presence of GR. In this 
experiment for those xenobiotics soluble in DMSO (including dexamethasone alone) 
the final DMSO concentration was 0.2%; for those xenobiotics soluble in absolute 
ethanol (clotrimazole, phenobarbitone and phenytoin) the final solvent concentration 
was 0.1% DMSO and 0.1% absolute ethanol.
The results of this experiment are illustrated in Figures 4-15 to 4-18, and Table 4-16. 
Dexamethasone alone, at a concentration of lOpM, caused induction (1.97 fold, 
p<0.05); this is lower than has been observed at this dose of dexamethasone in other 
experiments (data presented in Section 4.3). No combination produced significantly 
greater induction than dexamethasone alone.
In this experiment problems with experimental variation and cytotoxicity were more 
marked than expected. This is thought to be due to the higher concentration of 
solvents in this experiment, and the combinations of the xenobiotics.
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Figure 4-15 Effect of dexamethasone in combination with other xenobiotics on CYP3A4-
dependent reporter gene expression, in the presence of the glucocorticoid receptor (Part 1)
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HepG2 cells in passage 12. RLUs = relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours post­
transfection. Data shown as MEAN+/-SEM, where n = 8. Dex = Dexamethasone lOpM.
* = significant induction compared to solvent control (p<0.05).
Figure 4-16 Effect of dexamethasone in combination with other xenobiotics on CYP3A4- 
dependent reporter gene expression, in the presence of the glucocorticoid receptor (Part 2)
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HepG2 cells in passage 12. RLUs — relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours post­
transfection. Data shown as MEAN+/-SEM, where n = 8. Dex = Dexamethasone lOpM.
* = significant induction compared to solvent control (p<0.05).
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Figure 4-17 Effect of dexamethasone in combination with other xenobiotics on CYP3A4-
dependent reporter gene expression, in the presence of the glucocorticoid receptor (Part 3)
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HepG2 cells in passage 12. RLUs = relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours post­
transfection. Data shown as MEAN+/-SEM, where n = 8. Dex = Dexamethasone lOpM.
Figure 4-18 Effect of dexamethasone in combination with other xenobiotics on CYP3A4- 
dependent reporter gene expression, in the presence of the glucocorticoid receptor (Part 4)
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HepG2 cells in passage 12. RLUs — relative light units of alkaline phosphatase activity
following normalisation of activity 72 hours post-transfection against activity 24 hours post­
transfection. Data shown as MEAN+/-SEM, where n = 8. Dex = Dexamethasone lOpM.
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Table 4-16 Effect of dexamethasone in combination with other xenobiotics on 
CYP3A4-dependent reporter gene expression, in the presence of the 
glucocorticoid receptor
Fold induction Fold induction
Dexamethasone 1.97* + Phenylbutazone 1.26
(lOpM) (lOOpM)
+ Carbamazepine 1.70 + Phenytoin (lOpM) 1.11
(lOpM)
+ Clotrimazole 1.12 + Rifampicin (50pM) 1.71
(lOOpM)
+ Erythromycin 1.29 + Spironolactone 2.03
(lOOpM) (lOpM)
+ Metyrapone (lOjiM) 1.93 + Sulfinpyrazone 1.98
(lOOpM)
+ PCN(10pM) 2.28* + TAG (lOOpM) 1.20
+ Phenobarbitone 1.19
(lOOpM)
Significant fold induction compared to solvent control (p<0.05). ERN:6
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4.17 Testing for false positive induction of CYP3A4-dependent reporter gene
expression
From the results detailed in Sections 4.3 to 4.15 it appears that this system is capable 
of detecting many inducers of the CYP3 A subfamily. As well as the ability to predict 
induction, giving few false negatives, the system must also not produce false 
positives. To test this, transfected cells were dosed with a variety of compounds that 
have been shown to induce other P450s.
These compounds included clofibrate, isoniazid and P-naphthoflavone (inducers of 
the CYP4A, CYP2E and CYPIA families respectively (Okey, 1990)), and caffeine 
(an inducer of CYP1A2 and the CYP2B family (Ayalogu et al., 1995)).
As can been seen from the results in Figures 4-19 and 4-20, and Table 4-17, none of 
these other compounds induced this system, indicating that it is specific for CYP3A4.
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Figure 4-19 Negative controls for induction of CYP3A4-dependent reporter gene expression
in transfected HepG2 cells (Part 1)
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HepG2 cells in passage 12. RLUs = relative light units of alkaline phosphatase activity 
following normalisation of activity 72 hours post-transfection against activity 24 hours 
post-transfection. Data shovm as MEAN+/-SEM, where n = 8. p-NF = p-naphthoflavone.
Figure 4-20 Negative controls for induction of CYP3A4-dependent reporter gene expression
in transfected HepG2 cells (Part 2)
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post-transfection. Data shown as MEAN+/-SEM, where n = 8.
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Table 4-17 Negative controls for the assessment of xenobiotic induction of
CYP3A4-dependent reporter gene expression
lOpiM lOOpM ImM
Clofibrate 1.13 0.73 0.54
p-Naphthofiavone 0.82 1.01 -
Caffeine 0.58 0.84 -
Isoniazid 1.24 0.91 0.72
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4.18 Discussion
This chapter described the results of a number of experiments in which the CYP3 A4- 
reporter gene system was tested with a variety of xenobiotics, some of which are 
known in vivo inducers of the CYP3A subfamily. Of the knovm inducers, the system 
did not demonstrate induction by clotrimazole, erythromycin or TAG. This may 
indicate that these compounds act at a post-transcriptional level to induce the ÇYP3 A 
subfamily. Dexamethasone, rifampicin, carbamazepine, phenytoin and 
phenylbutazone all showed induction which was enhanced by the presence of the OR. 
Spironolactone caused induction in the presence of the OR only. In the cases of PCN 
and phenobarbitone the OR appeared to enhance induction at some but not all 
concentrations of xenobiotic. In the cases of sulfinpyrazone and metyrapone the OR 
did not enhance the observed induction. None of the xenobiotics tested enhanced the 
induction observed after treatment with 10|iM dexamethasone; RU-486 was shown to 
block dexamethasone-dependent induction. Possible implications concerning the 
molecular mechanisms of the induction of CYP3A4 are discussed in Chapter 5.
For several of the xenobiotics tested (e.g. PCN) results were observed at the highest 
concentrations (i.e. 100|iM or ImM) which did not appear to follow the trends 
observed at lower concentrations. There are thought to be two main factors 
contributing to this. The first problem is solubility; due to the low solvent 
concentration required, the xenobiotic stock solutions are 1000 times the desired final 
concentration. Many of the xenobiotics are poorly soluble at this concentration, and 
begin to precipitate out of solution following addition of the stock solution to the cell 
culture medium. It is therefore difficult to predict the exact concentration received by 
the cells, or the effect of the drug precipitate as it settles onto the cells during culture.
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The second consideration is the cytotoxic effects of the xenobiotics. As illustrated in 
Section 3.9 the levels of reporter gene expression in cells dosed with xenobiotics were 
occasionally lower than in those cells dosed only with the solvent control. This fall 
was believed to be due to either direct cytotoxicity of the xenobiotics, or to some 
other adverse effect, leading to a decrease in total reporter protein production by the 
cells; where this occurred the cells exhibited altered morphology upon microscopic 
examination, and there was an increased amount of debris in the cell culture medium 
from dead cells. This was particularly marked with rifampicin, although the dose at 
which it occurred varied greatly. In some experiments this effect was observed at 
doses as low as lOpM whereas in other experiments even doses of ImM did not 
decrease total reporter protein production. Calcium phosphate precipitation is known 
to harm cells; the extent of this is likely to be in part regulated by the quality of the 
transfected DNA, and the specific nature of the contaminants. Any cytotoxic effects 
observed upon dosing will represent the combined effect of the precipitate and the 
xenobiotic, which may be greater in those cases where the DNA contains impurities 
such as endotoxin contamination. The time-course of any such cytotoxic effect is also 
going to be an important determinant in the observed effects on reporter protein 
production; i.e. a combination leading to rapid toxicity is likely to have a far greater 
observed impact, whereas one where cytotoxicity does not occur until 48 hours post- 
dosing may have little or no visible effect on reporter protein expression.
The results of this chapter demonstrate that the transient transfection assay for the 
detection of induction of CYP3 A4 is capable of detecting induction by known in vivo 
inducers of CYP3A4. The system did not respond to compounds known to induce 
other cytochrome P450 isozymes indicating that the system is not likely to produce a 
high rate of false positives.
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CHAPTER 5 -  DISCUSSION
5.1 Introduction
Previously in our laboratory, a system was developed for the detection and assessment
of xenobiotic transcriptional induction of the human CYP3A4 gene (Williams, 1997).
In the latter project, approximately Ikb of the regulatory region of the CYP3A4 gene
(-1087 to -57bp) was isolated by PCR and engineered into a reporter plasmid pCMV-
cSPAP (referred to as pCMV throughout this project), to create a construct (named
p3A4) in which expression of the reporter protein Secretory Placental Alkaline
Phosphatase (SPAP) was regulated by the CYP3A4 region. This plasmid was
transiently transfected into the human liver hepatoma cell line, HepG2, in order to
study the effects of xenobiotics on the regulation of the human CYP3A4 gene.
Cells were transfected by calcium phosphate precipitation and reporter gene activities
were assessed using colourimetric assays. To assess the responsiveness of this system
transfected cells were dosed with known inducers of CYP3A4 including
dexamethasone, PCN, rifampicin, phenobarbitone and TAG. In this previous work no
solvent control was routinely tested, nor was the effect of different xenobiotic
concentrations on reporter expression from the control plasmid pCMV. It is therefore
not possible to calculate fold induction by the method used throughout this project;
during previous work, fold induction was presented as the ratio of the expression from
the test plasmid (p3 A4) in the presence of xenobiotic to the expression in the absence
of xenobiotic. This system therefore cannot account for any solvent effects or any
proliferative or cytotoxic effects of the xenobiotics. However, dexamethasone
appeared to cause a concentration dependent increase in reporter expression from the
transfected construct (p3A4), exhibiting a maximal response at lOpM dexamethasone
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(approximately 3.5 fold, calculated as described above). PCN also caused activation 
of the test construct exhibiting maximal activation at a dose of lOpM (approximately 
2.5 fold, calculated as described above). Phenobarbitone caused activation at doses of 
500piM and ImM (2.8 and 1.9 fold respectively). Rifampicin (IpM and 5pM) and 
TAO (0.1 pM, IpM and lOpM) did not cause significant induction, however this was 
only examined in one experiment (n=3).
Although these results were questionable due to lack of the appropriate controls, they 
indicated that this system might provide a useful means to assess the potential of new 
chemical entities to induce human CYP3A4.
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5.2 The reporter gene assay system for the detection of induction of CYP3A4
In part, the aims of this current project were to assess the system for possible 
improvements, to further develop the system to render it useful for high throughput 
screening, and to test a wider range of inducers than was tested in the original project. 
To improve and further develop the system it was first necessary to identify problems 
with the assay and areas that would limit the throughput capabilities.
5.2.1 Problems with the original system
All work in the initial project was carried out in 6 well culture plates. This 
immediately poses problems with regard to the use of this system in high throughput 
screening. Firstly, carrying out transfections in 6 well culture plates is time 
consuming. Secondly, because of the well volume (3ml), this method requires large 
amounts of DNA, cells and xenobiotics (which may often be in short supply). Even 
for small scale transfections in 6 well plates it can be necessary to pool DNA from 
several preparations thus increasing the risk of introducing a preparation containing 
enough endotoxin or other contaminant to adversely affect the transfection efficiency. 
Finally, 6 well plates are bulky, requiring a large amount of incubator storage space, 
thus when using 6 well plates it is not easily possible to assess many experimental 
conditions or to have large numbers of replicates.
The next major disadvantage of this system was the use of colourimetric assays for 
the assessment of reporter gene expression. These assays are very time consuming, 
and exhibit poor sensitivity, specificity and reproducibility. Even when detectable, 
the levels of activity were frequently close to background levels. Also the substrate 
for the colourimetric alkaline phosphatase assay is light sensitive, introducing further
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inaccuracies across a large transfection experiment. Heat deactivation in 
microcentrifuge tubes further increases sample manipulation, and thus assay time and 
possible errors.
The original method of calcium phosphate transfection was time consuming, and 
transfection efficiency was low and extremely variable both intra- and inter­
transfection. In the original work DNA was prepared using Wizard Maxipreps 
(Promega). These were frequently found to produce DNA of insufficient quality for 
transfection, even after further purification by ethanol precipitation, and the use of 
these preparations resulted in highly variable transfection efficiencies.
The method of normalisation used in the original project involved co-transfection of 
the p-galactosidase plasmid pCHl 10 with the CYP3A4-reporter constructs. 
Co-transfection was found to reduce the transfection efficiency and also greatly 
increased the variability. Frequently, P-galactosidase activities were too low to assess 
by colourimetric activities, thus invalidating all results in transfections in which this 
occurred. The requirement to lyse cells prior to p-galactosidase assay increased the 
number of sample manipulations, thereby increasing the experimental time required 
and introducing an additional source of variability.
In a number of transfections, particularly in cells of high passage number, it was 
observed that the responsiveness of the HepG2 cells to dexamethasone was lost, 
presumably due to the loss of expression of a factor critical for the induction of 
CYP3A4 by dexamethasone.
Another major source of variability in the original work was the use of untreated FCS 
in the growth medium, exposing the cells to unidentified, unquantified and variable 
levels of steroid contamination and other factors.
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The lack of use of a solvent control, and of a control plasmid for all doses of 
xenobiotics meant that this assay system was at risk of producing false positives and 
negatives in induction assessment. The failure to include these controls meant that 
calculations of fold induction could not take account of any proliferative or cytotoxic 
effects of the xenobiotics, and it was not possible to demonstrate with certainty that 
effects were due to the xenobiotics and not the solvents used.
Thus to summarise, the major concerns with the original assay were as follows:
• High variability introduced by a number of factors as discussed above. (This was 
particularly of concern due to the small number of replicates that could be 
processed at once thus making it statistically difficult to demonstrate induction).
• The limitations on sample throughput.
• The large percentage of transfections that had to be discarded due to failure of 
dexamethasone to induce, or the lack of detectable p-galactosidase making 
normalisation impossible.
• The potential for a large number of false positives and negatives due to the 
experimental design and data analysis.
5.2.2 Improvements with the optimised system
Much of the work on my project was spent addressing the problems raised above, 
leading to the development of the optimised system (as described in Chapter 3) which 
was subsequently used to obtain the results detailed in Chapter 4. These 
improvements and their implications are as follows.
The switch to the use of chemiluminescent assays for the detection of reporter gene 
expression solved many of the initial problems. The chemiluminescent assays greatly 
decreased the experimental time required and also provided increased sensitivity,
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specificity and reproducibility and lessened the problems introduced by poor 
transfection efficiencies. Importantly, these assays required smaller quantities of 
sample thus permitting the scaling down of the transfections.
A significant improvement was the use of 96 well plates (well volume of 120pl) for 
transfection, made possible by the use of chemiluminescent assays for the detection of 
reporter gene expression. Transfections carried out in 96 well plates dramatically 
reduced experimental time, the amount of incubator space required, and importantly 
the amounts of DNA and xenobiotics required. 96 well plates allow the use of a 
greater number of experimental replicates, again reducing the problems posed by 
intra-transfection variability; they also allow a far greater number of experimental 
conditions to be assessed within the same transfection enabling more accurate 
comparisons between xenobiotics. Because of the reduction in DNA usage the same 
plasmid preparations may be used for several transfections thus reducing inter­
transfection variability.
The optimised method of calcium phosphate precipitation was found to greatly 
increase the transfection efficiency over that achieved with the original method. The 
use of Qiagen EndoFree maxipreps to prepare DNA also improved the transfection 
efficiency and decreased intra- and inter-transfection variability.
By normalising SPAP activity 72 hours post-transfection (in the presence of the 
inducer) against SPAP activity 24 hours post-transfection (before dosing with the 
inducer) only a single plasmid had to be transfected. Firstly this improved the 
transfection efficiency and decreased the variability; it also removed any concerns 
that the two plasmids might be transfected with different efficiencies.
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The improved method of data analysis allowed factors such as endogenous activation 
or repression of reporter expression, cytotoxic and proliferative effects of xenobiotics, 
and any effects of the solvents to be taken into account.
The use of low passage cells reduced the problems of loss of dexamethasone 
induction but did not entirely solve the situation, and the use of dextran-coated- 
charcoal to strip probable steroid contamination from FCS greatly reduced some of 
the problems associated with apparent loss of induction by dexamethasone.
To summarise, these modifications to the assay format, experimental design, data 
analysis and protocols have resulted in a number of improvements. The variability, 
both intra- and inter-transfection, has been reduced, and the potential throughput of 
the assay has been greatly increased. The potential of the assay to generate false 
positive and false negative responses after challenge with xenobiotics has also been 
reduced.
5.2.3 Drawbacks of the optimised system
The optimised system is not without some drawbacks as summarised below.
Firstly, the reagents required for the chemiluminescent assays are expensive. This is 
offset to some degree by the saving in experimental time within an experiment, and 
also due to the reduced number of experiments that have to be discarded due to low 
levels of detection of reporter gene expression.
The use of Qiagen prepared DNA is also significantly more expensive than the use of 
Wizard maxipreps. Again this is offset by the reduced number of experiments that 
have to be discarded due to low transfection efficiency and high variability.
Variability both intra- and inter-transfection remains a concern. This is mainly due to 
the variability of the transfection efficiency achieved using calcium phosphate
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precipitation, which may itself be in part attributable to the clumping growth of the 
HepG2 cells.
In many cases the levels of a xenobiotic required to induce reporter expression in the 
HepG2 cells were observed to cause some toxicity in the cells. No useful means of 
directly assessing this was found during the course of the project.
5.2.4 Drawbacks of the HepG2 ceils
A number of the remaining concerns about the system can be attributed to the HepG2 
cells. Firstly the clumping growth of these cells means that it is difficult to ensure 
accurate cell seeding and transfection; this creates a large source of intra- and inter­
transfection variability. Attempts to break up the clumps by passing the cell 
suspension through a syringe resulted in poor cell viability, which increased the 
variability.
Despite the use of cells in low passage number and of DCC-treated FCS the 
unpredictable loss of responsiveness to dexamethasone remained a concern. It is also 
important to note that the levels of endogenous activation or repression of CYP3A4- 
dependent reporter gene expression, and also the fold induction by a xenobiotic, were 
observed to vary greatly even at the same cell passage number. It is not clear whether 
the failure to be induced at low passage is due to loss of expression of critical 
transcription factors involved in the induction response, or to increased repression of 
CYP3A4-dependent reporter gene expression due to the increased expression of 
endogenous factors such as cytokines.
There also remains the concern that the HepG2 cells do not appear to express 
detectable CYP3A4 either constitutively or after treatment with known inducers; this 
implies that HepG2 cells may be lacking a factor required for the constitutive and
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inducible expression of CYP3A4. Although HepG2 cells have previously been shown 
to express CYP3A7, inducible by a range of known in vivo inducers of the CYP3A 
subfamily (Guzelian, 1994; Schuetz et ah, 1993), and despite the fact that all of the 
known transcriptional inducers of the CYP3A subfamily tested in this project 
activated CYP3 A4-dependent reporter gene expression, there still remains the 
possibility that there might exist some xenobiotics which could not induce CYP3A4 
in this system due to the lack of appropriate factors. The only way to examine this is 
to test a wider range of known inducers of CYP3A to determine which are identified 
as inducers by this system.
Although the HepG2 cells have a number of major drawbacks the choice of 
alternative human liver cell lines remains poor. Of the alternatives, HepG2f cells 
have been reported to be less differentiated than HepG2 cells (Fukuda et al., 1992), 
Hep3B cells contain an integrated hepatitis B genome (Aden et al., 1979), and HuH-7 
cells have been reported to require the co-transfection of the GR for dexamethasone 
induction of a CYP3A5 reporter construct (Pickwell et al., 1996).
5.2.5 Possible future improvements to the optimised system
With further work the impact of the problems outlined in Section 5.2.3 could be 
reduced.
Firstly the use of a fluorescent protein reporter gene such as green- blue- or gold- 
fluorescent protein in place of SPAP would solve several problems. Fluorescent 
assays require no reagents thus once established would have negligible cost. For high 
throughput screening this would be a major consideration. These assays also require 
no sample manipulation; this would lead to a major saving in experimental time and
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would also remove several sources of variability from the experiment. It would also 
be easier to carry out experiments to investigate the exact time-scale of the induction 
response as no media samples would need to be taken.
Another major possibility would be the generation of a stable cell line; i.e. one which 
stably expresses the reporter gene under the control of the regulatory region under 
investigation. This would remove all the variability caused by transfection, and 
would lead to a major reduction in experimental time.
A further improvement would be to identify a cell line that continues to express all the 
factors required for induction of human CYP3A4 despite repeated passage. This cell 
line would be the best candidate for use in the development of a stable cell line.
Recent work in our laboratory (Sarah Giddings, personal communication) has 
demonstrated that with CYP4A1-reporter gene constructs, the dosing protocol used 
can greatly affect the fold induction observed. It would be of interest to examine the 
effect of different dosing protocols on the inducers examined in this project to attempt 
to further maximise the response.
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5.3 Discussion of xenobiotics
As described in Chapter 4, this system has been used during this project to examine 
the effects of a number of known inducers of the CYP3A subfamily on the regulation 
of CYP3A4-dependent reporter gene expression from the p3A4 construct.
5.3.1 Summary of the results obtained during this research
Table 5-1 illustrates the concentrations at which the highest fold induction was 
observed in the presence and absence of GR for each xenobiotic examined. 
Erythromycin, TAO and clotrimazole did not cause induction of CYP3 A4-dependent 
reporter gene expression. Dexamethasone, rifampicin, carbamazepine, phenytoin and 
phenylbutazone all demonstrated induction which was enhanced by the presence of 
the GR. Spironolactone caused induction in the presence of the GR only. In the cases 
of PCN and phenobarbitone the GR appeared to enhance induction at some but not all 
concentrations of xenobiotic, whereas for sulfinpyrazone and metyrapone the GR did 
not enhance the observed induction. None of the xenobiotics tested enhanced the 
induction observed by treatment with lOpM dexamethasone; RU-486 was shown to 
block dexamethasone-dependent induction.
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Table 5-1 Induction of CYP3A4-dependent reporter gene expression by 
xenobiotics
Xenobiotic ERN Concentration -GR +GR Fold enhancement 
byGR
Dexamethasone 1 50pM 3.70* 8.78* 2.37
lOOuM 3.60* 9.46* 2.63
Rifampicin 1 50pM 2.43* 4.55* 1.87
PCN 1 5[iM 1.78* 4.59* 2.58
Phenobarbitone 4 10p,M 1.39* 1.39* 1
100|iM 1.20 2.11* 1.76
Carbamazepine 4 lOpM 0.97 2.13* 2.20
lOOpM 1.37* 1.98* 1.45
Spironolactone 4 lOpM 1.03 1.71* 1.66
Phenylbutazone 4 lOOpM 1.23* 2.29* 1.86
ImM 1.40* 1.65* 1.18
Phenytoin 4 10|iM 1.31* 1.98* 1.51
lOOpM 1.37* 1.46* 1.07
Metyrapone 4 lOpM 1.74* 1.91* 1.10
ImM 2.18* 1.10 0.50
Sulfinpyrazone 4 lOOjiM 2.10* 1.59* 0.76
ERN = experimental reference number; -/+ GR = the absence or presence of co­
transfected glucocorticoid receptor plasmid, "indicates fold induction is statistically 
significant compared to solvent control (p<0.05).
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As reported in Chapter 4 (Sections 4.3-4.S) the fold induction achieved on treatment 
with a particular xenobiotic at a specified concentration varies greatly between 
transfections. There are a number of possible reasons that could contribute to this.
• Individual batches of FCS may contain differing levels of contaminants even after 
DCC-stripping. These may include steroids or hormones that might act to either 
induce or repress the induction of CYP3 A4-dependent reporter gene expression.
• Different plasmid preparations will contain differing quantities of impurities, of 
which the one of greatest concern is endotoxins. Endotoxins are potent activators 
of the inflammatory response involving the release of cytokines (such as 
interleukin-6) which have been shown to repress the induction of CYP3A4 and 
other P450s (Fukuda et al., 1992; Muntane-Relat et al., 1995). Even with the use 
of endotoxin-ffee maxipreps for the results obtained in Chapter 4 it is possible that 
trace amounts of endotoxin have been present in the plasmid preparations, 
affecting the observed induction in some cases.
• It is also not possible to predict what other factors will be released in response to 
the toxicity of the calcium phosphate precipitate or the xenobiotics. It is possible 
that such factors could act to repress induction, and might explain the apparent 
lack of induction seen at the highest concentrations of some of the xenobiotics 
tested (e.g. PCN)
• It has also been reported that the growth phase of the cells and the degree of cell 
to cell contact can affect the level of induction observed in cell culture (Greuet et 
al., 1997). This may be an important determinant in the variability of induction 
observed in this project, considering the tendency of the HepG2 cells to form 
clumps.
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• Immortalised cell lines have been reported to lose the expression of factors even 
from one passage to the next (Freshney, 1994). The results in Chapter 4 were 
obtained from cells in passages 11 and 12 and it is possible that some differences 
may exist in the factors expressed by the cells at these passages.
The main conclusion to be drawn from this is that when comparisons of the level of 
induction by different xenobiotics are required, all the xenobiotics should be assessed 
within the same transfection. It also highlights the need for reliable positive control 
reference inducers to be routinely used in the assessment of xenobiotic induction. 
These should include at least one compound that is enhanced by the GR (e.g. 
dexamethasone) and one that is not (e.g. metyrapone).
The results demonstrate that the CYP3 A4 regulatory region examined during this 
research contains the responsive elements required for the detection of induction by 
classically recognised transcriptional inducers of the CYP3 A subfamily. The results 
also demonstrate that the HepG2 cells are capable of supporting induction by all of 
the xenobiotics tested during this project, and therefore, at least initially, express the 
transcription factors required for CYP3A induction, although it appears that at least 
some of these factors may be lost upon repeated passage.
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5.3.2 Comparison of the assay with published in vitro data 
As described in detail in Section 1.6, several studies have investigated the effects of 
xenobiotics on the induction of members of the CYP3 A subfamily using reporter gene 
assays. These studies have successfully demonstrated the transcriptional induction of 
members of the CYP3A subfamily, including CYP3A4, CYP3A5, CYP3A7, CYP3A6 
and CYP3A23 by dexamethasone, rifampicin and PCN, however they do have a 
number of drawbacks. These problems include the use of a number of experimental 
replicates of less than 3 (Barwick et al., 1996; Burger et al., 1992), no normalisation 
for transfection efficiency (Barwick et al., 1996; Burger et al., 1992), the lack of use 
of control plasmid for each dose of xenobiotic tested (Williams, 1997), and the lack of 
a solvent control (Barwick et al., 1996; Burger et al., 1992). In some cases results are 
only shown as fold induction, without any data to show significance or the extent of 
any experimental error (Barwick et al., 1996). Therefore these studies must be 
interpreted with caution. Table 5-2 shows the values for fold induction as calculated 
in some of these studies for different isozymes of the CYP3A subfamily.
It should be noted that when using a small piece of CYP3A4 regulatory DNA (-179 to 
-35bp) in a reporter construct transfected into rat hepatocytes, fold induction values 
of 16.2 and 27.9 were observed on treatment with lOpM dexamethasone in two 
experiments; the same construct transfected into rabbit hepatocytes gave 2.1 and 3.1 
fold induction (Barwick et al., 1996). Although interesting, this cannot be regarded as 
a representation of the induction of CYP3 A4 as the region cannot contain the range of 
transcription factor-responsive elements found throughout the promoter region of the 
gene.
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Table 5-3 shows the values for fold induction obtained in other in vitro experiments in 
which fold induction was assessed by scanning densitometry analysis of either 
Northern or Western blots.
It can be seen from Tables 5-2 and 5-3 that the results obtained during this research 
are of the same order of magnitude as those achieved both in other transfection 
systems and in other in vitro work.
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Table 5-2 Xenobiotic induction of the CYP3A subfamily in reporter gene assays
Xenobiotic
CYP3A isozyme 
Fold Induction
CYP3A4 CYP3A5 CYP3A23
Dexamethasone lOpM 
PCN lOpM
Phenobarbitone 500pM
4.5-5.5‘, 3-4  ^ 1.4-4.0  ^ 2.5-9*'^
3.2-3,4‘,2^  1.3.2.9"
^(Barwick et al., 1996) Rat primary hepatocyte cultures.
^(Williams, 1997) HepG2 cells.
^(Schuetz et al., 1996) HepG2 cells transfected with a plasmid encoding the 
glucocorticoid receptor.
"^ (Burger et al., 1992) Rat primary hepatocyte cultures.
^(Huss et al., 1996) Rat H4IIE cells.
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Table 5-3 Xenobiotic induction of the CYP3A subfamily in vitro
Compound Experimental system Parameter
measured
Concentration Fold
increase
Dexamethasone HepG2 cells^ 3A7 protein lOpM 2.69
3A7 mRNA lOOpM 8.4
Human hepatocytes^ 3AmRNA lOpM 5.9
Rifampicin HepG2 cells" 3A7 protein lOpM 1.78
3A7 mRNA lOpM 5
Human hepatocytes^ 3 A mRNA lOpM 8.5
TAO HepG2 cells" 3A7 protein lOpM 1.64
Erythromycin HepG2 cells" 3A7 protein lOpM 1.2
Phenobarbitone HepG2 cells" 3A7 protein ImM 1.58
3A7 mRNA ImM 2
Human hepatocytes^ 3AmRNA 2mM 1.9
Spironolactone Human hepatocytes*’ 3 A mRNA lOpM 3.1
RU-486 Human hepatocytes** 3 A mRNA lOpiM 2.9
PCN Human hepatocytes*’ 3A mRNA lOpM 2.6
Results quantified by scanning densitometry of Northern (mRNA) or Western 
(protein) blots. ^(Schuetz et al., 1993) ^(Kocarek et al., 1995).
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5.3.3 Comparison of the assay with published in vivo data 
Due to the diverse basal levels of expression of CYP3 A4 within the human population 
(Guengerich, 1990; Krivoruk et ah, 1994), and the ethical barriers associated with the 
in vivo assessment of xenobiotic induction in humans there are very few studies that 
present reliable data on the in vivo induction of CYP3A4. In one study, rifampicin 
increased CYP3A4 mRNA 5-8 fold in vivo in human small bowel enterocytes (in 5 
patients; tissue obtained by biopsy), and increased CYP3A protein 10 fold in the one 
patient studied (Kolars et al., 1992). In a study of Chinese epileptics, induction was 
assessed using the ratio of 6|3-hydroxycortisol to urinary free cortisol, a recognised 
marker of the activity of the CYP3A subfamily. In this latter study, phenytoin and 
carbamazepine were observed to cause 2-fold and 3-fold induction of CYP3A activity 
respectively (20 control patients, and 6 patients per drug) (Tomlinson et al., 1996). 
Induction of CYP3A in man by dexamethasone, and by rifampicin, has also been 
demonstrated using the erythromycin breath test (described in Section 1.4.6.1) 
(Watkins et al., 1989). In a separate study, levels of CYP3A4 mRNA and protein 
were reported to be increased in a dose-dependent manner (to a maximum of 6-fold) 
in patients receiving dexamethasone (Molowa et al., 1986).
These results are again of the same order of magnitude as those obtained during the 
research presented in this thesis, and as those obtained in other in vitro experimental 
systems.
A number of studies have demonstrated the in vivo inducibility of the CYP3A 
subfamily in various animal species by a number of xenobiotics including 
dexamethasone, PCN, rifampicin, TAO and phenobarbitone (Simmons et al., 1987; 
Wrighton et al., 1985; Wrighton et al., 1985; Watkins et al., 1986). In the rat 
dexamethasone and PCN (150mg.kg'*.day‘* for 4 days) gave 15- and 13- fold
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increases in testosterone 6p-hydroxylation respectively (Williams et a l, 1994). In a 
separate study, the levels of CYP3A immuno-reactive protein in liver microsomes 
v^ere increased in rats by pre-treatment (100mg.kg'\day^ for 4 days) of the animals 
with PCN (20 fold), dexamethasone (30 fold), spironolactone (12 fold) and 
phenobarbitone (13 fold) (Henman et al., 1981). In another study, dexamethasone and 
PCN were reported to cause concentration-dependent increases in CYP3A1 mRNA, 
with dexamethasone inducing expression 1.5-, 6- and 12-fold, and PCN inducing 1.3-, 
4- and 19-fold at doses of 1,10, and SOmg.kg^day^ for 4 days (Pereira & Lechner,
1995). In primates (cynomolgus and patas monkeys) phenobarbitone was observed to 
induce testosterone hydroxylation between 2- to 5-fold (Jones et al., 1992). Several 
studies have also demonstrated that rabbit CYP3A6 is inducible in vivo 5- to 10-fold 
by rifampicin (50mg.kg'\day'^ to 100mg.kg'\day'^ for 1 to 4 days) (Pineau et al.,
1991; Potenza et al., 1989; Wrighton et al., 1985).
With regard to comparisons with in vivo work, the transient transfection reporter gene 
assay system described in this project is subject to all of the recognised handicaps of 
in vitro systems and should therefore be regarded as a preliminary or complementary 
screen for induction assays in animals, and not as a replacement. In an in vitro system 
of this nature it is not possible to mimic important biological processes such as 
absorption, distribution and excretion. The metabolism of xenobiotics may also be 
significantly different to that found in the living organism.
However, the in vitro system has a number of advantages with regard to in vivo 
studies including speed, reduced variability, the reduction in the amounts of 
xenobiotics required and the potential for a higher number of replicates and high 
throughput. Importantly it allows the study of human genes in human or animal cell 
lines rather than relying on animal genes or whole animals to be representative of the
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human situation. It may thus help to overcome many of the pitfalls of extrapolating 
data obtained by in vivo induction assessment in animals to man.
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5.4 The molecular mechanisms of induction of CYP3A genes
The molecular mechanisms underlying the xenobiotic induction of the CYP3A genes 
remain unclear. As described in Section 1.3.1 a number of P450 genes are induced at 
the transcriptional level through the interaction betv^een a ligand-activated receptor 
and a specific DNA-response element. As yet, no such receptor-mediated mechanism 
has yet been clarified for the CYP3A subfamily, however as the CYP3A subfamily is 
inducible by glucocorticoids a number of workers have investigated the possibility 
that the GR may be involved in the induction of these genes.
Much work has been done to attempt to clarify the mechanisms of induction of the 
CYP3A subfamily, however it is important to note that the majority of this work has 
been carried out using in vitro systems derived from either the rat or the rabbit. Since 
both of these species have been observed to respond differently to humans in their 
response to some xenobiotics (Barwick et al., 1996), and since the rat exhibits clear 
gender and developmental differences in the expression and induction of the CYP3A 
genes (Ghosal et al., 1996; Pereira & Lechner, 1995), any extrapolation to the human 
situation must be made with caution. Some work has been carried out in human 
hepatocytes (Guzelian, 1994; Schuetz et al., 1993), but these are also subject to a 
number of potential problems as, for several reasons, human hepatocytes are not 
always representative of the human in vivo situation, as described in Section 1.5.1.
The evidence, both published and from this current project, for the possible molecular 
mechanisms of the induction of the CYP3 A subfamily is presented and discussed in 
the following sections (Sections 5.4.1 to 5.4.10).
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5.4.1 Published evidence for different mechanisms of CYP3A induction
Some evidence within the literature exists to support the existence of different 
categories of inducer of the CYP3 A subfamily.
In a study in rats (Ghosal et al., 1996), phenytoin was reported to be the most potent 
inducer of CYP3A2 in female rats, but dexamethasone was the most potent inducer in 
males. In the same study, CYP3A1 was hardly induced by phenytoin, but was 
extensively induced by dexamethasone, clotrimazole, erythromycin and 
phenobarbitone. Phenylbutazone exhibited little or no induction of CYP3A1 and 
CYP3A2.
The species differences between the rat, rabbit and human, observed in the response 
to dexamethasone, PCN and rifampicin have been attributed to species specific 
cellular factors (Barwick et al., 1996; Guzelian, 1994; Kocarek et al., 1995). If this is 
the case then each of these three compounds may be acting through a different 
mechanism to induce members of the CYP3A subfamily.
5.4.2 Experimental evidence for and against different mechanisms of CYP3A 
induction
It appears from the results presented in Chapter 4, and summarised in Section 5.3.1, as 
though the inducers tested in this project may be subdivided into different classes of 
CYP3A inducer, each having distinct mechanisms of induction. The evidence for this 
proposal is as follows:
1. In some batches of cells dexamethasone-dependent induction was lost, as was 
induction by PCN. This induction was always restored by co-transfection with 
GR. Spironolactone did not induce in the absence of the GR.
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2. Rifampicin induced reporter expression on every occasion, even in experiments in 
which dexamethasone and PCN failed to induce. Induction by rifampicin was 
also enhanced by the GR.
3. Several compounds, e.g. carbamazepine and phenytoin, which are not reported to 
induce other glucocorticoid responsive genes (such as TAT and MMTV), were 
found to induce CYP3 A4-dependent reporter gene expression, and this induction 
was enhanced by the presence of the GR.
4. The induction of reporter expression by metyrapone and sulfinpyrazone was not 
enhanced by the addition of the GR.
5. TAG, clotrimazole and erythromycin did not induce CYP3A4-dependent reporter 
gene expression, even in the presence of co-transfected GR.
It has been proposed (Monostory & Vereczkey, 1994) that if compounds were acting 
to induce the CYP3A subfamily by different mechanisms then either synergistic or 
additive induction might be observed upon treatment with combinations of the 
xenobiotics. The effect of other xenobiotics on the induction by lOpM 
dexamethasone was examined in my thesis (Section 4.16), however neither synergy 
nor additive induction was observed. It is possible that at this concentration of 
dexamethasone the maximum possible response of the system had already been 
achieved.
A proposal for classification of the inducers, based upon the results in Chapter 4, is 
illustrated in Table 5-4 but further investigation is required to confirm these 
observations.
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Table 5-4 A preliminary classification of inducers of CYP3A4
GR-dependent GR-potentiated GR-independent
T ranscriptional Post-transcriptional
Dexamethasone Phenytoin Metyrapone Clotrimazole
PCN? Rifampicin Sulfinpyrazone Erythromycin
Spironolactone Carbamazepine TAG
Phenylbutazone
Phenobarbitone?
? Denotes uncertainty about the classification of this compound based upon the 
results presented in Chapter 4.
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5.4.3 The mechanism of induction of CYP3A4 by clotrimazole, TAO and 
erythromycin
During the assessment of xenobiotic induction, clotrimazole, erythromycin and TAO 
did not induce CYP3A4-dependent reporter gene expression. It is likely that these 
compounds induce the CYP3 A subfamily by acting at the post-transcriptional level, 
involving mRNA stabilisation, protein stabilisation or a combination of both. The 
lack of induction in the presence of the GR indicates that the GR is unlikely to play 
any role, whether direct or indirect, in induction by these compounds. This is in 
agreement with the literature in which workers have reported that clotrimazole, 
erythromycin and TAO stabilise CYP3A1 protein in vivo and in hepatocytes (Watkins 
et al., 1986; Hostetler et al., 1988). Clotrimazole and TAO have also been reported to 
increase the levels of CYP3A mRNA (Hostetler et al., 1988) indicating that both 
mRNA stabilisation and protein stabilisation play a role in the induction of the 
CYP3A subfamily by these xenobiotics.
5.4.4 Published evidence for the direct role of the glucocorticoid receptor in 
dexamethasone-dependent induction of the CYP3A subfamily
Some convincing evidence for the direct involvement of the GR in the induction of 
human CYP3A has been presented. Dexamethasone-dependent induction of a 
CYP3A7 reporter construct transfected into HuH-7 cells had an absolute requirement 
for the co-transfection of a plasmid encoding the GR (Pickwell et al., 1996). 
Dexamethasone-dependent induction of a CYP3A5 reporter construct transfected into 
HepG2 cells also required the co-transfection of the GR; when the cells were 
transfected with a plasmid encoding a mutated GR no induction was observed. RU- 
486 was found to block the dexamethasone-dependent induction of reporter gene
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expression. Computer analysis of the CYP3A5 region demonstrated the presence of 2 
GR half-sites (TGTTCT) separated by 160bp; mutation of either site abolished 
dexamethasone responsiveness indicating their co-operative role in dexamethasone 
induction. Electrophoretic mobility shifts indicated that the half-sites could 
specifically bind purified GR, and were able to displace binding of GR to a consensus 
GRE; the half-sites were also reported to shift a protein in HepG2 nuclear extracts that 
was super-shifted by GR antibody demonstrating that this enhancer region contains an 
authentic GRE (Schuetz et al., 1996).
It is interesting that this latter study demonstrates the clear involvement of the 
glucocorticoid receptor in the induction of CYP3A5 and yet CYP3A5 does not appear 
to be inducible in vivo (Wrighton et al., 1989) or in vitro (Guzelian, 1994; Schuetz et 
al., 1993).
The possible involvement of the GR in the induction of the CYP3 A subfamily has 
also been demonstrated in the rat, where RU-486 has been reported to inhibit the 
dexamethasone-dependent induction of CYP3A23 (Burger et al., 1992; Huss et al.,
1996).
5.4.5 Published evidence against a role of the glucocorticoid receptor in 
dexamethasone-dependent induction of the CYP3A subfamily
The majority of the published evidence against the role of the glucocorticoid receptor 
in the induction of the CYP3A subfamily is derived from experiments carried out on 
rat CYP3A isozymes. This is summarised as follows.
In CYP3A1, a 33 bp element was found to be inducible by dexamethasone, and was 
synergistically induced by dexamethasone and PCN in combination. Computer 
analysis demonstrated that this sequence did not contain a classical GRE and
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electrophoretic mobility shift assays demonstrated that it did not bind the GR 
(Quattrochi et al., 1995).
In CYP3A23, 2 sites were identified which acted co-operatively in dexamethasone 
induction; in gel shift assays neither site was found to bind the GR. A possible role 
for members of the oestrogen receptor family (which includes the vitamin D, thyroid, 
retinoic acid, and retinoid x receptors, and many orphan receptors) in the induction of 
CYP3A23 was proposed (Huss et al., 1996).
Several workers have reported that there is no correlation between the induction of rat 
CYP3A1 and other classical GR-responsive genes such as TAT and MMTV (Wright 
& Paine, 1994b). Firstly, the time course of induction appears to be different 
(Quattrochi et al., 1995; Huss et al., 1996). The rank order and the concentration- 
response of synthetic steroids are different for CYP3A1 induction compared to TAT 
(Quattrochi et al., 1995), with a number of workers reporting that induction of 
CYP3A1 required higher concentrations of steroids than induction of TAT (Waziers 
et al., 1992; Huss et al., 1996; Burger et al., 1992). One possible explanation for this 
observation however, could be the presence of different negative regulatory regions in 
CYP3A1, requiring a stronger stimulus before induction is observed. Also, 
dexamethasone inducibility of CYP3A7 mRNA in HepG2 cells has been 
demonstrated from concentrations of InM dexamethasone and above in a 
concentration dependent fashion (Schuetz et al., 1993). GR antagonists such as PCN 
and RU-486 inhibit dexamethasone induction of traditional GR-responsive genes, e.g. 
MMTV and TAT (Burger et al., 1992). In the induction of CYP3A, GR antagonists, 
such as PCN and RU-486 act as inducers of CYP3A, and in some cases enhance 
induction of CYP3A by dexamethasone (Wright & Paine, 1994b; Huss et al., 1996; 
Quattrochi et al., 1995), as has been demonstrated in studies in which CYP3A mRNA
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was induced by RU-486 or dexamethasone in rabbit, rat and human hepatocytes, and 
by PCN in rat and some human hepatocyte cultures (Kocarek et al., 1995; Barwick et 
al., 1996; Guzelian, 1994).
5.4.6 Experimental evidence for a direct role of the glucocorticoid receptor in 
dexamethasone-dependent induction of CYP3A4
In the experiments described in Section 4.3, the presence of co-transfected 
glucocorticoid receptor potentiated dexamethasone-dependent induction of CYP3A4- 
dependent reporter gene expression at every concentration tested. At the lowest 
concentration of dexamethasone tested (0.1 pM) the presence of the GR enabled 
induction where none was observed in the absence of the GR. The GR was also 
found to restore induction by dexamethasone in those passages of cells in which it had 
been lost.
Dexamethasone exhibited the highest fold induction without cytotoxicity at a 
concentration of lOpM. At all concentrations examined (IpM, lOpM and lOOpM) 
RU-486 blocked the induction by lOpM dexamethasone; the values obtained at lOpM 
and lOOpM RU-486 must be interpreted with caution as cytotoxicity was apparent. 
These results imply however that if RU-486 is binding to the same receptor protein as 
dexamethasone it has a higher affinity for this receptor than dexamethasone. RU-486 
has been reported to have a higher affinity for the glucocorticoid receptor than 
dexamethasone (Wingard et al., 1991).
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5.4.7 Experimental evidence for non-classical glucocorticoid receptor 
involvement in dexamethasone-dependent induction of CYP3A4
In classical GR-mediated induction, such as the induction of TAT or MMTV, PCN 
antagonises induction by dexamethasone (Wright & Paine, 1994b; Quattrochi et ah,
1995). In these experiments, not only does PCN induce, but induction by PCN is also 
enhanced by the GR, and is restored by the GR in those cell populations in which the 
response is lost. When combined with dexamethasone, PCN did not inhibit 
dexamethasone-dependent induction of CYP3 A4-dependent reporter gene expression. 
In these results the GR was found to enhance the induction of several xenobiotics that 
have not been reported as inducers of other glucocorticoid responsive genes.
Another concern is that the CYP3A4 region examined during this project does not 
contain a full classic consensus GRE (GGTACAnnnTGTTCT (Beato, 1989)), 
however this does not mean that the GR is incapable of binding to the CYP3A4 
regulatory region. The region examined in this research contains the sequence 
GGTCCATCTGGCTAT, which shows 58.3% homology to the consensus sequence 
(Dr. Nick Plant, personal communication), and the sequence 
AAGAACCCAGAACCC, which has been incorrectly reported to be a GRE 
(Hashimoto et al., 1993) based on sequence homology.
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5.4.8 Published evidence for a possible role of the glucocorticoid receptor in the
induction of CYP3A by other xenobiotics
The role of the glucocorticoid receptor in the induction of the CYP3 A subfamily by 
other xenobiotics also remains unclear.
Metyrapone induces the de novo synthesis of CYP3A protein in human hepatocytes 
(Wright et al., 1996), and induces transcriptional induction of CYP3A1 in rats within 
an hour of dosing (Wright et al., 1996). It does not compete with dexamethasone for 
binding to the glucocorticoid receptor in soluble fractions from rat liver, however the 
addition of glucocorticoids to cultured rat hepatocytes, at levels that induce GR- 
dependent genes, potentiates CYP3A1 mRNA induction by metyrapone without 
inducing CYP3A1 mRNA alone. A GR-dependent mechanism may therefore mediate 
the potentiation of CYP3A1 transcriptional induction by metyrapone (Wright et al.,
1996).
These data suggest that both glucocorticoids and non-steroidal compounds may 
trigger the transcriptional induction of CYP3A1 by a GR-independent mechanism that 
may be potentiated by a GR-dependent mechanism (Wright et al., 1996). Metyrapone 
has also been shown to potentiate dexamethasone-dependent TAT induction but does 
not induce TAT alone; this potentiation was reported to be due to inhibition of the 
metabolism of dexamethasone by metyrapone (Wright et al., 1994c).
Phenobarbitone has been well characterised as an inducer of many P450s including 
isozymes of the CYP2A, CYP2B, CYP2C and CYP3 A sub-families in man and 
various animal species, however the molecular mechanisms of phenobarbitone 
induction of these genes remains unclear (reviewed in Waxman & Azaroff, (1992)).
In rat F AO cells, both dexamethasone and phenobarbitone were reported to induce 
CYP2C6 mRNA, however the time-course of induction was very different, with an
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8-10 hour lag time in induction by phenobarbitone, suggesting a different mechanism 
of action. RU-486 blocked induction of CYP2C6 mRNA by both dexamethasone and 
phenobarbitone, and was also observed to block phenobarbitone-dependent induction 
of CYP2B1 and CYP2B2 reporter gene constructs transfected into the FAO cells 
(Shaw et al., 1993).
Although a number of workers have proposed the existence of a phenobarbitone 
receptor (Waxman & Azaroff, 1992) there are no obvious structural features relating 
phenobarbitone-type inducers (Okey, 1990). The phenobarbitone-type inducers 
exhibit low potency, and would thus be expected to have a low-affmity and low- 
specificity for their receptor making it difficult to identify by conventional receptor 
assay procedures; they are also not very effective inducers in cell culture (Okey,
1990).
5.4.9 Experimental data concerning the role of the glucocorticoid receptor in the 
induction of CYP3A by other xenobiotics.
As well as dexamethasone, the glucocorticoid receptor was found to enhance the 
induction of CYP3A4-dependent reporter gene expression by rifampicin, 
carbamazepine, phenytoin and phenylbutazone. Spironolactone caused induction in 
the presence of the GR only. In the cases of PCN and phenobarbitone the GR 
appeared to enhance induction at some but not all concentrations of xenobiotic. In the 
cases of sulfinpyrazone and metyrapone the GR did not enhance the observed 
induction.
In cells in which dexamethasone responsiveness was lost, it was restored by the GR; 
however in the same cells other drugs such as rifampicin were still able to induce.
This suggests that dexamethasone induction of CYP3A4 is dependent on the presence
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of the GR, whilst induction by rifampicin, although enhanced by the GR, is not 
dependent upon it. Interestingly none of the compounds tested showed potentiation of 
induction by lOpM dexamethasone, despite the potentiating effect of the GR.
5.4.10 Proposed mechanisms for the transcriptional induction of the CYP3A 
subfamily by xenobiotics
A number of other interesting observations have been published and are summarised 
as follows.
Dexamethasone has been shown to bind to rat liver microsomes in a specific (less 
than 5% non-specific binding) and saturable manner. Dexamethasone binding was 
antagonised with decreasing potency by PCN>metyrapone>phenobarbitone, but was 
not antagonised by TAO. It was concluded that induction of the CYP3A subfamily 
might therefore be associated with the interaction of inducers with a microsomal 
protein. Cellular levels of this microsomal receptor were high in comparison to other 
steroid receptors such as the GR (i.e. 20-fold), and it was therefore concluded that it 
might be one of a buffer for high levels of steroids, or it might be a steroid 
metabolising enzyme. The fact that a greater concentration of dexamethasone is 
required to induce CYP3A1 than TAT is consistent with the lower affinity of the 
microsomal receptor compared to cytosolic GR binding (Wright & Paine, 1994b). 
Metyrapone does not compete with dexamethasone for binding to the glucocorticoid 
receptor in soluble fractions from rat liver, and does not bind to cytosolic fractions 
from rat liver, therefore it does not bind the glucocorticoid receptor in the rat (Wright 
et al., 1996). It is possible that the proposed microsomal receptor is a P450, which is 
inhibited by metyrapone binding, blocking the metabolism of a pro-repressor of 
CYP3A (Wright & Paine, 1994a).
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It has been suggested that phenobarbitone may act indirectly to cause accumulation of 
an endogenous steroid, and that this molecule acting via its receptor would be the 
direct inducer; phenobarbitone induction has been observed in serum-ffee medium 
thus any steroid must be endogenous (Shaw et al., 1993).
PCN (lOOpM) has been shown to block dexamethasone binding to the GR in 21-day 
old rat liver soluble fractions, but was reported to be less effective in fractions from 
90-day-old rats. lOpM RU-486 was found to be equally effective at blocking 
dexamethasone binding in fractions from both age groups. The inability of PCN to 
fully compete with dexamethasone for cytosolic binding in adult animals suggests that 
there may exist variant receptors with different affinities for dexamethasone and PCN 
(Wright et al., 1996). This theory has been proposed to explain the observation that 
PCN does not antagonise the glucocorticoid induction of the CYP3A subfamily, and 
the observation that the concentration required for the maximal induction of 
CYP3A23 is approximately 100-fold higher than the concentration required for the 
maximal induction of TAT (Huss et al., 1996; Schuetz & Guzelian, 1984).
It has also been proposed (Quattrochi et al., 1995) that transcriptional activation of the 
CYP3A1 gene may involve proteins already bound to the CYP3A1 enhancer region in 
the basal, steady state.
A possible role for members of the oestrogen receptor family in the induction of 
CYP3A23 subfamily has been proposed based on sequence analysis and the 
observation that when the sequence of a dexamethasone-responsive element in the 
CYP3A23 regulatory region was altered to that of either a thyroid hormone or vitamin 
D responsive element induction by dexamethasone was enhanced (Huss et al., 1996).
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It should also be considered that glucocorticoids exert a range of tissue-specific 
effects in vivo, suggesting the existence of several pathways of glucocorticoid action, 
probably involving tissue-specific transcription factors and receptors.
From a consideration of all of the available information it appears likely that multiple 
transcription factors and multiple response elements interact in the induction of the 
CYP3 A sub-family. There may also be significant differences in the regulation of 
individual isozymes both intra- and inter-species, both in terms of the responsive 
elements present in the gene regulatory regions and of the transcription factors or 
cellular receptors expressed in different species.
299
5.5 Conclusions and further work
The system reported herein represents an advance in the assessment and detection of 
xenobiotic induction of the human CYP3 A4 gene, however there is still room for 
some improvement in the system, as described in Section 5.2.5.
Of the inducers tested during this research, all of the compounds previously reported 
to induce the CYP3 A subfamily by transcriptional activation were found to activate 
CYP3 A4-dependent reporter gene expression; induction observed using this system 
may thus be representative of the induction of human CYP3A4 in the liver. This 
system may therefore provide a useful complement to animal studies in the 
assessment of the xenobiotic induction of the CYP3A subfamily.
From the evidence presented both in this project and in the literature it appears that 
the induction of the CYP3A subfamily is complex. There are species and gender 
differences, as well as differences between isozymes within a species. There also 
appear to be different categories of inducer. The glucocorticoid receptor appears to 
play both a direct and an indirect role in the induction of members of this subfamily. 
Further work must be done to identify the regulatory factors involved in the molecular 
mechanisms of induction, for each isozyme in man, and in each species used 
experimentally to assess induction of the CYP3 A subfamily.
There are many possibilities for further investigation. In terms of the current 
transfection system it would be interesting to examine the effects of other plasmids 
encoding receptors, such as members of the oestrogen receptor family, on the 
induction of CYP3A4-dependent reporter gene expression by xenobiotics.
To confirm the observed effects of the GR it would be useful to obtain and transfect a 
plasmid encoding a mutated GR. It would also be of interest to examine the effects of
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other combinations of xenobiotics, for example the effect of RU-486 on induction by 
other inducers. It would also be of interest to examine more steroids, possibly in 
parallel with a construct encoding a gene classically induced by glucocorticoids, such 
as MMTV or TAT. It would also be of interest to examine carefully the time-scale of 
induction by each of the xenobiotics, in the presence and absence of GR, as this might 
highlight potential differences in the molecular mechanisms of induction by different 
xenobiotics.
In this project the cell system studied was a liver derived cell line. It has been 
reported (Lovm et al., 1994) that, in vivo, hepatic and intestinal CYP3A expression do 
not correlate well within individuals, thus high liver expression in an individual does 
not guarantee high intestinal expression within that individual and vice-versa, 
suggesting tissue-specific regulation of human CYP3A. It would therefore be of 
interest to examine the induction of CYP3 A4 using this system in intestinal cell lines, 
as the inducibility of intestinal CYP3 A may be an important determinant in the 
bioavailability of orally administered CYP3A substrates.
This thesis has examined the xenobiotic induction of CYP3A4; the factors involved in 
constitutive expression have not been conclusively addressed in the literature, 
however the system described herein could be used to examine the potential of 
endogenous steroids to regulate the expression of CYP3A4.
Another goal would be trying to identify other human liver cell lines that maintain the 
required regulatory factors in a more stable manner than HepG2 cells.
In addition to the study of CYP3 A4, similar methodologies could be used to study all 
the isozymes of the CYP3 A and other subfamilies in both man and animals. The 
ultimate goal of such a line of research would be to develop a rapid, reliable, high 
throughput screening system, capable of detecting induction of any relevant P450s by
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a new chemical entity during the drug developmental process. The study of animal 
CYP3 A reporter-gene constructs would also enable the identification of the most 
suitable animal species for any in vivo induction studies that have to be carried out to 
satisfy regulatory authorities. It would be of use to develop a system for the accurate 
assessment of cell cytotoxicity and stress caused by xenobiotic dosing and 
transfection.
Computer sequence analyses of responsive elements need to be backed up by 
conclusive studies involving foot-printing assays and electrophoretic mobility shift 
assays of the CYP3A4 promoter region. Computer analysis of the fit of the inducers 
for the ligand binding domains of receptors such as the glucocorticoid and oestrogen 
receptors might provide usefiil information.
In conclusion, the results presented in this thesis demonstrate that, although there is 
still potential for improvement, reporter gene assay systems may provide a rapid 
means of reliably detecting the induction of genes of interest by xenobiotics, and will 
assist in the elucidation of the molecular mechanisms of induction.
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APPENDIX 1
Solutions, Media and Buffers
For several of the solutions contained in purchased kits the companies concerned 
would not disclose the exact contents. In these cases all available information is 
listed.
Ammonium persulphate stock solution (10% w/v) (for Western blotting)
0 . 1  g ammonium persulphate 
1 ml distilled water 
Mix well. Prepare fresh 
Ampicillin stock solution
50 mg/ml ampicillin in distilled water. Store at -20°C; use at 50pg.ml'^ in growth 
media for selection of ampicillin resistant bacteria.
Aurora chemiluminescent alkaline phosphatase assay solutions 
The detailed contents of the following solutions were unavailable.
Assay buffer
Contains a mixture of differential alkaline phosphatase inhibitors.
Dilution buffer 
Reaction buffer
Contains StarLight chemiluminescent substrate and luminescence enhancer. 
p-Gal Staining Set solutions (Boehringer Mannheim)
X-Gal solution
X-Gal stock solution in DMSG
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Iron buffer
Potassium ferrocyanide and potassium ferricyanide in phosphate buffered 
saline (PBS), stabilised.
Fixative solution
2% formaldehyde (v/v) and 0.2% glutaraldehyde (v/v) in PBS.
Prepare fresh before use.
Staining solution
1 volume X-Gal solution diluted with 19 volumes of iron buffer and mixed for 
1 0  minutes prior to use; do not store.
BES (2x)
50mM BES (V,V-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid]
280mMNaCl 
1.5mM Na2HP0 4 .2 H2 0  
Distilled water to 90mls.
pH to 6.96 with HCl and make up to 100ml with distilled water.
Sterilise by filtration; store at -20°C in 1ml aliquots.
Calcium chloride (O.IM) for preparation of competent cells 
2.7g CaCl2 dissolved in 100ml distilled water. Sterilise by autoclaving.
Calcium chloride stock solution (2M) for transfection of mammalian cells 
Dissolve 10.8 g of CaCl2 .6 H2 0  in 20 ml of distilled water.
Sterilise by filtration; store in 1ml aliquots at -20°C.
Calcium chloride stock solution (2.5M) for transfection of mammalian cells
Dissolve 13.5g of CaCl2 .6 H2 0  in 20 ml of distilled water.
Sterilise by filtration; store in 1ml aliquots at -20°C.
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Cytolite cytotoxicity assay solutions (Packard)
The detailed contents of the following solutions were unavailable. 
Activator solution 
Chemiluminogenic probe 
Amplifier solution
Reduced coenzyme in a carrier solution.
DEA Buffer
For use in the colourimetric assay for alkaline phosphatase activity. 
IM diethanolamine (105.4g 1'^ )
0.28MNaCl(16.36gr')
0.5mM MgClz (0.102g hexahydrate r') 
pH to 9.85 with concentrated HCl.
Store at 4°C.
Easy-pure solutions (Primm Labs)
The contents of the following solutions were unavailable. 
Resuspension solution 
Lysis solution 
Neutralisation solution 
RNAse solution 
Resin suspension 
Ethanol wash buffer 
ECL detection solutions (Amersham, for Western blotting)
The contents of the following solutions were unavailable.
Solution A 
Solution B
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ECL Plus detection solutions (Amersham, for Western blotting)
The detailed contents of the following solutions were unavailable. 
Solution A
Lumigen PS-3 substrate in tris buffer 
Solution B
Acridan solution in dioxane and ethanol 
Ethidium Bromide
Stock solution of lOmg.ml'^ in TAB buffer.
F-10 HAM (Growth medium for CHO-Kl cells)
Nutrient Mixture F-10 (HAM) containing L-glutamine. 
Supplemented with 0.4% (v/v) gentamycin and 10% (v/v) FCS. 
FlexiPrep solutions (Pharmacia Biotech)
Solution I
lOOmM Tris-HCl (pH7.5) 
lOmM EDTA 
400|ig.mr^ RNase I 
Lysozyme
lOmg.ml'^ in solution I 
Solution II
IMNaOH 
5.3% SDS
Distilled water 130ml 
Solution HI
3M potassium, 5M acetate solution
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Sephaglass FP suspension
Sephaglass FP suspended in a buffered solution of guanidine-HCl [7M 
guanidine-HCl, 50mM Tris-HCl (pH7.5), lOmM CDTA]
Wash buffer 
20mM Tris-HCl (pH7.5)
2mM CDTA 
200mMNaCl
Add absolute ethanol to a final concentration of 60% prior to use. 
Galacto-Light Plus (Tropix; chemiluminescent p-galactosidase assay kit) 
solutions
Reaction buffer 
lOOmM sodium phosphate pH8.0 
ImM magnesium chloride 
Galacton-Plus chemiluminescent substrate 
Accelerator solution 
Solution of Light Emission Accelerator II 
Hybaid Recovery, Quick Flow Maxiprep solutions 
Equilibration solution 
600mM NaCl
lOOmM sodium acetate/acetic acid (pH 5.0)
0.15% Triton X-100 
Resuspension solution 
50mM Tris-HCl, pH8.0 
lOmMEDTA 
lOOpg.ml'  ^RNase A
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Lysis solution 
0.2MNaOH 
1% SDS
Neutralisation solution
3.2M potassium acetate, pH 5.5 
Wash solution 
SOOmMNaCl
lOOmM sodium acetate/acetic acid (pH5.0)
Elution solution
1250mMNaCl
lOOmM Tris-HCl (pH8.5)
HBS (2x) (HEPES-buffered saline)
For use in calcium phosphate transfection 
1.6gNaCl(280mM)
0.074g KCl (lOmM)
0 .0 2 7 gNa2HP0 4 .2 H2 0  (1.5mM)
0.2g Dextrose (12mM)
Ig HEPES (50 mM)
Distilled water to 90ml.
pH to 7.05 with 0.5 N NaOH; make up to lOOmls with distilled water.
Sterilise by filtration; store in 5ml aliquots at -20°C.
LB (Luria-Bertani) Agar
15g agar per litre of LB medium. Sterilise by autoclaving. Cool to 50°C before 
addition of ampicillin if required. Pour into petri dishes.
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LB (Luria-Bertani) Medium
lOgtryptone 
5 g yeast extract 
lOgNaCl
Add distilled water to IL; sterilise by autoclaving.
Loading buffer (for Western blotting)
4.8ml distilled water
1.2ml 0.5M Tris-HCl, pH6.8
0.96ml glycerol
1.92ml 10% SDS
0.48ml p-mercaptoethanol
0.6ml 0.05% (w/v) Pyronin Y
Store in dark, for a maximum of 2 weeks
Lysis solution
For cell extract preparation for western blotting and Galacto-Light Plus (Tropix) 
chemiluminescent p-galactosidase assay.
100 mM potassium phosphate pH 7.8 
0.2% Triton X-100 
Store at 4°C
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Lysis buffer (5x)
For cell extract preparation for p-galactosidase colourimetric assay.
lOmM MOPS
lOmMNaCl
ImM EGTA
1% Triton X 100
Store at 4°C. Dilute 5 fold in distilled water prior to use.
Miller protein assay solutions 
Solution A
1 ml 5% (w/v) CUSO4 .5 H2O
10 ml 1% (w/v) Potassium sodium (+) tartrate
100 ml 10% (w/v) Sodium carbonate anhydrous (made up in 0.5M NaOH) 
The final solution must be prepared fresh, but the stock solutions may be 
prepared in advance.
Solution B
Folin-Cioculteau reagent (lOx)
Diluted to Ix in distilled water immediately before use.
MEM (growth medium for HepG2 and H4-II-E-C3 cells)
Minimum essential medium; with Earle’s salts, without L-glutamine.
Supplied with or without phenol red.
Supplemented with 10% (v/v) FCS, 2mM L-glutamine, 1% (v/v) gentamycin, and 
1% (v/v) non-essential amino acids.
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Molecular Weight Markers (Amersham P450 3A kit, for Western Blotting)
Add 165 pi of loading buffer 
Vortex mix briefly
Heat at 37°C for 2 hours in a water bath 
Vortex mix briefly; store in aliquots at -20°C.
Nash reagent
4M ammonium acetate containing 4ml.l'^ acetylacetone 
ONPG stock solution
a-nitrophenyl-p-D-galactopyranoside (ONPG) 2mg.mf^ in Z buffer 
Store @ -20°C
Phosphate Buffered Saline (PBS), pH7.5
(Dulbecco ‘A’ tablets, Oxoid)
1 tablet dissolved in 100ml distilled water, sterilise by autoclaving.
PNPP lOOmM (20x) (p-Nitrophenylphosphate)
For use in the colourimetric assay for alkaline phosphatase activity.
Dissolve 742mg of PNPP (Sigma 104-0) in 20ml of DEA buffer.
Store @ -20°C in a glass universal, and shield from light by wrapping in foil. 
Dilute to Ix (5mM) in DEA buffer immediately prior to use.
Poly-D-lysine solution
10ml of sterile PBS was added to lOmg lyophilised poly-D-lysine, and mixed by 
vortexing. This stock was stored at -20°C in 1ml aliquots.
Prior to use the stock was diluted lOx (to O.lmg.ml'^) in sterile PBS.
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Qiagen Endofree maxiprep solutions 
Buffer PI (resuspension buffer)
50mM Tris-Cl, pH 8.0 
lOmM EDTA 
lOOng.ml'  ^RNase A 
Store at 4°C
Buffer P2 (lysis buffer)
200mM NaOH 
1%SDS
Buffer P3 (neutralisation buffer)
3M potassium acetate, pH 5.5 
Store at 4°C
Buffer QBT (column equilibration buffer)
750mM NaCl 
50mM MOPS, pH7.0 
15% isopropanol 
0.15% Triton X-100 
Buffer QC (Wash buffer)
1.6MNaCl
50mM Tris-HCL, pH 8.5 
15% isopropanol
Buffer ER (endotoxin removal buffer)
The content of this solution was unavailable.
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Buffer QN (Elution buffer)
1.6MNaCl 
50mM MOPS, pH7.0 
15% isopropanol 
STE buffer 
lOOmMNaCl 
lOmM Tris-HCl, pH8.9 
ImM EDTA
TAE electrophoresis buffer (lOx) ^
48.4g Tris base 
40ml 0.5M EDTA pH8.0
11.42ml glacial acetic acid 
Add distilled water to IL 
Dilute to Ix prior to use 
TCA (12.5%)
Trichloroacetic acid 12.5% (w/v) in distilled water.
TE buffer (Tris-EDTA) 
lOmM Tris-HCl, pH 7.5 
ImM EDTA
Dilute lOx for use in transfection. Sterilise by filtration.
Tris-HCL, 0.5M, pH 6.8 
6.0g Tris base
Make up to a final volume of 100ml with distilled water after adjusting pH to 6.8 with 
hydrochloric acid; store at 2-8°C.
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Western blotting buffers and gel recipes
Resolving Gel Buffer (for Western blotting)
181.6g Tris base 
4.0g SDS
Add 900ml distilled water. Mix to dissolve. Adjust pH to 8.8 with 
hydrochloric acid. Make up to a final volume of 1000 ml. Store at 2-8°C. 
Resolving Gel (12%) (for Western blotting)
3.55ml distilled water
4.5ml resolving gel buffer
7.5ml acrylamide stock solution (30% w/v)
2.95ml Bis-acrylamide stock solution (2% w/v)
18p,l N,N,N’,N’-Tetramethylethylenediamine (TEMED)
180|il Ammonium persulphate stock solution (10% w/v)
Running buffer (for Western blotting)
12.12g Tris base 
57.6g glycine 
4.0g SDS
Make up to a final volume of 4L with distilled water. Store at 2-8°C. 
Stacking gel buffer (for Western blotting)
60.6g Tris base 
4.0g SDS
Add 900ml distilled water. Mix to dissolve. Adjust pH to 6.8 with 
hydrochloric acid. Make up to a final volume of 1000 ml. Store at 2-8°C.
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Stacking gel (4%) (for Western blotting)
6.9ml distilled water
2.5ml stacking gel buffer
1ml acrylamide stock solution (30% w/v)
0.4ml Bis-acrylamide stock solution (2% w/v) 
lOfil N,N,N’,N’-Tetramethylethylenediamine (TEMED) 
50pl Ammonium persulphate stock solution (10% w/v) 
Transfer buffer (for Western blotting)
7.6g Tris base 
36.0g Glycine
Add 3200ml distilled water to dissolve 
Add 800ml methanol 
Store at 2-8°C.
Tris buffered saline (TBS), pH7.6 (for Western blotting)
2.42g Tris base
8.0g Sodium chloride
Make up to IL with distilled water
Adjust pH to 7.6 with hydrochloric acid
Store at 2-8°C.
TBS-Tween (for Western blotting)
Tween 20 (0.1% v/v) in TBS
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Wizard Maxiprep and Wizard Megaprep solutions 
Cell Resuspension Solution
50mM Tris-HCl, pH7.5 
lOmM EDTA 
lOOpg.mi'  ^RNase A 
Cell Lysis Solution 
0.2MNaOH 
1% SDS
Cell Neutralisation Solution
1.32M potassium acetate, pH 4.8 
Column Wash Solution 
80mM potassium acetate 
8.3mM Tris-HCl, pH 7.5 
40pMEDTA 
170ml EtOH(95%)
Z Buffer
0.06M N a2H P04.7H 20
0.04M N aH 2P04.H 20
O.OIMKCI
ImM MgS0 4 .7 H2 0
Distilled water
Store at 4°C
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